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Abstract
The overriding goal of this thesis was to further refine our understanding of the genetic architecture of car-
diomyopathies, Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) and Hypertrophic Cardiomy-
opathy (HCM). 407 patients with ARVC and 957 with HCM had 41 cardiomyopathy and other putative
candidate genes sequenced. By comparing these cohorts against each other and against ethnicity and phe-
notype matched controls, insights were gained into the role of different types of genetic variants in these
conditions.
This in part involved utilising 4500 Whole Exome Sequences (WES) that are part of the UCL-
exomes consortium, an in-house dataset that aggregates a diverse set of studies. High throughput DNA
sequencing technologies, WES or Whole Genome Sequencing (WGS) are revolutionizing the diagnosis and
novel gene discovery for rare disorders. As the field transitions from the early discovery for Mendelian
and near Mendelian diseases to more complex and oligo-genic diseases, there is substantial benefit in being
able to combine data across studies, performing the type of meta-analysis for cases and controls that have
proven to be so successful for Genome-Wide Association Studies (GWAS). However, WGS and WES are
substantially more affected by sequencing errors and technical artefacts than genome-wide genotyping arrays.
As a consequence, meta-analysis of sequence based association studies are often dominated by spurious
associations, which result in technical limitations. Here, we show that it is possible to take advantage of the
type of mixed models developed initially to control for population structure in GWAS studies, and apply
these ideas to control for technical artefacts.
In an attempt to ascertain the role of CNVs in HCM, these data were examined for the presence
i
of rare causative CNVs. 12 CNVs were identified from an initial Read Depth approach. 4 of these were
subsequently validated by CoNIFER, a bioinformatics method, and Array Comparative Genomic Hybridis-
ation (aCGH): one large deletion in MYBPC3, one large deletion in PDLIM3, one duplication of the entire
TNNT2 gene and one large duplication in LMNA. These results show that the role of CNVs in HCM is
small and highlight the efficiency of this two step-strategy.
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Chapter 1
Introduction
1.1 Thesis Overview
This thesis follows a broad theme; that of using High Throughput Sequencing and novel statistical approaches
in order to refine our understanding of three of the most common cardiac phenotypes. The rest of this chapter
serves as an introduction.
Chapter 2 discusses the analysis of a targeted sequencing experiment of genes related (or thought
to be) to HCM and ARVC in two relatively large cohorts of patients with these conditions. I will show how
the architecture of these traits, while broadly consistent with the literature, can also differ from published
work.
Following that, Chapter 3 builds on the work in [Lopes et al., 2013b] by examining the role of Copy
Number Variants (CNVs) in HCM. This is done through a stepwise approach that uses a combination of a
RD based method (ExomeDepth) with a Singular Value Decomposition (CoNIFER) followed by validation
with Array Comparative Genome Hybridisation (aCGH). RD refers to the number of DNA fragments, reads,
that map to a given region during a High Throughput Sequencing (HTS) run.
An in-house consortium of approximately 4500 human whole exome sequences (UCL Exome Consor-
tium) is used as the dataset for Chapter 4. There is substantial benefit in being able to combine data across
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studies, performing the type of meta-analysis for cases and controls that have proven to be so successful
for Genome Wide Association Study (GWAS). The issue of technical artifacts and genotyping batches has
been discussed extensively in the early years of GWAS, and similar concerns are now relevant to Whole
Genome Sequencing (WGS) and Whole Exome Sequencing (WES). These data are substantially more af-
fected by sequencing errors and technical artifacts than genome-wide genotyping arrays. As a consequence,
meta-analysis of sequence based association studies are often dominated by spurious associations, which may
result in false positive signals. These issues are usually dealt with by applying stringent quality control cut-
offs, which can lead to false negative results. Here, we show that it is possible to take advantage of the type
of mixed models developed initially to control for population structure in GWAS studies, and apply these
ideas to control for technical artifacts. I show that substantial reduction in the association statistic inflation
can be achieved by applying these novel analytical techniques, both for single variant and gene based tests,
while preserving the sensitivity of the test. We focus on several cardio-vascular traits (Arrhythmogenic Right
Ventricular Cardiomyopathy and Sudden Cardiac Death) to illustrate the ability of these novel methods to
produce more interpretable results.
1.2 Key Definitions
Throughout this thesis, some key concepts are referred to. In some cases, they are expanded on further, but
here I provide a concise summary for reference.
• MAF - For a given locus, we define Minor Alelle Frequency (MAF) as (the number of minor alleles in
the population) / the total number of alleles in the population.
• Effect size - The magnitude of an effect. Can be calculated by subtracting the mean of group 2
from group 1 and dividing by the pooled standard deviation, where pooled standard deviation is
(SD1 + SD2)
0.5/2.
• Population Stratification - Refers to the instance where the population in question is not a homogenous
population and is instead subject to structure which may or may not be known.
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• Missingness - The proportion of missing data. This may be randomly missing or not.
• Genomic Inflation - The genomic inflation factor λ is the ratio of the median of the empirically observed
distribution of the test statistic to the expected median. This quantifies the extent of the bulk inflation
and the excess false positive rate.
• Single variant and gene based tests - Single variant tests work well for variants that are common (here
defined as those with a MAF of ≥ 1%) and/or have a large effect size [Li and Leal, 2008b]. For rare
and/or low effect size variants, these tests are underpowered and thus have lead to region based testing
that assesses the cumulative effect of multiple rare and common variants.
1.3 Structural Variation in the Genome
SNPs are single base pair changes in a DNA sequence and small indels usually refer to variants no greater
than 10-20bp. The majority of known disease causing variants are Single Nucleotide Polymorphisms (SNPs)
or small indels, which partly reflects the easier challenge to characterise this class of variants in large cohorts.
Copy number variants (CNVs) are genetic variants of larger size, either deletion or duplications. CNVs can
range in size from kilobases to megabases and can occur spontaneously or be transmitted stably through
generations [Feuk et al., 2006].
2010 saw the publication of a 19000 person 8 disease study that identified 3432 CNVs, highlighting
the fact they play an important role in many diseases [Craddock et al., 2010]. Before such large scale CNV
studies, these loci may have been indirectly tagged by SNPs. Since then, CNVs have been shown to play a role
in other diseases, including Schizophrenia [Rees et al., 2014], Duchenne Muscular Dystrophy [Pagnamenta
et al., 2011], α-thalassemia [Grimholt et al., 2014] and even short stature [van Duyvenvoorde et al., 2013] as
examples. This includes ARVC, which identified a large segregating 122kb deletion in PKP2 [Li Mura et al.,
2013]. At the larger end of the CNV scale, whole chromosomal duplications can occur, leading to conditions
such as Trisomy 21 or Turner Syndrome. Large scale characterisation of CNVs is a technical challenge, and
therefore much remains to be understood about their role in disease aetiology.
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1.4 Exome Sequencing
It is a well established that the cost of the massively parallel sequencing of DNA has plummeted over the
recent years at a rate that outpaced Moore’s Law [Moore, 1998]. Despite this progress, it is not yet financially
viable for mainstream research to routinely sequence the whole genome, a method known as Whole Genome
Sequencing (WGS). Therefore, an economical and practical solution is to concentrate efforts on the 1-2%
of the genome that are more easily interpretable [Teer and Mullikin, 2010]. This process, Whole Exome
Sequencing (WES), covers the exome which consists of all of the known exons across the genome and spans
∼ 30 ×106 base pairs [Wang et al., 2013]. The basic methodology consists of randomly fragmenting the
sample DNA, enrichment of the target exome, exome hybridisation to an array, amplification and finally
sequencing [Ng et al., 2009] (Figure 1.1)
Despite its small size, the exome is thought to contain 85% of the variants that cause Mendelian
diseases [Wang et al., 2013]. Mendelian refers to genetic phenomena that display complete penetrance
(complete correlation between genotype and phenotype) and are caused by a single gene [Marian, 2012].
WES offers the potential to study SNPs and CNVs. Identification of the latter from short-read sequencing
offers somewhat more of a challenge than SNPs however as aligning reads to a region with a repetitive
sequence can be technically challenging and prone to errors. Three general methods do, however, exist;
those that use split reads e.g. [Karakoc et al., 2012], those that take a paired-end approach e.g. [Zeitouni
et al., 2010] and finally those that adopt a RD analysis method e.g. [Krumm et al., 2012; Plagnol et al.,
2012].
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Figure 1.1: Overview of various DNA capture methods. Replicated from [Teer and Mullikin, 2010]. The
light blue bar is the target Nucleotide sequence. The red bar represents off-target genomic sequence. (A) An
illustration of solid phase hybridisation. Probes (black and light blue) that are complementary to the target
sequence are hybridized to a microarray. The fragmented sample DNA is applied and the target sequence
binds to the bait probe. The probe is then washed and the fragments are sequenced. (B) Liquid-phase
hybridisation. Similar to (A) except the solid substrate (microarray) is replaced with an in-solution reaction
that is assisted by biotinylated probes and streptavidin beads.
1.5 Heart Conditions studied in this thesis
1.5.1 Sudden Cardiac Death
Sudden Cardiac Death (SCD) is defined as unexpected natural death that onsets rapidly and has a cardiac
origin [Zipes and Wellens, 1998]. Epidemiological studies have shown that the incidence of SCD is ∼ 3 to
4 times higher in men than women [Zipes and Wellens, 1998]. While coronary heart disease becomes more
frequent with increasing age, SCD in general is a disease of adolescence or early adulthood. Most notably, its
effects are exacerbated by physical exercise, leading to a 2.8 fold greater incidence in athletes compared to
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non-athletes [Chandra et al., 2013]. SCD is responsible for approximately 500 deaths in England and Wales
per annum [Behr et al., 2007]. Clinical screening alone identifies an inherited cardiac condition in 22-53 %
of families [Nunn and Lambiase, 2011; Nunn et al., 2015].
In this thesis, SCD refers to the inherited cardiac conditions collectively known as Sudden Arrhyth-
mic Death Syndrome. Sudden Arrhythmic Death Syndrome (SADS) is an umbrella term that describes
conditions that fall into two principle categories, structural and electrophysiological. The former consists of
Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Dilated Cardiomy-
opathy, the first two of which are examined in detail in this thesis. The latter category includes many
conditions, such as Long QT syndrome, Short QT syndrome, Brugada Syndrome, Catecholaminergic poly-
morphic ventricular tachycardia (CPVT) and Progressive cardiac conduction defect (PCCD) [Millar and
Sharma, 2015]. These conditions are all channelopathies in that they interfere with ion transport (and
therefore electrical conduction) in the heart.
1.5.2 Hypertrophic Cardiomyopathy
HCM is the most common inherited cardiac disease, with a prevalence of 1/500 in the general population
[Efthimiadis et al., 2014]. It is a myocardial form of HCM typified by left ventricular hypertrophy [Ho, 2012]
(Figure 1.2). Such hypertrophy, when otherwise unexplained, and greater than 15mm is regarded as the main
diagnostic criterion for HCM [Hickey and Rezzadeh, 2013]. Treatment of HCM includes recommendations
to reduce the level of physical activity undertaken and may progress to more serious interventions such as
β blockers or pacemakers. 50-60% of HCM cases are inherited in an autosomal dominant fashion [Lopes
et al., 2013b], caused by mutations in cardiac sarcomeric genes. Z-disc and calcium handling genes are also
associated with HCM, but are thought to explain <1% of cases. The sarcomere is the basic unit of muscle
that is comprised of myosin thick filaments and actin thin filaments arranged longitudinally [Rahimov and
Kunkel, 2013]. The Myosin Heavy Chain (MHC) gene on chromosome 14q1 alone counts for ∼ 30 to 50 %
of cases, followed by Myosin Binding Protein Cardiac 3 (MYBPC3 ). HCM is characterised by a variable
phenotype and incomplete penetrance. As a result of this, family screening of patients with HCM is vital
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for effective disease management, while also offering the potential to elucidate the genetic basis.
Figure 1.2: Comparison of a normal heart to one with Hypertrophic Cardiomyopathy. Reproduced from
[Hickey and Rezzadeh, 2013]
1.5.3 Arrhythmogenic Right Ventricular Cardiomyopathy
ARVC is another inherited cardiomyopathy, primarily affecting the right ventricle [Romero et al., 2013].
It is characterized clinically by fibrofatty replacement, myocardial atrophy, fibrosis, chamber dilation and
aneurysm formation [Thiene et al., 1997].ARVC affects men 3 times more than women and has an overall
incidence of about 1:5000 [Corrado and Thiene, 2006]. ARVC cases represent approximately 20% of the cases
of SCD in the United States [Dalal et al., 2005]. The pathological presentation of ARVC is quite variable,
rendering it more difficult to identify its genetic cause than well-defined diseases such as HCM. Nevertheless,
some genes have been implicated. The desmosomal gene Desmoplakin (DSP) was found to be associated
with an autosomal dominant form of ARVC [Rampazzo et al., 2002]. The finding that the genes Junction
Plakoglobin (JUP) and Plakophilin 2 (PKP2 ) frequently contained mutations in ARVC has suggested that
ARVC is a disease of cardiomyocyte junctions [McKoy et al., 2000; Tiso et al., 2001].
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1.6 Problems with data interpretation
1.6.1 Population Stratification
Consider this hypothetical situation. One is interested in disease X and knows little about its epidemiology.
One therefore decides to collect a cohort of disease samples (cases) from the general population. A prevalence
of N% is identified and it is then assumed that this is representative of people as a whole. Furthermore, a
particular variant Y (say a SNP) was flagged as associated with the disease. In general, this occurs when
it is shown that a variant is significantly over-represented in cases compared to control samples that do not
have disease X. There are a number of reasons as to why a variant may indeed have a different frequency
between cases and controls. First, Y is a simple false positive and it in actuality has the same frequency
in both cases and controls. Secondly, Y is truly disease causing, or is in linkage disequilibrium with the
causative allele, and in that case we can mark one more disease off the list of unsolved Mendelian conditions.
Finally, Y is neither of the above and is in fact associated with a subpopulation. If X is more common in
a particular population, then Y could be associated with their ethnicity rather than with X pathogenesis.
These possibilities are summarised in Figure 1.3.
In general, this phenomenon is referred to as Population Stratification (PS). A classic example of
a study that failed to implement an adequate control for PS is that in which it was erroneously claimed
that there was an association between diabetes and a Human Leukocyte Antigen (HLA) haplotype on a
Pima Indian reservation [Knowler et al., 1988]. This association was found because the target population
displayed genetic admixture between people of white European and Pima Indian ancestry. PS is thus a
source of false positives. When the analysis was restricted to the latter only, the association disappeared
[Cardon and Palmer, 2003]. Arguably the easiest solution to PS is to carefully match cases with controls so
that their epidemiological background is as similar as possible, except for disease status. With this approach,
it can therefore be difficult if not impossible to obtain a sufficiently large and accurate control set. It is not
particularly feasible when dealing with rare diseases as the less common the disease of interest is, the larger
the required sample size.
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Figure 1.3: The general method of case control studies. In the top panel a SNP frequency is ascertained
in 1000 heart disease cases and controls. The arrow indicates two possible explanations for the difference
in frequency between cases and controls. A shows how the original finding may be a false positive and the
frequency is in fact the same in cases and controls, seen at a larger sample size. B shows cases where the
finding is still the same but may be due to it being truly disease associated or caused by factors such as
Population Stratification.
An alternative approach is termed Genomic Control (GC). This posits that the χ2 statistic typically
used in case control studies is inflated by some constant factor when there is PS [Devlin and Roeder, 1999;
Cardon and Palmer, 2003]. The GC factor is multiplicative and proportional to the level of stratification.
It is estimated by examining the unlinked markers on a genome wide level and subsequently used to rescale
the χ2 statistic. GC is popular because it is relatively easy to use but it can be conservative and follows the
sometimes unrealistic assumption that all SNPs are affected equally.
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Another method, EIGENSTRAT [Price et al., 2006], employs Principal Component Analysis (PCA).
PCA was first used in genetics to construct a genetic timeline of how early farming spread across Europe
[Menozzi et al., 1978]. PCA calculates the axes that explain the most variation in the data. They are linearly
ordered, so the first PC is the axis that explains the most variation. This is a useful technique as it enables
visualization of the data in terms of its Principal Components (PCs), also known as Eigenvectors, rather
than the traditional X/Y graph approach which is only useful for 2-Dimensional Data. If PS is present
in data, the first/top PCs may have axes that have a geographic interpretation [Price et al., 2006]. After
PCA, EIGENSTRAT controls for association based on the top few PCs (2-10) before finally computing the
ancestry-adjusted association statistics. The top PCs are more likely to reflect large scale differences due to
population, rather than causal variation.
There remains a debate as to whether such PCA approaches or model based clustering methods such
as STRUCTURE or ADMIXTURE are more useful for association studies [Pritchard et al., 2000; Falush
et al., 2003; Patterson et al., 2006; Hoffman, 2013]. Controlling for PS with PCA normally allows you to
retain all samples in the study, while STRUCTURE & ADMIXTURE will identify samples that should be
removed. STRUCTURE works by using multilocus genotype data to infer population structure in an attempt
to probabilistically assign all individuals to one of M (an integer) populations, even where the value of M is
unknown. Indeed, Patterson et al. [2006] suggests that a merged system may be used, whereby PCA is used
to identify an initial likely value for M before running STRUCTURE. ADMIXTURE is a modification of
STRUCTURE; It employs a fast block relaxation scheme using sequential quadratic programming for block
updates that translates into a runtime that is nearly equivalent to the faster EIGENSTRAT [Alexander
et al., 2009]. Because of this runtime reduction, ADMIXTURE is preferred for studies that have larger
sample sizes than that which STRUCTURE could handle.
1.6.2 Other sources of bias
When one considers the potential that massively parallel HTS has to revolutionise population and disease
genetics, it should come as no surprise that there exists multiple technologies in this increasingly competitive
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market. Two of the most common are those provided by Illumina and Complete Genomics (CG). While the
throughput of HTS methods far outpaces that of the traditional Sanger sequencing, their accuracy is less
reliable. A study that sequenced the genome of an individual to a coverage of ∼76x found that just 88.1%
of the ∼3.7 million SNPs and Insertions-Deletions (INDELs) were agreed on between Illumina and CG [Lam
et al., 2012]. Despite millions of years of evolution, eukaryotes still display a spontaneous mutation rate of
10−10 − 10−12 [Hughes et al., 2005]. So it is not surprising that these technologies are not yet perfect. The
confounding that this low concordance could cause is exacerbated by the fact that 1676 genes were found to
have platform-specific SNPs. Naively, an argument could be made to remove this problem by simply using
one technology for all research. However, their methodologies have some unique advantages. For example,
this study found that Illumina reported more errors than CG. Illumina uses a longer read length than that
of CG which enables it to sequence regions that CG cannot, such as those that are rich in sequence repeats.
This may or may not explain the increased error rate, but it shows that it is beneficial to not discard Illumina
nonetheless.
This finding of such discrepancy is far from an isolated incident. The 1000 Genome project (1000G)
established to catalogue as much human variation as possible to improve our ability to deduce genotype
phenotype correlations [Abecasis et al., 2010]. Quality controls differed between the pilot and intermediate
releases and the usage of different technologies led to a false positive rate of 3-17%. This was substantially
improved by generating consensus calls from more than one platform, which led to an error rate of 1-4%
[Nothnagel et al., 2011]. Therefore, the weight of belief in a candidate variant may be bolstered by it being
called by more than one technology. For a lot of researchers however, this is not a practical validation
method because of the expense involved. Ultimately, 1000G sequenced 2,504 individuals from 26 different
populations [Auton et al., 2015] with this improved methodology.
While technologies that utilise longer read lengths offer a larger, more accurate coverage profile, they
do not fully solve these technical biases. The four letters of the DNA alphabet typically pair off in known
A-T and G-C couplets. AT bonds consist of two hydrogen bonds while GC pairs use three hydrogen bonds.
This fact has a noticeable impact on the performance of PCR and HTS systems, resulting in regions that
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contain high numbers of GC pairs (GC rich regions) presenting additional technical difficulties. Illumina has
been shown to struggle sequencing GC rich regions, which causes uneven or even a complete lack of coverage
[Dohm et al., 2008]. More recently, validation studies have shown that most HTS technologies suffer from
some degree of GC bias (Figure 1.4). As this figure shows, when the GC content is close to 50%, then the
four technologies examined here perform comparably well. This changes towards either tail (GC rich or GC
poor) with the Illumina HiSeq coping significantly better than Life Technologies and even CG.
System updates do not always mean that improvements have been gained in output quality. It has
been shown that even more recent versions of the commercially available capture platforms have problems.
For example, the WES platforms Agilent (SureSelect v5+UTR), NimbleGen (SeqCap v3+UTR) and Illumina
(Nextera Expanded Exome) were compared in a recent study [Chilamakuri et al., 2014; Meienberg et al.,
2015]. This showed that Agilent and NimbleGen now perform better than Illumina, despite the latter being
the market leader. The latest Agilent platform in particular is the best performer as Nimblegen has a more
pronounced GC bias.
Artefactual differences between cases and controls can sometimes exhibit a differential bias that
confounds real signal. This was shown in the first phase of the 1958 British birth cohort Diabetes study
[Clayton et al., 2005]. As is the norm with genetic first phase studies, the goal was to identify a subset of
SNPs from the initial panel that could subsequently be further tested for confirmation on a larger sample.
Taqman genotyping was used, which consists of fluorescently ligated PCR primers that target candidate
SNPs. The calls for individual genotypes are performed by examining the cluster of fluorescence from cases
and controls: in an artefact free world you would expect to see three distinct clusters, a heterozygote cluster
flanked by both homozygote pools. However for a range of NS SNPs, the heterozygote clouds for cases and
controls were unexpectedly discrete (Figure 1.5). Without correction, this can readily be misconstrued by
the clustering algorithm as a false positive. This could be avoided by increasing confidence level required
before declaring a call. This is also not ideal as that would both reduce the used variant set and also created
’informative missingness’ where missingness is no longer independent of genotype.
To test 2*K contingency tables, such as those seen in genotype studies, the Cochran Armitage (CA)
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Figure 1.4: GC Bias across four High Throughput Sequencing platforms [Rieber et al., 2013]. Log2 of base
coverage in 1 kilobase windows. Top Left panel is a merged picture of the three other panels. A smoothened
loess curve was fitted per dataset to show the local coverage.
test is typically used. The null being no association, this will be chi-squared with K-1 degree of freedom.
However, Devlin (1999) noticed that substructure in association studies can lead to an overdispersion such
that CA is distributed as CA/λ, chi-squared 1df. λ is a constant greater than one that is estimated from
a large number of loci throughout the genome. Testing a large number of loci, most of which will be
unrelated to the trait of interest, allows one to effectively calculate the background inflation level caused by
substructure. This GC is often used to corrected the observed test values by dividing by the estimation of
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λ. This method was refined in Clayton (2005) to create a λ that is not constant throughout the genome
but depends on regional markers of genotyping accuracy. If no assay based technical bias is present the
generalised linear model they implemented reverts λ to just GC.
Figure 1.5: Signal intensity plots for the CD44 SNP rs9666607 from the artefact containing phase 1 diabetes
study on the 1958 British birth cohort [Clayton et al., 2005]. The X-axis represents one allele and the Y
axis the other. Each dot represents a sample, with those in red cases and blue controls.
The incidence of melanoma, a type of skin cancer, in the Caucasian population has increased by
1.5% annually from 1950 to 2005 [Wang et al., 2009]. The primary cause is solar radiation, with UVA and
UVB inducing photoproducts of adjacent pyrimidines which if not adequately remedied can lead to base
substitution mutations. The pyrimidines in DNA (Adenine, Thymine and Uracil) would thus be expected
to be altered at an increased frequency in melanoma samples. However, in a deep sequencing study of 221
matched melanoma and healthy samples, researchers at the Broad Institute identified a significantly higher
rate of purine variants. Figure 1.6 shows that the frequency of this variant substantially increased over time.
As this increase was greater than the increase in prevalence, it is suggestive of an altered methodology of
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sample preparation, rather than a merely biological cause. Additionally, these were thought to be artefacts
as they occurred in a strand specific fashion; The G > T errors were in the first read of the Illumina HiSeq
run while the C > A errors were always found in the second read [Costello et al., 2013]. Given that these
variants were present in healthy and tumour samples alike and were perfectly correlated with the instrument
read order, they were confirmed to be artefacts Artefact (ArtQ).
During preparation for HTS, DNA is randomly fragmented by acoustic and restriction enzyme
shearing. The shear force per unit DNA is higher in WES than WGS. This makes it more susceptible to
damage, which can manifest as mutations that are erroneously thought to be real signal. This study further
identified that some types of DNA storage buffer when exposed to WES methods are responsible for inducing
this artefact. To try abrogate this, the best solution would be resequence all samples in ideal buffers and at
lower shear forces for WES. However, this method is often impractical and post sequencing corrections are
often the only solution.
� �
Figure 1.6: A technological ArtQ in a melanoma study. (A) ArtQ prevalence metric by library creation date
for the Broad institute’s Targeted Capture pipeline. (B) ArtQ for Pre- versus Post-targeted capture. For
a set of 370 samples, both the pre- and post-exome enrichment libraries were sequenced. ArtQ was well
correlated, indicating that the artifactual base changes had already been introduced before exome capture.
Adapted from [Costello et al., 2013].
1.7 Linear Mixed Models
Linear Mixed Models (LMMs) extend the standard Linear Model (Equation 1.1) by adding random effects.
They have been used to control for PS alongside methods such as EIGENSTRAT and ADMIXTURE [Zhang
15
et al., 2010]. LMMs have the form shown in Equation 1.2.
Y = Zα+Xjβj + e with e ∼ N(0, Iσ2e) (1.1)
Y = Zα+Xjβj + g + e with g ∼ N(0,Kσ2g) (1.2)
where
• Y is phenotype
• Z is a matrix of covariates
• α is Z’s fixed effects
• Xj are the SNPs for SNP j
• βj is the effect sizes of SNP j
• I is an identity matrix
• e is environmental noise
• and g is a random effect
As with the standard Linear Model, it is necessary to solve Equation 1.2 for each SNP in turn. LMMs
can control for multiple types of confounders simultaneously. While this strength is an advantage over these
other methods, it has traditionally been such a computationally intensive approach as to be infeasible for
GWASs that studied many thousands of markers across thousands of samples. When applied to genetics,
LMMs control for confounders by introducing a random effect with correlation structure specified by a
”kinship matrix”, which measures the genetic similarity between pairs of individuals. This kinship matrix
has been estimated with different methods, such as the Realized Relationship Matrix (RRM) [Hayes et al.,
2009], an Identity by Descent Approach [de Roos et al., 2009] or by sampling a small set of markers [Lippert
et al., 2011]. The last of these has been implemented in the software FaST-LMM.
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The LMM log likelihood of Y given X (N x d) which includes the covariates, the SNP and a column
of ones as a bias offset can be written as per Equation 1.3. A LMM with a SNP based RRM and without
fixed effects is equivalent to a linear regression of the SNPs on the phenotype, with weights integrated over
independent Normal distributions having the same variance [Hayes et al., 2009; Lippert et al., 2011]. By
replacing K with its spectral decomposition, K = USUT , and by defining δ as σ2g/σe, one can eventually
view this as the linear regression equation (Equation 1.4).
likelihood(Y |Data) = Normal(Y |Zα, σ2gK + σ2eI) (1.3)
where
• Normal(Y|,b) denotes a normal distribution with mean a and covariance matrix b
The key to solving Equation 1.2 is determining δ, that is the ratio of the residual variance to the
genetic variance. Solving δ naively for each SNP is very computationally intensive, so early implementations
such as Efficient Mixed Model Association (EMMA) provided an approximate method which instead solved
δ once under the null model, then used this value when testing each SNP. FaST-LMM improves on the
algorithm EMMA by reducing the required frequency of Spectral Decompositions from once per SNP to just
once [Kang et al., 2008]. It does this with an exact method, by realising that δ can be found rapidly for each
SNP after first performing a decomposition of the kinship matrix. FaST-LMM therefore has a runtime and
memory footprint that is linear in the number of individuals, making it amenable to data the scale of the
UCL-ex consortium.
likelihood(Y |Data) = Normal(UTY |UTZα, σ2e(δS + I)) (1.4)
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1.8 Bioinformatics - the Genome Analysis Toolkit
1.8.1 Unified Genotyper pipeline with GATK
Raw FASTA files in FASTQ format were aligned to the HG19 reference genome using Novoalign version
2.08.03. Duplicate reads were marked using Picard tools MarkDuplicates.
Until early 2014, and for all the analyses presented in this report, all variants were called using the
Unified Genotyper module of the Genome Analysis Tool Kit https://www.broadinstitute.org/gatk (GATK).
BAM files were reduced using the GATK ReduceReads module and calling was performed jointly for all
samples using GATK version 2.8.1.
1.8.2 Haplotype caller pipeline
Starting in January 2014, calling was performed using the haplotype caller module of GATK, creating gVCF
formatted files for each sample. The individual gVCF files were combined into combined gVCF containing
100 samples each. The final variant calling was performed using the GATK “GenotypegVCFs” module
jointly for all cases and controls. This process is still being tested. However, preliminary results are very
positive. In particular, the computational burden is substantially reduced by the use of this new calling
strategy.
1.8.3 VQSR
Variant filtering is central to the methodology presented in this report. The issue of filtering low quality
variants has been flagged by all variant calling algorithms, including GATK and Samtools. Traditional
methods used to flag variants of low quality examined their context, for example, the number of reads
covering the region, how many reads cover each allele or the proportion of reads in forward and reverse
orientation. Such values were then used to set a threshold and discard variants thus deemed unsatisfactory.
These methods are easy to implement but potentially suffer from their crudeness by being too stringent.
For UCL-ex data analysis, we followed the best practices as described byGATK to apply the VQSR steps.
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Briefly, a set of established summary statistics are computed for at a single variant level. A multi-dimensional
mixture model is then fitted to these summary statistics, which allows the computation of a likelihood score
for each variant. The further away the summary statistics are from the centers of the Gaussian mixture, the
lower the likelihood will be. A training set of established variants is then used, and a likelihood threshold
is then set such that a set fraction (typically about 99%) of these established variants passes the threshold.
This likelihood threshold is then applied to the dataset as a whole, and variants above that threshold receive
a PASS flag. Variants below that threshold are annotated with the “tranche” information that summarizes
how far away the summary statistics are from the acceptance threshold. For this report, PASS variants as
well as SNPs and INDELs in the top likelihood tranche were included for subsequent analyses.
1.9 Motivation and Aims
The overriding goal of this thesis was to further refine our understanding of the genetic architecture of
cardiomyopathies that cause SCD, ARVC and HCM. Several obstacles complicate this aim:
• As discussed already, these conditions display varying levels of penetrance. This makes their analysis
more difficult than simple Mendelian conditions.
• The variable phenotypes of these conditions raises the possibility that they are in fact not single
conditions and may represent overlapping syndromes. This would further complicate matters as it will
weaken any associations found.
• Their relative rarity in the general population means it is not straightforward to establish a cohort
with a large number of samples. This limits the possible statistical power.
• To achieve statistical power more samples are needed when studying rare conditions than common
ones. This led to the creation of UCL-ex, an in-house collaboration pooling some 4500 whole exomes
from cohorts with various rare diseases. This data comes from many different sources with widely
disparate results (e.g. in terms of variant call rates and read depth).
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Theses obstacles were approached in three distinct methods. Chapter 2 looks at a targeted sequenc-
ing approach of these three cohorts. 59 SCD patients are sequenced, using a targeted sequencing approach of
known or putative candidate genes, in an attempt to perform a “molecular autopsy” that has an informative
diagnostic yield. This is followed by a case control analysis on a targeted sequencing panel of both a HCM
and ARVC cohort.
Secondly, Chapter 3 builds on previously published work that examined the role of SNPs in HCM
[Lopes et al., 2013b]. It does so by using a three pronged approach to ascertain the role, if any, of CNVs in
HCM pathogenesis.
As mentioned already, HTS data can suffer from artefacts derived from many sources. These can
be more apparent in a dataset such as UCL-ex where samples from multiple sources are pooled and all have
rare diseases. Chapter 4 is devoted to an attempt to create a novel statistical model that adapts classical
methods from population genetics to try solve this problem. This is developed and then applied to all the
phenotypes in UCL-ex.
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Chapter 2
Elucidating the genetic architecture of
HCM and ARVC
2.1 Introduction
This chapter examines three cardiomyopathies, Sudden Cardiac Death (SCD), Arrhythmogenic Right Ven-
tricular Cardiomyopathy (ARVC) and Hypertrophic Cardiomyopathy (HCM).
59 SCD patients are sequenced, using a targeted sequencing approach of 135 known or putative
candidate genes, in an attempt to perform a “molecular autopsy” that has an informative diagnostic yield.
Non-synonymous, loss-of-function, and splice-site variants with a minor allele frequency ≤ 0.02% in the
NHLBI exome sequencing project and an internal set of control exomes were prioritized for analysis followed
by ≤0.5% frequency threshold secondary analysis. This initial part was done by others, but I performed the
control selection by PCA and the subsequent case control analysis.
This is followed by a case control analysis on a targeted sequencing panel of both a HCM and
ARVC cohort. These cohorts were compared against the population controls of UCL-ex to identify novel
associations. Additionally, they were compared against other in a bit to identify if this approach is useful in
refining our understanding of these somewhat similar conditions. Dr. Pier Lambiase and Dr Petros Syrris
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were involved in the sample collection and Dr. Vincent Plagnol performed the sample genome alignment
and variant calling. I performed the variant QC, and case control analysis.
2.2 Methods & Results
2.2.1 Molecular Autopsy of a Sudden Arrhythmic Death Syndrome cohort
The cohort analysed here consisted of families referred to specialised cardiovascular centres in seven European
centres. Recruited families had a proband who suffered from SADS and was aged between 1-55 with no cause
death identified at post-mortem. This study complied with the Declaration of Helsinki and a joint University
College London and University College London Hospital Research Ethics committee application. As part
of this, the families were offered clinical screening for inherited channelopathies and cardiomyopathies using
a standard protocol [Nunn and Lambiase, 2011]. This included an outpatient consultation and resting
and exercise electrocardiogram and ajmaline challenge if Brugada syndrome was suspected or was how the
proband died or if every other investigation was normal.
90 deceased probands met these initial criteria. 28 were rejected because of DNA quality and/or
quantity issues. The next of kin refused consent in 3 additional cases. In total, the DNA from 59 SADS
victims (mean age 25, range:1-51) was isolated [Nunn et al., 2016]. The clinical characteristics of these
remaining probands are summarised in Figure 2.1. 39/59 patients had structurally normal hearts and 20
had subtle structural abnormalities that were detected post-mortem. Targeted exome sequencing of 135 genes
associated with cardiomyopathy or ion channelopathies was performed on the Illumina HiSeq2000 platform
(The full list of candidate genes is in Tables 1 to 3 in the Appendix). Variants that were non-synonymous,
loss of function or splice site variants with a MAF of ≤ 0.02% in the NHLBI set of 6500 Exomes and the
internal control set were prioritised for analysis. Both of these control datasets were filtered to ethnically
match the Caucasian cases. The secondary analysis examined variants that had a MAF of ≤ 0.5%. Applying
this filter yielded 80 candidate coding variants, a mean of 1.36 variants per proband. The variants deemed
most likely to be causative based on the gene they are located in and the particular affect that had are listed
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in Table 2.1.
Additionally, data from the Exome Aggregation Consortium (ExAC) was used. ExAC is a publically
available collection of 60,706 unrelated individuals sequenced as part of various disease-specific and popula-
tion genetic studies. The large size of this dataset meant that it was deemed the most accurate determinant
of factors such as MAF. One caveat is the fact that it only became available when this thesis was already
at a late stage so it was not possible to retroactively use it in all cases. Despite this, this work gave insight
into the clinical utility of a molecular autopsy of sudden cardiac death.
Figure 2.1: Summary of proband characteristics in the SADS Molecular Autopsy Study. Reproduced with
permission from [Nunn et al., 2016].
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AgeAtDeath(yrs) Sex CircumstanceDeath Gene(Disease) AminoAcidChange UCLex-MAF(2867ex) NHLBI(6500ex) ExAC(60706ex)
4 F Sleep SCN5A(LQT3/BrS) R1623Q 0 0 0
6 M Sleep SCN5A](LQT3/BrS) V411M 0 0 0
26 F Phone call RyR2 (CPVT) N1551S 0 0 0.034
18 F DailyActivities TTN (DCM/HCM) E23106X 0 0 0.00083
32 M Sleep GJA5 (Familial-AF) Y197X 0 0 0
39 M DailyActivities MYOT (LGMD) Q453X 0 0 0.00165
44 M DailyActivities DSC2 (ARVC) S868F 0 0.0077 0.0058
23 M DailyActivities CACNA1C (BrS) P817S 0.127 0.33 0.0194
1 M DailyActivities LMNA(DCM) R644C 0.1385 0.1 0.121
22 F Sleep RANGRF (BrS) E61X 0.2646 0.42 0.3947
11 M Exercise CACNA2D1 (BrS) S709N 0.22 0.37 0.2677
33 M DailyActivities ANK2 (LQT) E1837K 0.29 0.31 0.267
27 M DailyActivities KCNH2 (LQT) P347S 0.16 0.0496 0.1293
41 M DailyActivities MYPN (HCM) Y20C 0.36 0.092 0.091
28 M Exercise RBM20 (DCM) E1125K 0.34 0.37 0.37
14 M Exercise DSP(ARVC) A2294G 0.12 0.23 0.085
34 M Sleep CACNA1C (BrS) G37R 0.3211 0.23 0.74
Table 2.1: Sudden Cardiac Death Molecular Autopsy variants. The first seven are very rare variants (Minor
Allele Frequency [MAF] of ≤ .02%) in NHLBI and the UCL-exome consortium control set. The last ten are
deemed quite rare, with a MAF of ≥ 0.02% & ≤ 0.5%
2.2.2 ARVC and HCM case control analysis
As described in Section 1.8.2, the best practises guide from the GATK endorses a joint calling procedure as
it has a lower artefact rate than more traditional single sample calling. This method was implemented to
more adequately integrate the 407 ARVC and the 955 HCM samples with the 3587 UCL-ex controls. The
genes sequenced for this analysis are listed in Table 4 in the Appendix. A case control analysis was then
performed, at a single variant and gene level. In total, 9206 variants were tested. The most significantly
associated SNPs for ARVC and HCM are listed in Tables 2.2 and 2.3. Given the population prevalence
of these conditions (1/500 for HCM and 1/5000 for ARVC) and the varying penetrance of the causative
variants, this study was underpowered for rare variants of small effects. For example, if we calculate power
for ARVC as it is the rarer condition, and assume:
• A disease prevalence of 1/5000 (0.0002)
• A risk variant population frequency of 0.0002 (A typical value of the most significant variants)
• A heterozygote relative risk of 5
• A homozygote relative risk of 10
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then we would need 1612 cases for 80% power of detecting a real causal variant at an Alpha of 0.1, or
4454 cases at 0.001. This was calculated with the power calculator at http://pngu.mgh.harvard.edu/ purcell/cgi-
bin/cc2k.cgi. This low power estimate is in agreement with recent literature highlighting the difficulty of
rare variant association studies [Auer et al., 2015].
To increase power, gene-based Fisher, χ2, Sequence Kernel Association Test (SKAT) and Sequence
Kernel Association Test Optimised (SKAT-O) p-values were also calculated (Tables 2.4 and 2.5). The SKAT
is a supervised method that performs regressions for each variant within a given region. It differs from
burden tests in that it does not upweigh rare variants or assume that pathogenicity increases inversely to
variant frequency. The C-Alpha test also allows for varying directions of effects and is essentially a simple
version of SKAT where the outcome is binary and no covariates are included. For a dichotomous phenotype,
such as case control status, consider the logistic model Equation 2.1.
SKAT has more power than burden tests when variants either have variable effect sizes or effects
in different directions, i.e. some SNPs in a gene can be protective and some deleterious [Wu et al., 2011].
However, the inverse is also true; in a scenario where all variants in a set have a unidirectional effect, a
burden test will outperform SKAT. SKAT-Optimal (SKAT-O) retains power in either scenario by using an
adaptive kernel that follows a multivariate distribution with exchangeable correlation structure [Lee et al.,
2012]. For a given set, if the variants effects are uncorrelated, it is effectively a SKAT test, while reducing to
a burden test if the effects are unidirectional. Additionally, SKAT can handle singletons by collapsing those
with the same directionality of effect into a single value and combining this with the other variants in the
region. In general therefore, SKAT-O is more accurate than SKAT as assumptions about variants effects’
based on criteria such as predicted function are less important.
logitP (yi = 1) = α0 +α
′Xi + β′Gi + i (2.1)
where
• y is a binary phenotype vector
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• α0 is an intercept term
• α is the vector of regression coefficients for covariates
• β is a vector of regression coefficients for the p variants in the region.
A lack of statistical power, particularly for ARVC, hindered the ability to identify variants or genes
of weak effect here. Additionally, a targeted gene panel of limited size offers little potential to find real novel
insight. The findings discussed here do support the literature.
2.2.3 Examining the veracity of candidate gene lists
Table 4 lists the genes with the strongest support for involvement in HCM (16 genes) and ARVC (12 genes).
A minority of significantly associated SNPs (here defined as those with a Fisher pvalue of ≤ 0.0001 ) were seen
in candidate genes for HCM (8/53), while 21/28 of the top ARVC SNPs were in candidate genes. HCM Candi-
date genes TNNI3,TNNT2,TPM1,MYL2,MYL3,ACTC1,CSRP3,ACTN2,MYH6,TCAP,TNNC1,PLN,MYOZ2,NEXN
did not contain significant SNPs; similarly in the ARVC analysis CTNNA3,DES,DSC2,DSP,JUP,LMNA,TGFB3,PLN
SNPs failed to reach significance. Loss of function variants were defined as those predicted to be exonic splic-
ing, stopgain/stoploss or frameshift. Tables 2.6 and 2.7 show that MYBPC3 contains 61% of such variants
in HCM while PKP2 contains 27% of the LOF variants seen in the ARVC samples. Figure 2.2 shows the
range of pvalues from the SKAT test for pooled variants and whether or not the fact that the genes are
currently candidate genes is a good indicator of the statistical significance that they reach.
As the gene encoding the largest protein in the human body it is unsurprising that variants within
Titin have been linked to a number of conditions [Brun et al., 2014; Herman et al., 2012; De Cid et al.,
2015]. Because of this clinical importance much work has been done to elucidate its role in these varying
pathologies. In terms of SCD, it has been shown that variants in different protein domains are associated
with particular types of SCD, as seen in Figure 2.3.
In general, the risk allele for qualitative traits is the minor allele [Park et al., 2011]. One possible
definition of effect size is the coefficient ( β ) for a SNP when it is modeled in a logistic regression against the
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Figure 2.2: The predictive ability of known gene status. Boxplots showing pvalues for the SKAT tests on
known and unknown candidate genes (True and False on the X-axis,respectively). Varying filters were used
for determining variants included per gene test: no Functional Filter (’ARVC’ and ’HCM’ plots), Functional
variants (non-synonymous and splicing). and Loss of Function - frameshift and stop-gain or stop loss (LOF)).
outcome, here phenotype. The idea that the effect size might increase as the MAF lowered was examined
(Figure 2.4 ). The distribution of SNP effect sizes and Odds Ratios was also calculated (Figure 2.5) .
This section aimed to gain improve our understanding of ARVC and HCM. While it was not possible
to identify a clear difference in the pattern of SNP effect sizes or Odds Ratios between these conditions, the
trend of increasing effect with decreasing MAF was clear for both.
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Figure 2.3: The distribution of candidate variants across the Titin coding sequence. (A) Variants with a
pvalue of ≤ 1∗10−4 from the case control analysis were plotted in relation to their respective locations across
the TTN gene, where the X-axis is the position of the variant along the Titin sequence and the y axis is
unused. The color of each mutation represents the associated pathology. (B) Reproduced from [Neiva-Sousa
et al., 2015]. Mutations associated with cardiomyopathies distributed along the canonical TTN sequence
(UniProtKB: Q8WZ42-1). The type of domain in TTN is represented by the color of each block in the
sequence. Abbreviations: DCM is dilated cardiomyopathy,HCM hypertrophic cardiomyopathy, ARVC ar-
rhythmogenic right ventricular cardiomyopathy, RCM restrictive cardiomyopathy, Ig immunoglobulin, PEVK
region rich in proline (P), glutamate (E), valine (V) and lysine (K), TK titin Ser/Thr kinase
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Figure 2.4: Characterising variants in ARVC and HCM across the Minor Allele Frequency (MAF) spectrum.
’ARVC’ shows all variants while ’Significant’ indicates those with a pvalue of ≤ 0.0001. Top Panel - X axis:
log10 of control MAF, Y axis: Squared regression coefficients of the model phenotype SNP. Loess regression
and standard error shown as line with grey perimeter. Lower Panel: Y axis represents the log10 of the risk
Odds Ratio.
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gene funcSKAT funcSKATO funcFisher funcChiSq LoFSKAT LoFSKATO LoFFisher LoFChiSq
1 PKP2 1.82E-33 2.73E-43 1.75E-30 3.84E-44 8.70E-34 5.26E-53 5.40E-34 5.35E-48
2 DSG2 1.47E-10 4.57E-13 3.29E-09 2.14E-11 6.45E-02 1.59E-02 2.11E-02 2.39E-02
3 TMEM43 4.53E-04 7.46E-04 3.47E-02 5.23E-02
4 DSP 1.42E-03 8.24E-04 1.01E-02 1.03E-02 4.76E-09 8.05E-16 3.38E-09 1.29E-12
5 TPM1 1.28E-03 1.19E-03 2.36E-03 1.23E-03
6 TTN 2.32E-03 5.12E-03 7.54E-01 7.92E-01 4.56E-01 6.43E-01 6.89E-01 6.90E-01
7 LMNA 3.95E-03 7.58E-03 8.63E-02 1.58E-01
8 KCNE2 9.81E-03 1.36E-02 5.72E-02 8.89E-02
9 ACTC1 1.91E-02 1.91E-02 1.57E-01 3.45E-01
10 PNN 1.85E-02 3.26E-02 2.63E-01 3.67E-01
11 DSC2 4.04E-02 6.73E-02 6.07E-01 6.80E-01 1.64E-01 2.19E-01 5.02E-01 6.15E-01
12 TTN-AS1 6.57E-02 9.82E-02 3.23E-01 7.87E-01
13 SCN5A 1.21E-01 1.35E-01 1.31E-01 1.47E-01
14 CAV3 1.15E-01 1.81E-01 4.09E-01 9.79E-01
15 JUP 2.29E-01 2.07E-01 1.78E-01 2.53E-01
16 DES 2.34E-01 2.18E-01 1.35E-01 2.67E-01
17 RBM20 1.79E-01 3.06E-01 8.11E-01 9.57E-01
18 MYBPC3 1.95E-01 3.36E-01 4.44E-01 6.12E-01 6.26E-01 6.26E-01 1.00E+00 1.00E+00
19 KCNE1 3.89E-01 3.81E-01 2.78E-01 4.20E-01
20 GJA1 2.51E-01 3.82E-01 1.00E+00 1.00E+00
21 KCNQ1 2.60E-01 3.92E-01 3.08E-01 5.24E-01
22 MYL2 3.98E-01 3.98E-01 4.03E-01 9.67E-01
23 LDB3 2.96E-01 4.77E-01 8.02E-01 1.00E+00
24 CSRP3 8.94E-01 4.89E-01 1.00E+00 7.24E-01
25 MYH6 3.55E-01 5.56E-01 6.62E-01 8.38E-01 8.26E-01 6.71E-01 1.00E+00 1.00E+00
26 KCNJ2 3.83E-01 5.65E-01 1.00E+00 1.00E+00
27 PLEC 7.99E-01 5.94E-01 4.93E-01 4.65E-01
28 TNNI3 8.01E-01 6.39E-01 1.00E+00 1.00E+00
29 TCAP 8.79E-01 6.47E-01 7.60E-01 6.46E-01
30 PLN 8.19E-01 6.61E-01 1.00E+00 1.00E+00
31 KCNH2 8.26E-01 6.71E-01 1.00E+00 1.00E+00
32 TGFB3 6.52E-01 7.24E-01 1.00E+00 8.23E-01
33 CASQ2 9.73E-01 7.37E-01 8.57E-01 7.82E-01
34 PDLIM3 5.24E-01 7.39E-01 1.00E+00 9.36E-01
35 TNNT2 6.29E-01 8.27E-01 1.00E+00 1.00E+00
36 ANK2 6.70E-01 8.53E-01 7.82E-01 7.47E-01
37 VCL 6.94E-01 8.81E-01 1.00E+00 9.33E-01
38 MYH7 7.20E-01 9.07E-01 1.00E+00 8.92E-01 8.95E-01 5.95E-01 1.00E+00 1.00E+00
39 RYR2 7.19E-01 9.13E-01 8.87E-01 9.10E-01 7.88E-01 6.23E-01 1.00E+00 1.00E+00
40 PKP4 7.71E-01 1.00E+00 8.45E-01 1.00E+00 1.06E-02 1.39E-02 7.39E-02 1.21E-01
41 MYL3 8.08E-01 1.00E+00 1.00E+00 1.00E+00
Table 2.4: ARVC Gene based Results. Here, each gene has multiple pvalues as the variants included were
varied as was the exact statistical test used. ’func’ refers to variants that were predicted to have any impact
on the transcribed DNA sequence, including synonymous, non-synymous and splicing changes. ’LoF’ refers
to Loss of Function which is frameshift, stopgain, stoploss or conserved splicing. Both of these variant sets
for each gene was then tested with the Fisher, SKAT and SKATO tests. Absent values indicate no variants
remain after filtering.
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gene funcSKAT funcSKATO funcFisher funcChiSq LoFSKAT LoFSKATO LoFFisher LoFChiSq
1 MYBPC3 3.73E-23 1.23E-47 2.12E-31 2.07E-33 9.79E-07 1.07E-15 1.95E-14 4.34E-14
2 MYH7 8.30E-22 8.00E-41 2.32E-25 1.52E-27 4.54E-01 6.30E-01 1.00E+00 1.00E+00
3 TNNI3 4.21E-06 5.31E-09 4.44E-08 4.11E-08
4 TTN 1.50E-04 4.12E-04 1.77E-01 1.86E-01 5.89E-01 7.25E-01 3.67E-01 3.60E-01
5 TPM1 4.19E-02 6.08E-04 2.28E-04 2.50E-04
6 CSRP3 1.37E-03 2.30E-03 2.89E-02 3.27E-02
7 ACTC1 5.37E-02 4.40E-03 8.46E-03 1.29E-02
8 TNNT2 6.21E-03 7.44E-03 2.81E-02 3.48E-02
9 PKP2 1.56E-02 7.55E-03 7.59E-03 7.74E-03 1.43E-02 4.24E-04 8.85E-04 1.31E-03
10 DSP 7.21E-03 1.44E-02 1.00E+00 9.93E-01 4.72E-01 4.72E-01 1.00E+00 1.00E+00
11 PDLIM3 1.07E-02 2.12E-02 1.40E-01 1.70E-01
12 MYL2 1.01E-01 2.87E-02 3.10E-02 5.24E-02
13 ANK2 3.27E-02 6.36E-02 9.22E-01 1.00E+00
14 RBM20 3.97E-02 7.28E-02 1.96E-01 2.04E-01
15 SCN5A 4.28E-01 8.47E-02 4.84E-02 5.91E-02
16 PLN 1.23E-01 9.24E-02 7.86E-02 1.48E-01
17 TTN-AS1 1.08E-01 1.04E-01 1.13E-01 2.20E-01
18 VCL 1.13E-01 1.16E-01 1.01E-01 1.12E-01
19 CASQ2 5.40E-01 1.59E-01 1.37E-01 1.62E-01
20 MYL3 1.26E-01 2.12E-01 1.00E+00 1.00E+00
21 DSG2 1.26E-01 2.22E-01 5.14E-01 6.08E-01 5.03E-01 4.24E-01 5.56E-01 5.42E-01
22 RYR2 3.59E-01 2.42E-01 1.58E-01 1.68E-01 2.62E-01 3.97E-01 6.06E-01 8.68E-01
23 TCAP 1.78E-01 2.86E-01 1.00E+00 1.00E+00
24 DSC2 2.88E-01 3.54E-01 1.43E-01 1.71E-01 3.57E-01 2.91E-01 1.20E-02 3.54E-02
25 MYH6 4.14E-01 3.66E-01 1.84E-01 2.16E-01 2.48E-01 3.77E-01 5.91E-01 7.70E-01
26 TMEM43 5.56E-01 3.84E-01 3.68E-01 3.78E-01
27 KCNH2 2.53E-01 3.85E-01 5.86E-01 7.26E-01
28 KCNE1 4.24E-01 3.85E-01 3.68E-01 3.81E-01
29 GJA1 2.86E-01 4.12E-01 4.45E-01 5.65E-01
30 LDB3 2.55E-01 4.18E-01 3.80E-01 4.32E-01
31 KCNE2 3.80E-01 4.71E-01 3.82E-01 5.73E-01
32 LMNA 4.27E-01 5.02E-01 5.29E-01 4.83E-01
33 PLEC 3.06E-01 5.06E-01 9.17E-01 9.91E-01
34 PKP4 3.36E-01 5.40E-01 4.12E-01 5.15E-01 2.78E-01 3.79E-01 5.36E-01 1.00E+00
35 TGFB3 3.74E-01 5.70E-01 5.92E-01 7.59E-01
36 KCNJ2 6.12E-01 6.46E-01 6.74E-01 7.58E-01
37 DES 6.72E-01 7.23E-01 5.50E-01 7.29E-01
38 KCNQ1 5.33E-01 7.26E-01 1.00E+00 1.00E+00
39 JUP 5.55E-01 7.67E-01 1.00E+00 1.00E+00
40 CAV3 6.56E-01 7.82E-01 1.00E+00 1.00E+00
41 PNN 7.32E-01 8.98E-01 7.87E-01 1.00E+00
Table 2.5: HCM Gene based Results. Here, each gene has multiple pvalues as the variants included were
varied as was the exact statistical test used. ’func’ refers to variants that were predicted to have any impact
on the transcribed DNA sequence, including synonymous, non-synymous and splicing changes. ’LoF’ refers
to Loss of Function which is frameshift, stopgain, stoploss or conserved splicing. Both of these variant sets
for each gene was then tested with the Fisher, SKAT and SKATO tests. Absent values indicate no variants
remain after filtering.
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Gene Nb.variants PercentOfTotal
1 MYBPC3 64 61
2 TTN 22 21
3 MYH7 8 7
4 TPM1 5 4
5 MYH6 2 1
6 PLN 2 1
7 TNNT2 1 1
Table 2.6: Number of LOF variants in HCM Candidate Genes
Gene Nb.variants PercentOfTotal
1 PKP2 28 37
2 DSP 14 18
3 DSC2 11 14
4 TTN 9 12
5 DSG2 4 5
6 PKP4 3 4
7 JUP 2 2
8 LMNA 2 2
9 DES 1 1
Table 2.7: Number of LOF variants in ARVC Candidate Genes
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Figure 2.5: The distribution of effect sizes and odds ratios in ARVC and HCM.
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2.3 Discussion
2.3.1 Molecular autopsy of Sudden Cardiac Death patients
The molecular autopsy of the SCD cohort showed that for a small portion of people who die suddenly
with no identifiable cause, even post-mortem, rare potentially pathogenic DNA variants harboured in genes
associated with SCD may be the answer. Throughout this study, rare variants were thought more likely
candidates because common variants with large enough effects to cause SCD were thought quite unlikely
to exist. Reasonable disease associated ion channel mutations were found in 3 (5%) probands. 2 of these
families had private mutations; mutations that are found in only that respective family. These were R1623Q
and V411M and were concomitant with negative clinical screens. The third family had a RyR2 mutation
with a malignant history but no clear phenotype. A further 6 (10%) had rare ion channel variants which
have previously been associated with Brugada Syndrome and Long QT syndrome. They were not extremely
rare in controls however, at 0.02− 0.5%. Finally, eight (14%) had rare or very rare cardiomyopathy variants
of unknown significance.
The case control tests of these samples against UCL-ex were suggestive of an excess of rare variants
in cases, but not statistically significant. This might be due to the fact that our sample size was relatively
limited. A large number of families refused access to DNA and were therefore not included in the study.
24% of the DNA that was collected was unsuitable for analysis. This highlights the need for improved
consistent guidelines as to how to adequately store tissue samples for further investigations, potentially
years later. Traditional methods of sample storage, such as Formalin Fixed Paraffin Embedded (FFPE),
have been shown to have inadequate DNA preservation [Tournier et al., 2012]. Alternatively, it may be
because our knowledge of the relevant genes and the impact different variants will have is still incomplete.
This is made more difficult because the hearts of SCD probands are structurally normal and typically there
is no associated ante-natal clinical phenotype data.
That being said, for the families that did receive a diagnosis, even if post mortem, some solace can be
gained. It might result in increased participation with proactive family genetic screening, altered reproductive
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choices or simply relief from the resolution of the mystery as to the cause of death. In conclusion, while
the approach of molecular autopsy is undoubtedly useful in SCD, its limited diagnostic yield means it can
augment but is not a viable replacement of traditional clinical testing.
2.3.2 ARVC and HCM case control analysis.
407 ARVC and 955 HCM samples were sequenced for the genes listed in Table 4 in the Appendix. These
genes are known or thought to be associated with either HCM or ARVC. Single variant and gene based case
control tests were then performed against 3587 UCL-ex ethnicity and phenotype matched controls.
Table 2.2 lists the top associations for the targeted sequencing ARVC analysis (Fisher pvalue of
≤ 1 ∗ 10−4) . This is dominated by PKP2 and DSG2, which is in agreement with the literature. The most
significantly associated variant is the previously reported splice site altering rs193922674 SNP [Gerull et al.,
2004]. The role of Titin in ARVC however is less clear. A recent study on 38 ARVC families identified 8
unique TTN variants across 7 families. One of these variants, Thr2896Ile, perfectly segregated the ARVC
phenotype in a large family [Taylor et al., 2011]. This group has gone further and associated that TTN
variant carriers are at greater risk of supraventricular arrhythmias and conduction disease [Brun et al.,
2014]. While intriguing, this has yet to be independently verified so more work needs to be done.
Table 2.3 lists the variants most associated with HCM. As is the case with ARVC, these data largely
agree with the currently understood genetic architecture of HCM; one largely driven by MYBPC3. A manual
examination of the rs1805123 KCNH2 variant showed that in multiple samples, this multiallelic locus is low
RD. This reduces our confidence in this being a true call, but the concordance between our control MAF
(0.25) and that of ExAC (0.19) in comparison to the HCM MAF of 0.38 does make this a candidate worthy
of following up. At the very least, it highlights the importance of a stringent QC process controlling for as
many parameters as possible.
RBM20 was first associated with Dilated Cardiomyopathy in 2009 [Brauch et al., 2009]. Since then,
it has further been found that it is a splicing regulator of TTN [Li et al., 2010]. In December 2015, the first
human induced Pluripotent Stem Cell (hIPSC)model of RBM20 model was published [Wyles et al., 2015].
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This took dermal fibroblasts from two patients carrying the R636S missense variant and transformed them
into hIPSC derived cardiomyocytes. These cell lines exhibited a downregulation of RBM20 concomitant
with a downregulation of the adult isoform of TTN N2B and upregulation of the foetal TTN N2BA isoform.
LDB3, CAMK2D and CACNA1C genes were also affected. The net result of these changes was that
the sarcomeres, when developed, exhibited increased sarcomeric length and decreased width. This makes
RBM20 ’s role in HCM a relatively plausible one. In our data, rs35141404 has a HCM MAF of 0.27 and has
a frequency in our ARVC cohort of 0.17 and our control frequency is 0.18. The ExAC MAF is 0.15, agreeing
with our control frequency. However, the low call rate we observed for this variant is cause for concern; a
concern somewhat lessened by the fact that the ExAC data does report the same issue at this locus. Thus,
this variant is an interesting candidate and will be further assessed with Sanger sequencing and when our
sample size increases.
Figure 2.4 characterises the SNP effect size and the odds ratio across the MAF spectrum for both
ARVC and HCM. Here, the effect size is the coefficient from the logistic regression when phenotype is
modelled as the outcome against each SNP. When all SNPs are examined together, no clear pattern is
visible. However, when one restricts this to those with a significant pvalue, it becomes clear that both the
risk odds ratio and the effect size has an inverse relationship with the MAF in controls.
The single variant tests were accompanied with gene based tests. Functional variants, non-synonymous,
frameshift or stop site altering and those with a MAF ≤ 0.05 were retained. Testing was then performed
in a number of different ways: basic Fisher & χ2 tests that counted all unfiltered variants and SKAT and
SKATO. SKAT aggregates individual SNP test statistics in a given set (here, a gene) and then calculates
the corresponding pvalue. PKP2 was the most associated ARVC gene with a SKAT p-value of 1.82 ∗ 10−33,
followed by DSG2 (1.47 ∗ 10−10) [Table 2.4]. These were the only statistically significant genes found here.
Furthermore, the top HCM genes were found to be MYBPC3 (3.73 ∗ 10−23) and MYH7 (8.3 ∗ 10−22) [Table
2.5]. The SKAT-O Loss of Function (LOF) test differs from SKAT for ARVC in that it indicates that DSP
plays a more important role than DSG2. DSP based ARVC can follow an autosomal dominant or autosomal
recessive model of inheritance and may be associated with palmoplantar keratadoma and Carvajal disease
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[Sen-Chowdhry et al., 2007]. Having access to such patient phenotype data would be informative as it would
enable us to create a more refined picture of the architecture of the subtypes of ARVC.
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Chapter 3
Analysis of Copy Number Variants in
Hypertrophic Cardiomyopathy
3.1 Introduction
Professor Perry Elliott, Dr. Luis Lopes and Dr. Petros Syrris at the Heart Hospital, University College
London, have collected a cohort of 505 patients with HCM [Lopes et al., 2013b]. A targeted panel of 41
genes (Table 5) was chosen based on the knowledge, at the time the array was designed, of the genetic basis
of HCM and ARVC. The average Read Depth across the 2.1Mb region was 120. A variant was included
in the filtered list of potentially disease-causing variants if it was both rare (defined as having a MAF of
≤ 0.5%) and non-synonymous, LOF or a splice site variant. Excluding Titin, 152 candidate variants were
identified, 89 of which were novel.
The role of copy-number variants (CNV) as a cause of hypertrophic cardiomyopathy (HCM) is
poorly studied. The aim of this chapter was to use high-throughput sequence (HTS) data combined with a
read-depth strategy, to screen for CNVs in cardiomyopathy-associated genes in a large consecutive cohort of
HCM patients. Identified CNVs were then validated by Array Comparative Genome Hybridisation (aCGH)
A large portion of this chapter is published in Lopes et al. [2015]. I did all of the CNV analysis: the read
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depth approach with ExomeDepth, designed the probes for the aCGH and employed the SVD approach of
CoNIFER.
3.2 Methods & Materials
3.2.1 Patients and Clinical Evaluation
The study cohort was comprised of 505 patients diagnosed with HCM at the Heart Hospital, University
College London, UK. A 12-lead Electrocardiogram (ECG), echocardiography and exercise testing were used
in the diagnosis. A left ventricular wall thickness on two-dimensional ECG of ≥ 13mm, after correction for
age, sex and size was the diagnostic threshold used.
3.2.2 Targeted gene enrichment and high-throughput sequencing
In total, the 41 target genes spanned a 2.1Mb region of genomic DNA [Lopes et al., 2013b] per patient.
This included exonic, intronic and certain regulatory regions, 20 of which were either associated with HCM,
ARVC or Dilated Cardiomyopathy (DCM), a related phenotype. The remaining genes are implicated in other
cardiomyopathies or arrhythmias. The capture and sequencing methodology used for the first 233 patients
has been reported in detail previously [Lopes et al., 2013b]. From the 234th patient onwards, successive
updated versions of the Agilent sample preparation protocol were used according to the manufacturer’s
instructions. The main changes referred to smaller initial quantities of genomic DNA (200 ng to 3 mg), use of
Agilent enzymes and reagents throughout the protocol, optimisations of hybridisation steps and replacement
of in-solution PCR procedure with an on-bead PCR method. Introduction of additional SureSelect indexes
allowed multiplexing of 16 samples in a single pool. The resulting index-tagged sample pools were sequenced
on the Illumina HiSeq 2000 system. Cluster generation on Illumina cBot was carried out according to the
manufacturer’s protocol. A total of 128 HCM samples (16 multiplexed samples * 8 lanes) were sequenced
(100 bp, paired end) per instrument run, using standard methods (Illumina).
The paired-end reads were then aligned using the Novalign Software V.2.7.19 against the hg19 human
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reference genome. Once duplicated regions were excluded with Picard MarkDuplicate Tool, indels and SNPs
were called with SAMtools [Li et al., 2009]. A minimum genotype quality threshold of Phred score 30 was
implemented to curate the resultant variant list. A Phred value of 30 is equivalent to a 99.9% [Ewing et al.,
1998] base call accuracy rate. Annovar was used for sample annotation [Wang et al., 2010].
3.2.3 ExomeDepth
It is recommended practice to compare a sample against another sample or set of samples to estimate a
normalised measure of RD [Plagnol et al., 2012]. This is more accurate than creating an intra-individual
measure as there is a high degree of exon to exon variability. By comparing the target region/sample against
this null, one can calculate the likelihood of the presence of a Duplication or Deletion. ExomeDepth, the R
based implementation of a RD approach, fits a beta binomial model that builds an optimised reference set
that maximises the CNV detection power [Plagnol et al., 2012]. This can work on even small (1 - 2 exons)
CNVs even in the midst of technical variability.
The samples were sequenced in 22 batches. To minimise the effect of the resultant technical vari-
ability on the CNV calling, and to generate sample sets of a size that maximises the CNV calling algorithm,
the samples were analyzed by these batches (Figure 3.1). A script was written in R that did this using
the ExomeDepth R package (on CRAN) (Figure 3.1). Sorted, indexed BAM files that had duplicate reads
removed with PICARD MarkDuplicate were used. For each sample, all other samples in its set were used as
potential controls. ExomeDepth then identifies the optimum set of sample(s) from this group to compare the
test sample against. This is done by identifying reference samples that are comparable to the test sample.
RD similarity is the main criterion.
3.2.4 CoNIFER
Another widely used bioinformatic approach to call CNVs from targeted sequencing is CoNIFER [Krumm
et al., 2012]. CoNIFER takes as input sample Reads per kilobase per milllion (RPKM) values. This is a
sequence length standardised measure of the number of reads per region. CoNIFER then uses Singular Value
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Figure 3.1: QR Codes.(A) The HCM sample sequencing plate informa-
tion. https://github.com/CianMurphy/Upgrade/blob/master/bamFileList.csv (B)
The ExomeDepth R script used to generate the CNV calls with ExomeDepth.
https://github.com/CianMurphy/Upgrade/blob/master/ExomeDepth.R
Decomposition (SVD) to remove biases in the data. If X is the mean and standard deviation standardised
RPKM values in the form of an exon by sample matrix, then the SVD of X takes the form X = USV T .
SVD is related to PCA in that the singular values S are the square roots of the eigenvectors of the covariance
matrix XXT . One can visualise the proportion of variance explained by each of the components (Singular
Values) as a screeplot (Figure 3.2). Typically, K components are removed based on the inflection point of the
scree plot to eliminate as much as noise as possible. For the screeplot included here, a K of 4 was thus chosen.
CoNIFER can detect CNVs of 3 exons or larger. These data were then exported to R, where the DNAcopy
package was used to implement the Circular Binary Segmentation (CBS) algorithm. This is a more sensitive
segmentation algorithm than the inbuilt one in CONIFER. CBS recursively splits chromosomes into either
two or three subsegments based on a maximum t-statistic. A reference distribution is used to decide whether
or not to split is estimated by permutation.
The different methods to detect CNVs have been rigourously compared against each other. In one
such study, it was found that ExomeDepth had higher sensitivity than CONTRA, XHMM and CoNIFER
[Tan et al., 2014]. Therefore, for a given set of samples, one would expect ExomeDepth to pick up the most
CNVs, albeit with a higher false positive rate. This fact helped guide our experimental design here in that
we used ExomeDepth as a first pass and combined CoNIFER and aCGH to subsequently validate the calls.
3.2.5 Array CGH
Comparative Genome Hybridisation (CGH) is a technique whereby you differentially fluorescently label two
DNA samples [Oostlander et al., 2004]. They may come from different individuals, be a tumour pair or any
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(a) Screeplot of SVD-RPKM values from a plate of 84 HCM samples.
(b) A graphical representation of the procedure for removing K SVDs.
Figure 3.2: CoNIFER analysis: Removing the components of the Singular Value Decomposition that dis-
proportionately contribute to the variance.
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other combination. Classically, the fluorescent dyes Cyanine-3 (Cy3) and Cyanine (Cy5) are used as their
emission spectra are readily distinguishable. Both the test DNA and the reference DNA are then hybridized
to cloned DNA fragments that have been spotted in a gridlike fashion on a glass slide, the ”Array” portion
of array CGH(aCGH). Subsequently, CNVs will be visible by a measurable difference in the emission spectra
of the spots.
An aCGH was designed to validate the CNVs called by ExomeDepth R script and to verify that its al-
gorithm identified all CNVs. This was done via the Agilent eArray server (https://earray.chem.agilent.com/earray/).
This was designed to cover 2.1Mb of sequence across the target genes, with one probe every 100bp (Fig-
ure 3.3). Once the aCGH probe set was designed, it was submitted to Agilent with the 12 samples of interest.
The array was built and once the samples were processed the data was sent back to us.
The data are in the form of probe intensity ratios (typically in the log2 scale). An experiment
without measurement or normalization errors run on a normal CNV null clone would yield a Log2 ratio of 0
because the test and reference sample would be equivalent [Guha, 2008]. The Log2 ratio of a heterozygous
deletion is Log2(1/2) = -1 and a heterozygous gain is Log2(3/2)= 0.58.
To determine if the aCGH called any CNVs in the 12 samples, the log2 ratios were processed in R.
SnapCGH, aCGH and limma were the principal packages used. A brief overview of the process is as follows:
Firstly, the data are read into R and a valid object is created to store it. The data are mined for the array
positional information for the clones. In this aCGH experiment, Cy5 was used to fluoresce the reference
sample, so this results in the addition of a design vector with a value of -1 (Cy3 for reference would be
given +1). The next step is to control for the background intensity for each spot to improve the resolution
later on. The ”minimum” method in snapCGH was used which simply subtracts the background value from
that of the foreground. The data are then normalized, before the segmentation model is fitted. This fits a
homogenous Hidden Markov Model (HMM). Segmentation is vital as it splits the data into probe sets that
share the same DNA copy number [Ben-Yaacov and Eldar, 2008]. Segmentation has a tendency to fit states
that have similar means, which can obfuscate the true copy number state of the sample. One method to
ameliorate this is to merge states that have means within a defined threshold. Once this has completed, the
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data are ready for plotting as identifying CNVs works well from a visualization approach.
Figure 3.3: QR Code for HCM CNV aCGH validation probes.https://github.com/CianMurphy/Upgrade/blob/master/CGH cardio.bed
The 2 colour aCGH was performed by Agilent. Their proprietary Feature Extraction software creates
detailed quality control reports, in addition to the probe intensity ratios. The Spot Finding image in Figure
3.4 allows you to determine whether or not the spots have been correctly located centrally on the array. If
this was not the case, the results would be unreliable. The bottom left table in this figure details population
attributes. If this showed a greater than expected number of non-uniform or population outliers then this
would indicate a hybridization/wash step error. The plots above this table show the spatial distribution
of both the population and non-uniform outliers on the array. This is a useful method to determine if a
given subset of samples are outliers. The panel ’Evaluation Metrics for CGH QCMT Sep09’ describes array
attributes such as background noise and the signal to noise ratio and offers suggestions as to which do or do
not meet their quality thresholds. This is a guide to assist further evaluation. Here, it is noted that the red
background noise is high, but in practise there was no issue in calling CNVs from this sample. The histogram
of Signals Plots the number of points in discrete intensity bins against the log2 of the processed signal to give
the shape and level of signal distribution. Figure 3.5 top plot shows the spatial distribution of the positive
and negative log ratios. A lack of discernible pattern in this is what is expected. Figure 3.5 bottom plot
shows the log of the red background corrected signal against the log of the green background corrected signal
for non-control inlier features. The linearity or curvature of this is a guide for choosing the appropriate
background method choices as this plot should be linear. The intersection of the red horizontal and vertical
lines shows the position of the median signal while the numbers below the plot indicate the number of non
control features that have a background corrected signal less than zero. Overall, these reports show the
aCGH was performed to a high quality, allowing confidence in their data.
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QC Report - Agilent Technologies : 2 Color CGH
Date Wednesday, August 14, 2013 - 17:24 Sample(red/green)
User Name scan FE Version 10.7.3.1
Image 0938_UCL_255024210023_S01 [1_1] BG Method Detrend on (NegC)
Protocol CGH_107_Sep09 (Read Only) Multiplicative Detrend True
Grid 050242_D_F_20130617 Dye Norm Linear
Saturation Value 65526 (r), 65525 (g)
Spot Finding of the Four Corners of the Array
Grid Normal
Outlier Numbers with Spatial Distribution
384 rows x 164 columns
•Red FeaturePopulation •Red Feature NonUniform
•Green FeaturePopulation•Green Feature NonUniform
Feature Red Green Any % Outlier
Non Uniform 9 13 16 0.03
Population 64 59 108 0.17
Evaluation Metrics for CGH_QCMT_Sep09 : 
Excellent (7) ; Good (3) ; Evaluate (1) 
Metric Name Value Excellent Good Evaluate
IsGoodGrid 1.00 >1 NA <1
AnyColorPrcntFeatNonUn... 0.03 <1 1 to 5 >5
DerivativeLR_Spread 0.12 <0.20 0.20 to 0.30 >0.30
gRepro 0.10 0 to 0.05 0.05 to 0.20 <0 or >0.20
g_BGNoise 8.02 <5 5 to 10 >10
g_Signal2Noise 168.67 >100 30 to 100 <30
g_SignalIntensity 1352.55 >150 50 to 150 <50
rRepro 0.09 0 to 0.05 0.05 to 0.20 <0 or >0.20
r_BGNoise 16.20 <5 5 to 10 >10
r_Signal2Noise 128.10 >100 30 to 100 <30
r_SignalIntensity 2074.67 >150 50 to 150 <50
♦ Excellent ♦ Good ♦ Evaluate 
Histogram of Signals Plot (Red)
Histogram of Signals Plot (Green)
Figure 3.4: Quality metrics for sample 0938 UCL 255024210023 S01 CGH 107 Sep09 from the Agilent
aCGH.
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Figure 3.5: Quality metrics for sample 0938 UCL 255024210023 S01 CGH 107 Sep09 from the Agilent
aCGH.
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3.3 Results
3.3.1 ExomeDepth HCM CNVs
ExomeDepth was the first method used to identify CNVs in this cohort [Plagnol et al., 2012]. In brief, the
mean value of the per-sample average RD in the exonic target region across the samples was 348.09±142.59.
Combining all samples and taking the mean value across all samples, 92.41% of the target region was covered
to a RD of 15 or more. A 2010 study generated a 42 million probe tiled microarray that identified 11,700
CNVs, thought to include 80-90% of common CNVs [Conrad et al., 2010]. These data are incorporated into
ExomeDepth and are used as an initial filter to remove common variants on the basis that they are unlikely
to be disease causing. At our selected confidence threshold level after filtering, 12 CNVs in 12 patients (2.4%
of the 505 cohort) were identified using ExomeDepth.
3.3.2 aCGH Validation of the HCM CNVs
The Log2 ratios have been normalised, segmented and quantified. To plot the varying intensities from probe
to probe, a region file was first drawn up demarcating the location of the 41 genes of interest. 4 of the 12
most likely CNVs from ExomeDepth, in 4 patients (0.8% of the cohort) were validated by aCGH:
• one large deletion in MYBPC3 (involving 4 exons) shown in Figure 3.6
• one duplication of the entire TNNT2 gene shown in Figure 3.7
• one large deletion in PDLIM3 (involving the first 4 exons) shown in Figure 3.8
• and one large duplication in LMNA (involving 5 exons) in Figure 3.9
Three of them did not harbour any variant in a potentially causal sarcomere gene and one is a carrier of a
variant of unknown significance in TNNT2.
Eight CNVs were not validated by the aCGH analysis, including three single exon duplications and
one single exon deletion in MYBPC3, two two-exon deletions and one single exon duplication in TNNI3 and
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one single exon duplication in ACTC1 (Figures 3.10 - 3.17). Owing to the high probe density of the aCGH
in these genes, my interpretation is that these 8 CNV calls are false positives. Nevertheless, I cannot exclude
that some of these CNV calls are real but too small to be validated by other techniques. The aCGH did not
identify additional CNV calls in these 12 samples.
Because the accuracy of CNV calling algorithms are limited [Tan et al., 2014] I compared the
ExomeDepth CNV calls with the output of CoNIFER [Krumm et al., 2012]. Using the suggested settings,
CoNIFER identified a much larger number of CNV calls (120 calls overall). CoNIFER called the 4 CNVs
validated by the aCGH experiment but did not call any of the 8 CNVs not validated by the aCGH experiment
(Figures 3.10 - 3.17). Owing to the intuitively excessive number of CNV calls, combined with the fact that a
visual analysis of CoNIFER output plot was largely unconvincing, I assumed that owing to technical factors
specific to this experiment, the false positive rate of CoNIFER was high and did not follow-up these calls.
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(a) Panel (A): ExomeDepth plot. The red crosses indicate the ratio of observed/expected number of reads (RR).
The grey-shaded area is the estimation of the 99% Confidence Interval for the RR in the absence of a CNV call. The
X axis shows the affected gene plotted underneath, with the vertical lines showing the location of the exons.(B)
aCGH plot. The blue line represents the fitting of a homogenous Hidden Markov Model for Segmentation by
snapCGH.
(b) Panel(C): The CNV as called by CoNIFER using Sin-
gular Value Decomposition. The red line is the result
from the Circular Binary Segmentation algorithm applied
to the CoNIFER data.
Figure 3.6: Deletion in MYBPC3 in patient H1.
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(a) Panel (A): ExomeDepth plot. The red crosses indicate the ratio of observed/expected number of reads (RR).
The grey-shaded area is the estimation of the 99% Confidence Interval for the RR in the absence of a CNV call.
The X axis shows the affected gene plotted underneath, with the vertical lines showing the location of the exons.
(B) aCGH plot. The blue line represents the fitting of a homogenous Hidden Markov Model for Segmentation.
(b) Panel(C): The CNV as called by CoNIFER using Sin-
gular Value Decomposition. The red line is the result
from the Circular Binary Segmentation algorithm applied
to the CoNIFER data.
Figure 3.7: Patient H2 Exonic Duplication in TNNT2.
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(a) Panel (A): ExomeDepth plot. The red crosses indicate the ratio of observed/expected number of reads (RR).
The grey-shaded area is the estimation of the 99% Confidence Interval for the RR in the absence of a CNV call.
The X axis shows the affected gene plotted underneath, with the vertical lines showing the location of the exons.
(B) aCGH plot. The blue line represents the fitting of a homogenous Hidden Markov Model for Segmentation.
(b) Panel(C): The CNV as called by CoNIFER using Sin-
gular Value Decomposition. The red line is the result
from the Circular Binary Segmentation algorithm applied
to the CoNIFER data.
Figure 3.8: Patient H3 Exonic Duplication in PDLIM3.
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(a) Panel (A): ExomeDepth plot. The red crosses indicate the ratio of observed/expected number of reads (RR).
The grey-shaded area is the estimation of the 99% Confidence Interval for the RR in the absence of a CNV call.
The X axis shows the affected gene plotted underneath, with the vertical lines showing the location of the exons.
(B) aCGH plot. The blue line represents the fitting of a homogenous Hidden Markov Model for Segmentation.
(b) Panel(C): The CNV as called by CoNIFER using Sin-
gular Value Decomposition. The red line is the result
from the Circular Binary Segmentation algorithm applied
to the CoNIFER data.
Figure 3.9: Patient H4 Exonic Duplication in LMNA.
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Figure 3.10: The first of eight unconfirmed CNVs called by ExomeDepth. Here, it called a duplication
in the gene MYBPC3 of patient H5 (panel A). The red crosses indicate the ratio of observed/expected
number of reads (RR). The grey-shaded area is the estimation of the 99% Confidence Interval for the RR in
the absence of a CNV call. The X axis shows the affected gene plotted underneath, with the vertical lines
showing the location of the exons. (B) The subsequent aCGH/snapCGH (Panel B) plot. The blue horizontal
line represents the fitting of a homogenous Hidden Markov Model for Segmentation. (C) CoNIFER plot.
The red line is the result from the Circular Binary Segmentation algorithm applied to the CoNIFER data.
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Figure 3.11: The second of eight unconfirmed CNVs called by ExomeDepth. Here, it called a duplication
in the gene MYBPC3 of patient H6 (panel A). The red crosses indicate the ratio of observed/expected
number of reads (RR). The grey-shaded area is the estimation of the 99% Confidence Interval for the RR in
the absence of a CNV call. The X axis shows the affected gene plotted underneath, with the vertical lines
showing the location of the exons. (B) The subsequent aCGH/snapCGH (Panel B) plot. The blue horizontal
line represents the fitting of a homogenous Hidden Markov Model for Segmentation. (C) CoNIFER plot.
The red line is the result from the Circular Binary Segmentation algorithm applied to the CoNIFER data.
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Figure 3.12: The third of eight unconfirmed CNVs called by ExomeDepth. Here, it called a duplication
in the gene MYBPC3 of patient H7 (panel A). The red crosses indicate the ratio of observed/expected
number of reads (RR). The grey-shaded area is the estimation of the 99% Confidence Interval for the RR in
the absence of a CNV call. The X axis shows the affected gene plotted underneath, with the vertical lines
showing the location of the exons. (B) The subsequent aCGH/snapCGH (Panel B) plot. The blue horizontal
line represents the fitting of a homogenous Hidden Markov Model for Segmentation. (C) CoNIFER plot.
The red line is the result from the Circular Binary Segmentation algorithm applied to the CoNIFER data.
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Figure 3.13: The fourth of eight unconfirmed CNVs called by ExomeDepth. Here, it called a duplication
in the gene MYBPC3 of patient H8 (panel A). The red crosses indicate the ratio of observed/expected
number of reads (RR). The grey-shaded area is the estimation of the 99% Confidence Interval for the RR in
the absence of a CNV call. The X axis shows the affected gene plotted underneath, with the vertical lines
showing the location of the exons. (B) The subsequent aCGH/snapCGH (Panel B) plot. The blue horizontal
line represents the fitting of a homogenous Hidden Markov Model for Segmentation. (C) CoNIFER plot.
The red line is the result from the Circular Binary Segmentation algorithm applied to the CoNIFER data.
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Figure 3.14: The fifth of eight unconfirmed CNVs called by ExomeDepth. Here, it called a duplication in the
gene TNNI3 of patient H9 (panel A). The red crosses indicate the ratio of observed/expected number of reads
(RR). The grey-shaded area is the estimation of the 99% Confidence Interval for the RR in the absence of a
CNV call. The X axis shows the affected gene plotted underneath, with the vertical lines showing the location
of the exons. (B) The subsequent aCGH/snapCGH (Panel B) plot. The blue horizontal line represents the
fitting of a homogenous Hidden Markov Model for Segmentation. (C) CoNIFER plot. The red line is the
result from the Circular Binary Segmentation algorithm applied to the CoNIFER data.
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Figure 3.15: The sixth of eight unconfirmed CNVs called by ExomeDepth. Here, it called a duplication in
the gene TNNI3 of patient H10 (panel A). The red crosses indicate the ratio of observed/expected number of
reads (RR). The grey-shaded area is the estimation of the 99% Confidence Interval for the RR in the absence
of a CNV call. The X axis shows the affected gene plotted underneath, with the vertical lines showing the
location of the exons. (B) The subsequent aCGH/snapCGH (Panel B) plot. The blue horizontal line
represents the fitting of a homogenous Hidden Markov Model for Segmentation. (C) CoNIFER plot. The
red line is the result from the Circular Binary Segmentation algorithm applied to the CoNIFER data.
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Figure 3.16: The seventh of eight unconfirmed CNVs called by ExomeDepth. Here, it called a duplication in
the gene TNNI3 of patient H11 (panel A). The red crosses indicate the ratio of observed/expected number of
reads (RR). The grey-shaded area is the estimation of the 99% Confidence Interval for the RR in the absence
of a CNV call. The X axis shows the affected gene plotted underneath, with the vertical lines showing the
location of the exons. (B) The subsequent aCGH/snapCGH (Panel B) plot. The blue horizontal line
represents the fitting of a homogenous Hidden Markov Model for Segmentation. (C) CoNIFER plot. The
red line is the result from the Circular Binary Segmentation algorithm applied to the CoNIFER data.
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Figure 3.17: The eighth of eight unconfirmed CNVs called by ExomeDepth. Here, it called a duplication
in the gene ACTC1 of patient H12 (panel A). The red crosses indicate the ratio of observed/expected
number of reads (RR). The grey-shaded area is the estimation of the 99% Confidence Interval for the RR in
the absence of a CNV call. The X axis shows the affected gene plotted underneath, with the vertical lines
showing the location of the exons. (B) The subsequent aCGH/snapCGH (Panel B) plot. The blue horizontal
line represents the fitting of a homogenous Hidden Markov Model for Segmentation. (C) CoNIFER plot.
The red line is the result from the Circular Binary Segmentation algorithm applied to the CoNIFER data.
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3.4 Discussion
505 consecutive and unrelated patients that have been diagnosed with HCM underwent targeted exome
sequencing of 41 genes that are either known or thought to be involved with disease pathogenesis. In
addition to the SNP analysis discussed in [Lopes et al., 2013b], a RD based CNV identification strategy was
used here. This was motivated by evidence that approximately 50-60% of HCM patients remain genetically
undiagnosed [Lopes et al., 2013a]. This methodology was however hindered by the recognized difficulty in
short-read approaches that negatively affects sensitivity/specificity [Duan et al., 2013].
In an attempt to deal with these technical issues, two other approaches were used to validate the
12 calls made by ExomeDepth. Both CoNIFER, which utilised an SVD-RPKM approach, and the Array
CGH cytogenetic method validated 4/12 calls. This is in line with the previously high false positive rate of
all available algorithms [Duan et al., 2013; Tan et al., 2014]. Using this multi-step design, we detected and
validated potentially disease causing CNVs in 0.8% of samples. This has direct implications for diagnostic
and counselling services: some patients without mutations found through direct sequencing may still have
transmissible CNVs in sarcomeric protein genes.
Information about the contribution of CNVs for the genetics of cardiomyopathy is limited. Reports
in HCM include a Multiplex Ligation-Dependent Probe Amplification (MLPA) based study that failed to
detect any CNVs in MYBCP3 or TNNT2 in a cohort of around 100 unrelated HCM patients [Bagnall et al.,
2010]. Additionally, work on a single family identified a large MYH7 deletion as the probable cause [Marian,
2012], which was detected using a PCR-based method and more recently another MPLA study found a single
MYBPC3 deletion [Chanavat et al., 2012] in a cohort of 100 unrelated genotype-negative patients.
Despite the fact that CNVs were only detected in a small percentage of our cohort, it raises the
possibility that a patient with no identifiably causative variants can in fact harbour a structural variation
not detected by direct sequencing. Consistent with this view, 3 out of 5 patients with confirmed CNVs did
not carry any potentially causal variants in a sarcomeric or related gene, and a fourth patient only had a
variant of unknown significance in TNNT2.
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The patient with the most plausible single-nucleotide variant candidate (R495G in MYBPC3 ) also
carries a CNV in the gene LMNA. This is an interesting finding because LMNA has traditionally been
associated with DCM and not HCM [Vaikhanskaya et al., 2014; Pe´rez-Serra et al., 2015]. Furthermore,
mutations in LMNA also cause Familial Partial Lipodystrophy 2 (FPL2), one of a group of heterogenous
disorders that cause abnormal fat distribution. While DCM causing variants can occur across the gene, FPL2
variants are generally restricted to the the C-terminal [Lalitha Subramanyam, 2010]. Intriguingly, there have
been reports of patients who present with FPL2 and are subsequently found to also have HCM [Arau´jo-Vilar
et al., 2008; Chirico et al., 2014]. Information about the cholesterol levels or patterns of deposition and
other FPL2 criteria were not available for the patients studied here. Analysis of such clinical data would be
a natural way to investigate the potential role of LMNA in HCM further and to expand on recent work on
refining phenotypes of a subset of these patients [Lopes et al., 2014].
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Chapter 4
A novel method to deal with technical
artefacts in exome sequencing data
4.1 Introduction
Population Stratification, Cryptic Relatedness (CR) and GC bias are three of many possible reasons why
artefacts may exist in association studies based on High Throughput Sequencing data. This can confound
the association between marker genotype and disease. Various methods have been implemented to account
for this. One of the most commonly used involves performing Principal Component Analysis to identify
orthogonal axes (PCs) which explain most genetic variation, which typically corresponds to PS and CR,
then including the top PCAs as covariates in the regression to allow for any phenotypic variation caused by
these sources. This can be incorporated into a PCA, thereby controlling for PS. Association studies that
utilise pooled data, perhaps to increase study power, are more likely to suffer from technical artefacts/batch
effects. These originate from the heterogenous nature of such studies, whether the samples can be grouped
as cohorts that differ in their preparation, storage, sequencing technology etc. Spurious associations will
arise when case/control ratios differ between cohorts; at the most extreme when some cohorts are all cases
or all controls.
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I introduce the concept of Technical Kinship (TK). TK is defined as a similarity matrix estimated
on the SNP and INDEL missing/nonMissing matrix. Adapting the PCA approach of controlling for PS,
we attempt to control for this by removing ten ”technical” Principal Components in the LMM. This novel
idea fails, highlighting the fact that technical bias in the data renders a more subtle effect than PS. By
then using a LMM with a random effect with a correlation structure specified by the TK, I improve the
ability to control for SNPs/INDELS that are more likely artefacts than true positives. This reduction of
false positive inflation readily leads to more accurate association studies, thereby increasing the ability to
identify disease causing genes. This analysis is performed on the UCL Exome Consortium of ∼ 4500 disease
exomes which includes both Hypertrophic Cardiomyopathy (HCM) and Arrhythmogenic Right Ventricular
Cardiomyopathy (ARVC) samples.
Different HTS machines and chemistries have different RD profiles but in general low coverage is a
sign of low quality. This novel LMM is further refined by including a RD similarity matrix. The combination
of this RD matrix and the TK matrix yields an improved result when compared to the standard linear
regression with no such correction for artefacts.
4.1.1 Retinal Dystrophy - a motivating example
Retinitis Pigmentosa refers to a group of inherited retinal diseases that are characterised by photoreceptor
and retinal pigment epithelium degeneration [Testa et al., 2014]. Symptoms typically include night blindness,
visual field constriction and reduced electroretinographic waves (Figure 4.1). The gene Retinitis Pigmentosa
GTPase Regulator (RPGR) is known to be responsible for ∼ 8.5% cases of the autosomal dominant form
[Meindl, 1996; Churchill et al., 2013]. In a recent study we found a novel association between the gene
Tubulin Tyrosine Ligase-Like family member 5 (TTLL5 ) and 28 individuals with ”cone-first” retinal disease
and clinical features that were atypical for ATP-binding cassette, sub-family A (ABC1 ), member 4 ABCA4 -
retinopathy [Sergouniotis et al., 2014]. TTLL5 came second only to RPGR (Table 4.1). Two RPGR LOF
variants, c.1586 1589delAGAG and c.401delT, a nonsense c.1627G>T and a missense c.1627G>A were found
in the 88 cases examined (Figure 4.2).
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Figure 4.1: Color Fundus Photographs, Fundus Autofluorescence Images, and Foveal Optical Coherence
Tomographs of the Right Eyes of Subjects CD1, CD2, CD3, and CD5. Images from subjects CD1 (aged 35
years; A), CD2 (aged 45 years; B), and CD5 (aged 53 years; D) are highly similar. Fundus autofluorescence
imaging revealed a high-density concentric perifoveal ring surrounding irregular foveal autofluorescence in
subjects CD1, CD2, and CD5; outside this ring, normal signal was observed (A, B, and D). In subject CD3
(aged 46 years; C), hypoautofluorescent patches were noted in the fovea and parafovea; this was combined
with irregular autofluorescence outside the foveal region, suggesting more generalized retinal pigment ep-
ithelial dysfunction (C). Optical coherence tomography revealed abnormalities consistent with photoreceptor
loss; they were either confined to the foveal region (subjects CD1, CD2, and CD5) or observed throughout
the scan (subject CD3). Scale bars represent 200 m. Adapted from Sergouniotis,Chakarova, Murphy et al,
2014. I did not make this figure, included for illustration.
The support for these two genes is therefore well founded. However, when one looks at the third gene
in the list, C1R, it becomes more difficult to verify its association. C1R is one of the proteases involved in
the complement pathway, a vital part of the immune system [Rossi et al., 2014]. This fact alone fails to lend
credence to it being thought of as a real association. Upon further examination of this gene, it was found
that its entire signal was driven by the presence of the same LOF variant, chr12:7244369C>T, in 3 cases.
As explained in detail in the Methods section (4.4.5), a PCA was performed on the missing/nonMissing
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Figure 4.2: The number of presumed LOF alleles in both cases and controls (x-axis) and their proportions
in the 23 retinal dystrophy samples (y-axis). The area above the red line is the gene based p-value threshold
of p ≤ 10−4. I did not make this figure, included for illustration.
genotypes from UCL-ex to examine variant artefactual status. By including each of the PCs individually
as covariates in separate linear regressions of phenotype on genotype, it was possible to determine that
this variant is in fact strongly associated with the the 66th Principal Component (pvalue of 5.54e-25). The
carriers of this SNP are outliers on the relevant PCA plot (Figure 4.3). It should be noted however that as
Figure 4.4 illustrates, typically PCs after the 5th explain little of the total variance so the 66th is unlikely
to influence the results significantly.
The C1R signal was thus declared an artefact. This filtering methodology is not the norm and differs
largely from that employed by GATK (Section 1.8.3 on page 18). Be that as it may, it is an onerous approach
as it required manually examining the most significant genes. A more thorough and efficient approach is
therefore needed. That is one aim of this thesis.
Gene Position CaseCount ControlCount SKAT Binomial
RPGR chr23:38128893-38182760 4 2 0.000384659 2.57163e-06
TTLL5 chr14:76127372-76368547 4 5 0.000851088 2.05575e-05
C1R chr12:7187848-7244382 3 3 0.000422697 0.000164897
OR5AU1 chr14:21623166-21624176 2 0 0.003364555 0.000420963
CDH3 chr16:68679283-68732274 2 0 0.003117345 0.000420963
Table 4.1: Top 5 Retinal Dystrophy candidate genes based on a binomial test for excess of variants in 23
cases compared to 1098 controls.
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Figure 4.3: The first two principal components from the technical PCA. Highlighted are the locations of
samples that contain the minor allele for the variant causing the false positive (chr12:7244369).
4.1.2 Crohn’s Disease
The inflammation in Crohn’s Disease (CD) is a transmural form of IBD (occurs across the entire wall of
an organ). It can affect the entire gastrointestinal (GI) tract, from the mouth to the anus (Marshall et al.,
2010). The affected regions may be discontinuous throughout the GI tract, and may locally involve strictures,
abscesses or fistulas. Other symptoms include diarrhoea or constipation, abdominal pain, passing blood and
signs of clinical obstruction (Baumgart and Sandborn, 2007). Diagnosis of CD is made by endoscopy and
histology (Benevento et al., 2010). In addition to the incidence of CD varying from country to country, it
also fluctuates between ethnic groups. The prevalence is 2-4 fold higher in people of Ashkenazi Jewish origin
compared to non-Jewish Europeans [Kenny et al., 2012]. 800 such patients are included in UCL-ex.
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Figure 4.4: Principal Component Analysis of the Combined 1000 Genome Project and UCLex data for
missingness estimation. (A) The samples are the dots, coloured on a scale from dark to light blue where the
lighter the dot the higher the percentage of that samples SNPs that were not successfully called. (B) Same
samples, but now they are coloured based on what research group they came from. (C) Scree plot showing
the level of variance explained by each of the top 20 PCs.
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4.1.3 Chapter aims
Dr. Vincent Plagnol created a pipeline that performs the initial alignment and variant calling of the UCL-ex.
The work here builds on this, extending the pipeline to perform quality control, filtering and case control
tests for all phenotypes within. This was all my work.
As mentioned already, HTS data can suffer from artefacts derived from many sources. These can
be more apparent in a dataset such as UCL-ex where samples from multiple sources are pooled and all have
rare diseases. This chapter is devoted to an attempt to create a novel statistical model that adapts classical
methods from population genetics to try solve this problem. Dr. Plagnol and Dr. Doug Speed assisted with
technical and statistical advice while the implementation and testing is my work.
4.2 Methods
4.2.1 UCL-ex Samples
Table 4.2 lists the breakdown of the samples, by number of samples and disease.
Phenotype #Samples
Inflammatory Bowel Disease 799
Huntington’s Disease 48
Ophthalmology 71
Ophthalmology 38
Ophthalmology 101
Ophthalmology 90
Ophthalmology 23
Ophthalmology 24
Ophthalmology 23
Dermatology 63
Sudden Cardiac Death 98
Keratoconus 12
Primary Immunodeficiency 128
Prion Disease 1112
Epilsepsy 164
ARVC 28
Bone Marrow Failure 184
Cone Rod Dystrophy 40
Table 4.2: UCLex Sample Information. Phenotype and number of samples
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4.2.2 Data quality assessment
As might be expected, combining samples that have been prepared differently is not without some difficulty.
For the most part, there is a high concordance rate. However, despite this, some SNPs will not be called in one
or more methods (Figure 4.5A). The mean failure rate within each group was also examined (Figure 4.5B).
Figure 4.5: Genotyping call failure rate (A) across all samples within UCL-ex and (B) by group.
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4.2.3 Attempting to identify samples with similar missingness patterns
Principal Component Analysis
A set of 5000 SNPs were chosen that are known to be well covered across all commonly used sequencing
technologies. This was used because it would enable the PS control to be free from any bias associated
with sample preparation differences. The 1000 Genome Project (1KG) provides a valuable resource of 1092
samples of known ancestry that have been sequenced with low-coverage genome and exome sequencing
[Abecasis et al., 2012]. These data were combined with the UCL-ex samples at these 5000 loci. A PCA was
then run on this subset. Generally, using the first two PCs is regarded as enough to adequately control for
large scale PS [Price et al., 2006]. By comparing these first two PCs, one can readily see the separation of
different populations (Figure 4.6). This PCA will be herein referred to as PCpop.
In an attempt to identify any patterns of missingness in the data, the genotype matrix was converted
to a missing/nonMissing matrix. Unlike PCpop, this was performed on all SNPs as the sample preparation
differences are of interest here. Regardless of exact genotype, if a SNP in a particular sample is called it was
recoded as 1. If it was not called it was coded as 0. A PCA is then performed on this matrix to identify
patterns of missingness (PCtech). This can be visualised in the same way as the PCpop (Figure 4.4A). As this
shows, the first two PCs of this technical PCA can readily discriminate between samples that exhibit different
missingness patterns. To understand this better, one can alternatively colour the samples based upon what
research group they come from (Figure 4.4B). There is clear structure visible in the data. Removing samples
based on this to create a more homogenous data set was attempted but the result is the removal of too many
samples to be acceptable.
Adapting ADMIXTURE
ADMIXTURE is a model based clustering method that is used in population genetics to probabilistically
assign samples to one of M populations, whether or not M is known. Traditionally, this is implemented on a
matrix of sample genotypes and samples with similar haplotypes clustering together. As per the Pima Indian
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Figure 4.6: Principal Component Analysis of the Combined 1000 Genome Project and UCLex data for
population estimation. The 1000G samples are yellow circles and the UCL-ex samples are shown as blue
crosses. The coordinates for the different populations of the 1000G samples are shown. The green box
demarcates the location of the Caucasian samples (CEU,TSI,GBR,IBS,FIN).
example mentioned in the introduction, restricting analyses to a closely matched population, as opposed to
performing it on all samples can yield better quality data. The hypothesis here was that if it was possible
to identify a group of samples (both cases & controls) that have a similar patterns of missingness, then this
would allow for the calculation of more accurate case control association statistics.
To achieve this, the missing/nonMissing matrix was first converted to PLINK format [Purcell et al.,
2007]. This was then supplied to ADMIXTURE, which was then ran 24 times, each time M was specified
as a unique integer between 1 and 24. 24 was chosen as the maximum number of theoretical groups based
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on the known number of batches of samples in UCL-ex (23). Figure 4.7 shows the estimated population
assignation for M = 1:8.
ADMIXTURE plot of Missingness in UCLex
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Figure 4.7: ADMIXTURE plot of the UCLex data illustrating the clustering of samples based on their
missingness patterns. The y-axis shows the clustering of samples based on differing values of M, the sub-
population limit for the ADMIXTURE algorithm. In each horizontal section, samples that are coloured the
same are predicted by ADMIXTURE to have similar patterns of missingness. The individual samples are
represented as vertical lines along the x-axis, with the grouping of samples based on their respective groups
of origin labelled.
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4.2.4 Mixed Model Association Testing
Imagine a given cohort comprised of distinct case and control samples. It is routine to imagine that sample
preparations can differ between groups, at a rate higher than the within group variability (Figure 4.4).
This can introduce confounding when one progresses to case-control association studies. This can present
as not overly dissimilar to population stratification and cryptic relatedness, which are essentially the same
confounder [Astle and Balding, 2009].
When testing SNPs for association with a phenotype, the basic linear model is most commonly used
(Equation 4.1), where Y contains the phenotype, Z covariates, α fixed effects, Xj is the SNP being tested
and βj its effect size. The noise e is assumed to be normally distribution, e ∼ N(0, σ2e)). This is typically
solved using a score test, which estimates βˆj and its standard error, then tests whether βˆj is significantly
non-zero.
Y = Zα+ βjXj + e (4.1)
Generally, the covariates might include clinical factors such as age and sex, as well as often including
top axes from PCA, in order to guard against population structure, as described above. In recent years,
mixed model association testing has become more popular, where a random effect term is added to the basic
linear model (Equation 4.2):
Y = Zα+ βjXj + g + e (4.2)
g is a random effect, with distribution N(0,Kσ2g), where K is a specified kinship matrix, which is a measure
of pairwise similarity across individual. Most commonly, K = XXT /N , where the matrix X contains the
standardized genotypes for the N SNPs, in which case we have Equation 4.3, where I is is the Identity matrix.
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V ar(Y ) = σ2gXX
T /N + σ2eI (4.3)
Y = Zα+ βjXj +
N∑
l=1
γlXle with γjN(0, σ
2
g/N) (4.4)
Written this way (Equation 4.4), it becomes clear that mixed model analysis is equivalent assuming
each SNP used when constructing the kinship matrix contributes to the phenotype with effect size γl. The
random effect g is designed to pick up patterns due to PS and CR, and can also increase power by accounting
for the contribution of causal variants away from the SNP being tested. Moreover, this approach avoids the
need to decide how many PCs to include.
The aim of this chapter is to consider alternatives kinship matrices. Therefore, instead of representing
genome-wide correlations across SNPs, we consider constructing K to reflect patterns of missingness and
variance in RD.
4.2.5 Controlling for Read Depth
Another manifestation of the differing results from different capture technologies, or indeed from something as
specific as the discrepancies between one lab’s standard protocol to anothers might be a regional fluctuation
in RD. For variant calling, particularly CNV identification, regional RD can be an important determinant of
whether or not a call is made. However, most HTS technologies utilise a Polymerase Chain Reaction (PCR)
amplification step, which introduces a bias in the library [Aird et al., 2010]. This skewed representation of
reads can hinder accurate calling. A mostly effective way to control for this is to simply remove variants that
have a depth below a given threshold. This is standard practise for many association studies [DePristo et al.,
2011], with Picard (http://broadinstitute.github.io/picard/faq.html) being a widely used implementation.
It has been recently shown though that this practise can introduce a bias, one that increases with RD [Zhou
et al., 2014]. One goal of this project is therefore to attempt to refine Equation 4.3 to incorporate a correction
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for RD. The logic is that one can create a ’Read Depth Kinship’ matrix so that including it in the LMM
will control for RD without the need for filtering. This is similar to the methods of calculating traditional
kinships based on genotype in order to estimate and therefore control for ancestry.
4.2.6 Single Variants
To clarify, the models listed here are not all part of the final model used in the results section; they are
instead included to discuss the process of model development.
These models were created and implemented with the help of Dr. Vincent Plagnol and Dr. Doug
Speed.
Model 1 - Establishing a baseline with a standard Fixed Effect Linear Regression
Equation 4.5 was the basic model run for SNP j. Here, the covariates (Z) are PCpop, the fixed effects
Principal Components. Figure 4.8A illustrates the distribution of resultant pvalues. This clearly displays a
false positive inflation, highlighting the need for correction.
Y = PCpopα1 + βjXj + e (4.5)
Model 2 - Adding Technical Principal Components to the Linear Regression
In the field of population genetics, the first two principal components are often used in a model to control for
population stratification. The technical PCs were used here in a similar way to try to control for technical
artefacts/bias. To that end, the top 10 PCtechs were added as covariates into the model (Equation 4.6).
This did not have a noticeable correction effect as shown by the pvalue distribution in Figure 4.9.
Y = PCpopα1 + PCtkα2 + βjXj + e (4.6)
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Figure 4.8: QQplots of Single Variant LMM with technical kinship correction on the PID cohort with the
rest of UCL-ex as controls. The threshold of ”common”, in terms of observed counts of a particular variants
minor allele, was varied to determine the least stringent useful cutoff.
Model 3- Linear mixed model with traditional kinship matrix.
As introduced in Section 1.7, SNP kinship matrices in LMMs can control for many confounders. Given that
the PCs in the previous section did not work, I then tried Equation 4.7 which includes such a kinship matrix,
gSNP .
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Figure 4.9: QQplots of Single Variant Linear Regression with ten technical Principal Components included to
control for technical artefacts. This analysis was performed on the Sudden Cardiac Death (SCD) , Primary
Immunodeficiency (PID) and Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) cohorts. The
”base” QQplots include no artefact correction. These are compared to the ”tech” models that do include
these covariates.
Y = PCpopα1 + βjXj + gSNP + e with gSNP ∼ N(0, XXT /Nσ2SNP ) (4.7)
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Model 4 - Adding the technical kinship matrix into the Linear Mixed Model
Essentially, Equation 4.8 differs from Equation 4.5 solely by replacing the traditional SNP kinship Matrix
with the TK kinship previously described. The theory behind this is that SNPs that are artefacts will be
explained by TK and therefore will not retain statistical significance as they will be controlled for. In theory,
this should perform better than Equation 4.6 at correcting for artefacts as the kinship matrix will explain
all the variability attributable to missingness.
Y = PCpopα1 + βjXj + gTK + e with gTK ∼ N(0, TKσ2TK) (4.8)
Model 5 - Addition of Read Depth Kinship Matrix.
The final model builds upon Equation 4.8 by adding a RD Kinship Matrix to further control for the data
artefacts. The log of the raw RD values was used to gain a more sensible representation and in an attempt
to reduce its correlation with TK. Ten SNP PCs and five Hapmap PCs were further included to eliminate
PS, creating the final model shown as Equation 4.9. SNPs that had a MAF of ≥ 1%, missingess rate of
≤ 20% and a Hardy-Weinberg Equilibrium (HWE) pvalue of ≥ 0.001 were kept for this analysis.
Y = PCpopα1 + βjXj + gTK + gRD + e with gTK ∼ N(0, TKσ2TK) and gRD ∼ N(0, RDσ2RD)
(4.9)
4.2.7 Computational cost considerations
As discussed in Section 1.7, exact solving of the mixed model for each SNP is computationally feasible with
just one kinship random effect. However, we progress to situations with more than one kinship such as
Equation 4.9 in which case it is necessary to use the approximation used by GRAMMAR.
Performing a GWAS on a dataset the size of UCL-ex, with 4500 WES’ at the time of writing, is
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computationally demanding. The burden of such LMMs are well known in the literature, as the computation
time increases to the scale of n3 Zhang et al. [2010]; Yu et al. [2006]. This was mentioned in Section 1.7.
Throughout this thesis, PCs were used instead of full Kinship matrices where possible as they are far less
computationally demanding while still offering adequate correction for PS.
LMMs do however offer the ability to correct for population stratification and cryptic relatedness
alongside NGS artefacts by Variance Component Estimation (VCE). VCE has a long history in genetics, from
its origins in animal breeding to Quantitative Trait Loci (QTL) analysis [Amos, 1994; Almasy and Blangero,
1998]. Estimating these parameters is intensive in its own right, as iterations are required for each marker
[Gilmour, A; Thomson, R; Cullis, 1995]. 2007 saw the introduction of GRAMMAR, an expedited solution to
this problem [Aulchenko et al., 2007]. This combines a mixed model analysis with a basic linear regression.
This divides the analysis into at least two steps; firstly the VCE without marker data. The residuals from
this step are then used as a novel phenotype for a classical association test with linear regression. In our
case, the initial step uses Restricted Maximum Likelihood (REML) to estimate the variance explained by
two Kinship matrices, ”RD” and ”TechnicalKinship”, and any population stratification parameters that are
additionally included (Equation 4.10). The residuals from this, now free from artefacts associated with RD
and informative missingness, are used in Equation 4.11.
Y = Zα+ gRD + gTK + e (4.10)
i.e. Equation 4.4 without the SNP Xj , then use the resulting estimates of the fixed and random
effects, αˆ and gˆ respectively, to compute the ”residual phenotype” (Equation 4.11). This phenotype is
compared against the original phenotype in Figure 4.10. Finally, the residuals Y ∗ can be used as the
phenotype in Equation 4.1.
Y ∗ = Y − Zαˆ− ˆgRD − ˆgTK (4.11)
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Figure 4.10: Comparison of phenotype to its residuals for a given trait in UCL-ex. The X axis represents the
case control (1/2) phenotype while the Y axis is the ’Residual Phenotype’ as discussed for use in Equation
4.11.
4.2.8 Gene based tests
Variants with a MAF of ≤ 1% are not tractable to single variant approximations such as Equation 4.6 due
to a lack of statistical power to detect a signal. Various methods were used during this work in an attempt
to glean sensible data from these less tractable variants. Different forms of Gene based tests were used.
Here, the hypothesis was that one could first remove variants that are associated with the technical PCs,
PCtech1:10. This would remove variants that are thought to be technical artefacts. To do so, each variant
was regressed as in Equation 4.12. This is an exclusion test, as a significant pvalue (p <0.0001) indicates
that there is a significant association between the variant and PCtech1:10. Therefore such associated variants
were removed from further analysis.
SNP ∼ Y + PCpop1:2 + e (4.12)
SNP ∼ Y + PCpop1:2 + PCtech1:10 + e
Rare (MAF <0.3%) and non-synonymous, LOF or splicing variants were retained from the variants
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that remained after the PCtech filtering of Equation 4.12. MAF was defined separately based on the 1000G
samples and on a random quarter of the UCL-ex controls (which were not used for subsequent analyses).
This filtered list of variants was then subjected to both SKAT and a basic binomial test that tests for an
excess of variants in cases compared to controls.
4.3 Sudden Cardiac Death
4.3.1 SCD-UCLex Single Variant Association Tests
68 samples diagnosed with Sudden Cardiac Death were included in the UCL-ex consortium. When one has a
low number of cases like this, an improperly designed study may remove any possibility of retaining enough
power to detect SNPs of weak or moderate effect. In general, case control studies using unrelated samples
have more power than family based studies, in part due to the increased ease of obtaining large numbers of
samples [Risch and Teng, 1998]. However it has been shown that including families with multiple affected
siblings in a case control of mostly unrelated individuals can further increase the power because it enriches
the study with disease alleles [Risch, 2000]. This may be more true in polygenic diseases such as SCD than
in monogenic diseases [Li et al., 2006]. Much work has been done to try identify the optimal study design,
using different combinations of classical tests such as the Transmission Disequilibrium Test [Spielman et al.,
1993] with linkage and association studies [Fingerlin et al., 2002]. This was further improved with likelihood
based strategies, such as a combined likelihood approach that multiplies the likelihood contributions of
families and unrelated samples together [Nagelkerke et al., 2004]. Even more recently, it has been shown
that by combining aggregated haplotype weighted counts from case control and trios under a generalised
linear model, you can have a more powerful and cost effective study than other version alone [Wen and Tsai,
2014].
This cohort includes a family whose pedigree is shown in Figure 4.11). 2 case control tests were
performed on this cohort, one with the family excluded (everyone except the proband) (Table 4.3) and one
with them included (Table 4.4). This was done to ascertain if inclusion of family members substantially
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increased the power to detect real signal and did not simply highlight the existence of private mutations of
no clinical consequence. The related QQ plots are in Figure 4.12. This does not display a good correction
for PS with a large level of inflation remaining so the results may be artefactual.
Figure 4.11: Pedigree of the J wave Family discussed in relation to Table 4.4. A blue line underneath the
phenotype indicates that this sample was present in this study. The sample highlighted with the red box is
the proband
rsID SNP Gene Fisher LRp LMMp OR #Hom.SCD(#n62) #Hom.ctrl(#n4268) #Het.SCD #Het.ctrl
NA c.2084 2107del C10orf71 1.74E-15 1.00E-16 1.00E-16 1.73E+01 6 22 7 8
NA c.2093 2094insCACACG C10orf71 1.05E-16 1.00E-16 1.00E-16 2.03E+01 6 22 7 8
NA c.185C>T OR10G4 2.24E-02 3.32E-01 1.51E-11 8.91E+01 0 4 1 34
rs11538191 c.-398C>T C12orf44 1.00E+00 1.37E-02 4.56E-09 0.00E+00 0 3 0 18
Table 4.3: Sudden Cardiac Death(SCD) Single Variant Results without Jwave family. SNP details the
position of the tested variant (hg19). Gene is the HUGO name for the gene in which the SNP resides.
FisherP is the pvalue from Fisher’s exact test. LRp is the Linear Regression pvalue with no covariates or
kinship matrices. LMMp is the pvalue from Equation 4.9. OR is the risk odds ratio. ’Homs’ are homozygotes
for the minor allele, while ’Hets’ are heterozygotes
rsID SNP Gene Fisher LRp LMMp OR #Hom.SCD(#n68) #Hom.ctrl(#n4268) #Het.SCD #Het.ctrl
rs141832071 c.3463C>G FOCAD 9.17 ∗ 10−4 ≤ 1. ∗ 10−16 ≤ 1. ∗ 10−16 69 0 0 2 3
NA c.209C>T ZNF323 4.51 ∗ 10−19 ≤ 1. ∗ 10−16 5.52 ∗ 10−13 NA 1 0 7 0
NA c.237G>T ZNF323 4.46 ∗ 10−19 ≤ 1. ∗ 10−16 6.14 ∗ 10−13 NA 1 0 7 0
NA c.781C>T OR5V1 6.41 ∗ 10−19 ≤ 1. ∗ 10−16 7.03 ∗ 10−13 NA 1 0 7 0
rs11466802 c.2413G>A ADAM19 7.29 ∗ 10−4 ≤ 1. ∗ 10−16 3.23 ∗ 10−12 90 0 0 2 2
NA c.591A>G FSTL1 6.17 ∗ 10−15 ≤ 1. ∗ 10−16 4.01 ∗ 10−12 NA 0 0 7 0
rs146280894 .285G>A CEP97 6.55 ∗ 10−15 ≤ 1. ∗ 10−16 5.4 ∗ 10−12 NA 0 0 7 0
rs376775426 c.333C>T BTG2 7.32 ∗ 10−15 ≤ 1. ∗ 10−16 7.18 ∗ 10−12 NA 0 0 7 0
rs267603590 c.306G>A HSD17B6 1.26 ∗ 10−12 ≤ 1. ∗ 10−16 8.8 ∗ 10−10 NA 0 0 6 0
Table 4.4: Sudden Cardiac Death(SCD) Single Variant Results with Jwave family. SNP details the position
of the tested variant (hg19). Gene is the HUGO name for the gene in which the SNP resides. FisherP is the
pvalue from Fisher’s exact test. LRp is the Linear Regression pvalue with no covariates or kinship matrices.
LMMp is the pvalue from Equation 4.9. OR is the risk odds ratio. ’Homs’ are homozygotes for the minor
allele, while ’Hets’ are heterozygotes.
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(a) These plots illustrate the case control analysis of only unrelated cases and controls
(b) The J wave family is included in the case control analysis shown here.
Figure 4.12: Sudden Cardiac Death (SCD) single variant mixed model association results. QQplots of the
uncorrected (a) and corrected (b) SCD analysis for variants with a MAF of ≥ 1% are shown.
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4.3.2 An enhanced model for gene based correction of technical artefacts
As mentioned previously, Equation 4.9 on page 81 worked well for at least some traits and for variants with
a MAF of ≥ 1%. This left rare variants uncorrected. Power to detect and correct rare variants would be
gained by pooling variants into a region based testing procedure. For this, grouping variants based on what
genes they lie in seems intuitive biologically. For all sequenced genes, the SCD samples were compared to
the rest of UCL-ex with SKAT and a Binomial test (further methodological details in Section 4.2.8). Figure
4.13 shows that this region-centric approach improves the distribution over the single variant scores shown
in Figure 4.12. The most significant genes, ranked by Binomial pvalue are shown in Table 4.5. This table is
dubious as none of these genes have been reliably associated with SCD previously: The SCD cohort remains
difficult to interpret, so a different approach is needed.
Gene Position Case Counts(n=90) Control Counts(n=2,236) SKAT Binomial
OR5V1 chr6:29323076-29323905 10 7 3.011447e-15 1.831340e-12
PCDHGA9 chr5:140782689-140784943 13 34 1.934987e-10 3.476049e-09
PHKA1 chrX:71800901-71933724 11 1 1.430687e-10 1.212894e-08
ZNF280A chr22:22868366-22869937 15 31 2.629286e-10 1.496724e-08
RSAD2 chr2:7017943-7027279 9 13 5.225212e-14 2.682962e-08
Table 4.5: Top 5 Sudden Cardiac Death candidate genes based on the binomial test. The criteria for retaining
variants are: GATK Variant Quality score of PASS, MAF (MAF of ≤ 0.3%) , ≤ 10% missingness across all
samples, non-synonymous, LOF or affecting splicing.
Methods
In an effort to increase the improvement, two alternative methods, similar to each other, were implemented.
The single variant permutations of Figure 4.14 reveal the power of this approach. To create a null distribution
based on our dataset, phenotype status for all samples was permuted using the software LDAK (v3.0). This
entails retaining the same number of cases and controls, but altering randomly which samples are assigned
as cases and controls, respectively. While such permutations will not improve the low resolution caused by a
small sample size, it will remove the technical artefacts that are associated with case control status. A 100
such permutations were run to create a null distribution relevant to the data. This was compared to the real
pvalue from both the basic LMM and Equation 4.9. The QQplots from a random permutation, and both
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Figure 4.13: SKAT Gene based tests for the PID, ARVC and SCD cohorts. Each circle is the gene based
pvalue from the SKAT test. QQplots compare the observed distribution of pvalues to the expected Chi
Squared distribution. Before the pvalue for each gene is calculated, some variants are filtered/removed. On
the left graphs, the criteria for retaining variants are: GATK Variant Quality score of PASS, MAF (MAF
of ≤ 0.3%) , ≤ 10% missingness across all samples, non-synonymous, LOF or affecting splicing. (B) For the
graphs on the right, the same criteria are used but additionally variants are filtered based on the technical
PCA. The first ten principal components (PC) are included in the linear regression as covariates. SNPs
that are associated with the technical PC are removed. The percentage of SNPs/INDELs removed across
all genes is included in the figure titles.
non-permuted tests are shown in Figure 4.15. As this shows, Equation 4.9 goes some way to correcting the
test, resulting in data that is somewhat interpretable.
TK was included in the mixed effects model of Equation 4.4. Here, TK is calculated only on the
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Figure 4.14: Association results for SNPs/INDELs with PID. The -log10 (y-axis) of the pvalues from 20
permutations (grey), Linear Regression (red) and Linear Mixed Model with technical kinship (blue).
SNPs in the gene of interest. The likelihood ratio statistic −2log(L(Y |σˆ2e , σˆ2g , TK)/L(Y |σˆ2e , 0, TK) has an
approximate null distribution χ2(Equation 4.3)/2. σ2e is calculated individually for the numerator and the
denominator. Restricted Maximum Likelihood (REML) then derives the model likelihood from Equation
4.3, an efficient process when you have more SNPs(N) than individuals (n). On a gene based level however,
n is typically greater than N, so to expedite model likelihood calculation, Equation 4.4 is used to abrogate
the need for K calculation (Speed et al, in preparation).
To identify candidate genes from this, some pvalue comparisons were made. Firstly, a gene is unlikely
to be truly disease causing if it has a pvalue within the range of pvalues seen in the permutations. Table
4.6 therefore includes the minimum permuted pvalue for each gene. LRRC37A2 has an uncorrected pvalue
of 2.40e-30, but the corrected pvalue is less extreme than the permuted pvalue, thereby rendering it a false
positive. The gene Phosphodiesterase Interacting Protein 4 (PDE4DIP) has an uncorrected pvalue of p
<1e-40. Phosphodiesterases regulate cyclic nucleotide signalling, and are therefore of clinical importance
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Figure 4.15: Comparing the distribution from different Sudden Cardiac Death Gene based tests.
[Jeon et al., 2005]. PDE4DIP/MMGL4 has been reported to phosphorylate MYBPC3 [Uys et al., 2011].
Variations in MYBPC3 are known to confer an increased risk to developing Hypertrophic Cardiomyopathy.
While this would place PDE4DIP as a likely novel gene for SCD risk, the pvalue when TK is included
changes to 1 (while the minimum permuted pvalue is 7.97e-05). Even if PDE4DIP is in actuality a disease
causing gene for SCD, this corrected pvalue of 1 means that any real signal correlates strongly with the batch
effect removed by TK. To determine if it is a real signal or a false positive, the batch effect would have to
be non existent. This could be achieved, for example, by preparing cases and controls in entirely the same
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fashion. This would include everything from DNA extraction, to sample storage all the way to sequencing
and processing. The same can be said for RIMS3. The remaining genes in this table retain significance
with the inclusion of TK, meaning that it corrects for batch effects. When their permuted pvalues are less
significant than the corrected pvalues, then that is evidence for a true association.
Gene Position Pvalue.no.correction Pvalue.with.correction Min.Permuted.pvalue
SPACA5B chr23:47990038-47991995 1 1.26e-08 3.33e-06
FAM58A chr23:152853382-152864632 0 1.26e-08 4.26e-05
SSX6 chr23:47967366-47980068 1 5.88e-08 1.18e-06
RIMS3 chr1:41086351-41131324 1 2.06e-06 1.11e-07
PROKR2 chr20:5282685-5295015 3.94e-01 2.51e-06 2.93e-03
LRRC37A2 chr17:44590075-44633014 2.40e-30 2.04e-05 1.91e-06
PDE4DIP chr1:148889463-149033016 <1e-40 1 7.97e-05
Table 4.6: Top 5 Sudden Cardiac Death candidate genes based on the gene based technical kinship corrected
pvalue. 98 cases were compared to 4,236 controls.
4.4 Results
4.4.1 Initial data quality assessment
The 4334 exomes were stored in a 4334 * 884887 matrix (Samples * variants). All variants were either exonic
or altered splicing. An initial quality check examined the call rate across all SNPs (Figure 4.5). As expected,
the vast majority had a failure rate of <20%. The call rate varied from group to group however, over a range
of 2-25% (Figure 4.5B).
4.4.2 Principal Component Analysis
A PCA was performed on the ∼ 5000 SNPs that are known to be well covered across all commonly used
sequencing technologies. This was used because it would enable the Population Stratification (PS) control to
be free from any bias associated with sample preparation differences. The first two Eigenvectors of this PCpop
were readily able to discriminate population substructure in UCL-ex by comparing it against the samples of
known ethnicity from the 1000G project (Figure 4.6). While the majority of UCL-ex was determined to be
of Caucasian origin, as expected, some were more likely African or Asian. Such population substructure was
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controlled for in the association testing used here by including the top PCs as covariates in both the Linear
Regression and the Linear Mixed Model.
In addition to the PCpop approach, a PCA was performed on the missing/nonMissing matrix of
all variants (PCtech). Figure 4.4A shows the first two PCs’ ability to differentiate samples based on their
patterns of missingness. The samples are the dots, coloured on a scale from light to dark blue where the
darker the dot the higher the percentage of that samples SNPs that were not successfully called. The general
trend from this is that samples with similar numbers of NA SNPs/INDELs cluster together. Figure 4.4B is
the same plot except for the fact that samples are coloured based on their research group of origin. This
reinforces the idea that technical artefacts can be highly associated with case control status. Figure 4.16A
illustrates this further by including just the samples whose sequencing chemistries are known. Samples from
different traits readily cluster together when viewed by Technical PCs. Figures 4.16B and C show how by
overlaying these well characterised samples across all of UCL-ex, you can reliably predict the HTS platform
used. The same method was applied to a RD matrix. Figure 4.17 shows the PCA plot from this. It is
relatively uninformative as it does not offer much discrimination. The Scree plot in the lower section of this
Figure shows that there is little variance (≤ 5%) explained by PCs and below. By comparing these Figures,
it shows that read depth is not as useful a determinant as missingness in identifying clusters in the data.
4.4.3 ADMIXTURE based sample separation
ADMIXTURE, the model based clustering approach to identifying population stratification, was used here
to see if it was possible to identify a group of samples (both cases & controls) that have a similar patterns of
missingness. This may then allow for the calculation of more accurate case control association statistics by
filtering controls so that they matched the cases as closely as possible. This programme was run numerous
times; each time the parameter M that governed the desired number of subpopulations for ADMIXTURE to
resolve was varied from 1 to 25. Values of M ≥ 4 start to show signs of empty resolution (Figure 4.7). Similar
to Figure 4.4B, this ADMIXTURE plot highlights the Prion samples as outliers. A case control study that
naively used all samples in UCL-ex could be affected by this grouping. Variants may be erroneously called as
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(a) Missingness PCA on a subset of UCL-ex samples.
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(b) Missingness and RD PCA on all UCL-ex samples.
Figure 4.16: Identifying clusters of samples based on sequencing capture technique used during preparation.
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(a) Principal Component Analysis plot of the UCL-ex RD kinship matrix.
The samples are coloured by research group of origin.
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(b) Scree plot showing the level of variance explained by each of the top 20
PCs.
Figure 4.17: Analysis of the UCL-ex RD kinship matrix.94
protective or deleterious if their frequencies in cases compared to controls vary as a result of this missingness
discrepancy.
4.4.4 Identifying technical PCs that explain missingness
By taking the sum of the squares of the standard deviations of each PC, the level of variance explained by
each PC was found. This showed that the first five PCs explains approximately ∼ 52% (Figure 4.18A). Be
that as it may, this did not offer sufficient correction when included as fixed effects in Equation 4.6.
The 1025 variants that had a pvalue that was ≥ 0.9 smaller in the Linear Regression of Equation
4.5 than the corresponding corrected pvalue in Equation 4.8 were defined as Corrected Variants (CVs).
To determine if this was caused by any identifiable subset(s) of the Technical Kinship Matrix, a separate
linear regression was run on each CV with one of the 1763 PCtechs as covariates (1763 regressions per CV).
There are 1763 PCs here because that was the number of samples we had at the time. A χ2 test compared
these models to the standard regression of phenotype on SNP with no covariates to determine which, if any,
PCtechs are associated with case control status (p <= 1×10−8). Figure 4.18B illustrates the extent to which
different PCtechs survive this threshold. This shows that even when the level of variance explained by a PC is
negligible many if not all of these SNPs can be strongly associated with it. If the dataset remained small then
this approach of identifying variants as artefacts by their association with PCs may be amenable. However,
it is not computationally tractable at a larger scale and required too many assumptions and arbitrary filters.
4.4.5 Single Variant Model Optimisation
A cohort of 104 exomes with PID were included in UCL-ex. These samples were used as cases to refine the
model. Equations 4.1 and 4.8 were used to perform a case control association on this data. 9.2% (62060 /
672504) of variants were first removed as they failed the GATK quality metric. The QQplot of the remaining
variants pvalues from Equation 4.8 shows that the mere inclusion of TK did not correct the test statistics
completely, as Figure 4.8A shows a deviation from the expected χ2 distribution. Rare variants were then
pruned until the distribution reflected a χ2 distribution (Figure 4.8B-I). The threshold at which a satisfactory
95
Figure 4.18: Assessing the importance of each Technical Principal Component(PC): (A) The percentage of
variance explained by each technical PC. (B) The 1000 SNPs/INDELs with a pvalue difference of ≥ 0.9
between Equation 4.1s and 4.8 were tested for their associations with each of the 1763 technical Principal
Components (PCtechs). The x-axis displays each PCtech and the y-axis is the number of these 1000 SNPs
that associate with that particular PCtech.
distribution was reached was assigned as variants that have ≥ 20 calls of the alternative allele.
Equations 4.1 and 4.8 were compared to a series of 20 models in which case control status was
permuted randomly. This tested the theory that a large number of these technical artefacts are strongly
associated with case control status, so it was expected that you would see few if any significant associations
in the permutations. While such permutations would remove any true signal too, the number of variants
that you would expect to be artefacts is higher than the expected number of true signals, so this approach
remains valid. Figure 4.14 shows that while the permutations exhibit a much lower range of pvalues as
expected, the Equation 4.1 is more extreme than 4.8, suggesting that 4.8 works to correct outliers.
A variant (E1021K) was previously identified in these samples to be a dominant gain of function
that alters the PIK3CD gene [Angulo et al., 2013]. This was used as a positive control throughout the model
development process (Table 4.7). E1021K’s disease association was confirmed with an Equation 4.1 pvalue
of 1.162e-23 and an Equation 4.8 pvalue of 1.809e-08. The latter being closer to the reported association of
4.767e-08.
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C1R variant
The C1R variant from Section 4.1.1 was used as a negative control for the single variant analysis of the cone
rod dystrophy cohort. The naive single variant linear regression pvalue of 1.10e-04 for chr12:7244369C>T is
close to the gene based pvalue of C1R of 4.22e-04 from SKAT and 1.64e-04 for the binomial test. However, its
artefactual status is confirmed by the corrected pvalue of 0.144 (from Equation 4.8). The Genomic Inflation
Factor λ was calculated for every UCL-ex trait for three models; Equations 4.5, 4.9 and a permuted model
for an idealised distribution. These λs were compared at a range of MAF thresholds (Figure 4.19).
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Genomic Inflation across UCLex Cohorts by Model
Figure 4.19: The GIF across all UCL-ex cohorts. Base (red) is the mean of the uncorrected GIFs from all
cohorts, green is the corrected GIF while blue is the Permuted GIF. The X-axis indicates the MAF less than
which SNPs were excluded to calculate their respective GIFs.
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4.4.6 Final Single Variant Model Application
Table 4.7 in Section 4.4.5 showed that the correction applied by Equation 4.9 was performing as desired in
that it successfully removed variants known to artefacts while retaining known risk loci. To further test this,
it was applied to another of the UCL-ex cohorts, 800 mostly Ashkenazi Jewish Samples with Inflammatory
Bowel Disease (IBD). The most associated single variants are in Table 4.8. The associated QQplots and
Manhattan plots are show in Figure 4.20. While the corrected QQplot in this Figure does show a reduced
Genomic Inflation, it remains quite elevated which, combined with the unusual genes with the strongest
pvalues, makes it unlikely to be fully controlling for both artefacts and other noise such as PS.
rsID SNP Gene Fisher LRp LMMp OR #Hom.IBD(#n799) #Hom.ctrl(#n3535) #Het.IBD #Het.ctrl
rs201286142 c.1957G>A GRM3 6.16E-04 4.78E-02 2.30E-16 25 0 0 3 5
rs184616940 c.2624C>T LRRCC1 2.34E-18 4.59E-11 1.21E-15 90 0 0 14 6
rs77786095 c.1376G>T DTX3L 1.08E-07 3.49E-07 2.09E-15 44 0 0 6 6
rs200843707 c.658G>A GUF1 4.39E-17 1.75E-12 4.39E-15 60 0 0 14 9
rs201337101 :c.2597T>C ITGAM 1.77E-05 3.77E-14 6.23E-15 21 0 1 5 8
rs139134493 c.2328A>G TTC27 1.99E-11 6.68E-07 1.41E-14 55 0 0 9 7
rs139555612 c.1966T>A RTN4 6.66E-04 ≤1.00E-16 1.79E-14 25 0 0 3 5
rs104895423 c.662T>G NOD2 5.53E-05 1.27E-03 1.60E-07 15 0 0 5 15
Table 4.8: IBD Single Variant Test Results, with 799 cases and 3535 controls. SNP details the position of
the tested variant (hg19). Gene is the HUGO name for the gene in which the SNP resides. Fisher is the
pvalue from Fisher’s exact test. LRp is the Linear Regression pvalue with no covariates or kinship matrices.
LMMp is the pvalue from Equation 4.9. OR is the risk odds ratio. ’Homs’ are homozygotes for the minor
allele, while ’Hets’ are heterozygotes.
4.4.7 Gene Based Model Optimisation
Variants that were not deemed to be artefacts based on the linear regression of Equation 4.12 were filtered
further by selecting for rare variants and those that were either non-synonymous, LOF or splicing. The
region based Binomial and SKAT tests were then run on these variants for each gene separately for the PID,
ARVC and SCD cohorts. The top PID gene for the Binomial test was CASC5 (p <5.765e-06). The counts
for the 5 top genes for the PID cohort are in (Table 4.9) and the QQplots for both tests of all three cohorts
are in Figure 4.21 for the Binomial pvalues and Figure 4.13 for SKAT. As these figures show, this gene based
model did not work so no reliable results were generated.
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Figure 4.20: Artefact correction in the Inflammatory Bowel Disease cohort of UCL-ex. The qqplot and the
Manhattan plot in the top row show the uncorrected LMM results. In contrast, the bottom row displays the
results from Equation 4.9.
4.4.8 REML Estimates of variance explained by Kinship component
The estimations of variance explained by the TK/RD Kinship matrices initially showed that some phenotypes
were very highly correlated with these kinships, indicative of being artefacts. To start, the only variant
filtering performed was removing variants that GATK ’PASS’ flag. However, as Figure 4.22 shows, the
GATK flag was rather uninformative. This meant that many cohorts had ≥ 95% variance explained by
100
Gene Position Case Counts(n=143) Control Counts(n=1,956) SKAT Binomial
CASC5 chr15:40895128-40954311 14 31 1.245890e-05 5.765778e-06
LRRC46 chr17:45909365-45914403 9 12 4.838810e-05 1.451893e-05
C4orf17 chr4:100434240-100463258 12 25 3.836317e-04 1.657423e-05
PGAM2 chr7:44102399-44105115 7 6 2.188516e-04 2.137651e-05
PZP chr12:9302172-9360933 11 22 1.189751e-03 2.781703e-05
Table 4.9: Top 5 PID candidate genes based on the binomial test. The criteria for retaining variants are:
GATK Variant Quality score of PASS, MAF (MAF of ≤ 0.3%) , ≤ 10% missingness across all samples,
non-synonymous, LOF or affecting splicing.
the kinships. This was thought to explain why the initial corrections appeared to work well; it was in fact
explaining most of the variance in the data which lead to an inability to detect any true signal.
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Figure 4.21: Binomial Gene based tests for the PID, ARVC and SCD cohorts. Each circle is the gene based
pvalue from the binomial test. QQplots compare the observed distribution of pvalues to the expected Chi
Squared distribution. Before the pvalue for each gene is calculated, some variants are filtered/removed. On
the left graphs, the criteria for retaining variants are: GATK Variant Quality score of PASS, MAF (MAF
of ≤ 0.3%) , ≤ 10% missingness across all samples, non-synonymous, LOF or affecting splicing. (B) For the
graphs on the right, the same criteria are used but additionally variants are filtered based on the technical
PCA. The first ten principal components (PC) are included in the linear regression as covariates. SNPs
that are associated with the technical PC are removed. The percentage of SNPs/INDELs removed across
all genes is included in the figure titles.
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Figure 4.22: Effect of SNP filtering using different criteria on amount of variance explained by technical
kinship. (A) Filtering SNPs by MAF. The X axis indicates the minimum MAF of the retained SNPs and the
Y axis shows the averaged level of variance explained by the Technical Kinship for all UCL-ex phenotypes.
(B) Low quality SNPs that did not receive a ’PASS’ flag from the GATK VQSR test were removed. (C) The
required variant call rate is increased across the X axis.
103
4.5 Arrhythmogenic Right Ventricular Cardiomyopathy
4.5.1 ARVC-UCLex Single Variant Association Tests
28 ARVC exomes were also included in the UCL-ex consortium. They were subjected to the Single Variant
analysis (Equation 4.9) of common variants and Gene based testing for rare variants as previously described.
Figure 4.23 illustrates the QQ plots of both the uncorrected and corrected models. The 5 SNPs most strongly
associated with ARVC are in Table 4.10. These results should be interpreted with caution however as 28
samples does not provide adequate power to detect all but the largest signals and may yield many artefacts.
The gene based testing procedures involving SKAT and the binomial test were additionally applied to the
ARVC cohort, with Table 4.11 detailing the genes with the strongest association.
rsID SNP Gene Fisher LRp LMMp OR #Hom.ARVC(#n28) #Hom.ctrl(#n4306) #Het.ARVC #Het.ctrl
rs368209124 c.1162-3C>T COL9A2 1.59 ∗ 10−4 ≤ 1. ∗ 10−16 ≤ 1. ∗ 10−16 172 0 0 2 3
rs149175095 c.1123A>C PHF7 3.14 ∗ 10−4 ≤ 1. ∗ 10−16 ≤ 1. ∗ 10−16 106 0 0 2 5
rs199640194 c.20318G>A TTN 0.034 3.68 ∗ 10−9 ≤ 1. ∗ 10−16 0 1 0 0 4
rs150671437 c.1619G>A EFHB 9.46 ∗ 10−4 ≤ 1. ∗ 10−16 3.42 ∗ 10−10 54 0 0 2 9
Table 4.10: ARVC Single Variant Results. SNP details the position of the tested variant (hg19). Gene is
the HUGO name for the gene in which the SNP resides. Fisher is the pvalue from Fisher’s exact test. LRp
is the Linear Regression pvalue with no covariates or kinship matrices. LMMp is the pvalue from Equation
4.9. OR is the risk odds ratio. ’Homs’ are homozygotes for the minor allele, while ’Hets’ are heterozygotes.
Gene Position Case Counts(n=16) Control Counts (n=4318) SKAT Binomial
TAS2R40 chr7:142919173-142920122 6 7 1.83 ∗ 10−3 6.35 ∗ 10−9
ANO5 chr11:22225349-22301267 5 34 2.80 ∗ 10−4 1.27 ∗ 10−4
PPP1R3F chr23:49126534-49143288 2 1 1.42 ∗ 10−3 4.72 ∗ 10−4
CIITA chr16:10989219-11017124 4 31 1.09 ∗ 10−2 9.65 ∗ 10−4
ATF7IP2 chr16:10524564-10576102 3 13 4.20 ∗ 10−3 9.90 ∗ 10−4
Table 4.11: Top 5 ARVC candidate genes based on the binomial test using the rest of UCL-ex as controls.
The criteria for retaining variants are: GATK Variant Quality score of PASS, MAF (MAF of ≤ 0.3%) , ≤
10% missingness across all samples, non-synonymous, LOF or affecting splicing.
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(a) Left - qqplot of the uncorrected ARVC analysis for variants with a MAF of ≥ 1%. Right - Manhattan plot
showing the associations per chromosome. Red horizontal line is pvalue of 1 ∗ 10−8 and blue is 1 ∗ 10−5.
(b) Left - qqplot of the corrected ARVC analysis for variants with a MAF of ≥ 1%. Right - Manhattan plot
showing the associations per chromosome. Red horizontal line is pvalue of 1 ∗ 10−8 and blue is 1 ∗ 10−5.
Figure 4.23: Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) single variant mixed model asso-
ciation results.
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4.6 Comparing Coding and NonCoding variants in ARVC to HCM
In addition to the main UCL-ex work, this analysis was applied to 359 Arrhythmogenic right ventricular
cardiomyopathy (ARVC) and 875 Hypertrophic Cardiomyopathy (HCM) genome/exome samples. These
samples were prepared in the same lab, using the same capture methodology. From HCM ”plate 3 rerun” on,
the sequencing platform differed - it occurred on a HiSeq2000 instead of a GAIIx, with increased multiplexing
for plates 4 and 5 (96 samples) and again for 6 (120) and 7,8,9 (128). The exact sample breakdown by platform
is GaIIx (252 samples), HiSeq2000 (12) and HiSeq2000.Multiplexed (695). A Principal Component Analysis
was performed on the missing/nonMissing genotype matrix to ascertain what the missingness patterns in
the data were. The initial step in analysing this consisted of determining if there was a significant difference
that correlated with phenotype. Figure 4.24A reveals that these technological disparities affect the PCtech
more than the disease differences.
Processing this many samples is routinely performed in batches. These samples were prepared in
12 distinct batches, some of which involved re-running samples for Quality Control purposes. Figure 4.24B
shows that this batch effect is readily visible. While some batches are distinct from each other with almost
no overlap, the majority are similar. This effect is less powerful than that influenced by the transition from
the Illumina GAIIx to its HiSeq 2000 sequencing system (Figure 4.24C).
As these samples included non coding regions, a gene based test was infeasible. While a region can
be defined in any arbitrary way to offer an alternative, this has not yet been performed. As noted previously,
TK is better suited to correcting common artefacts than rare ones. Rare variants, those with less than 20
calls of the non-reference allele between cases and controls were therefore excluded. Any related samples were
removed before the analysis as part of the standard QC based on clinical pedigree data and plink estimates
of relatedness. The top 5 variants are listed in Table 4.12 and the number of variants that are significant at
a range of levels summarised in Table 4.13.
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Figure 4.24: Technical PCA of ARVC vs HCM: (A) Arrhythmogenic right ventricular cardiomyopathy
(ARVC) in red compared to Hypertrophic Cardiomyopathy (blue). (B) Samples were prepared in batches.
(C) Different sequencing technologies.
4.6.1 ARVC, HCM and UCLex joint artefact analysis
As discussed already in this thesis, pre-sequencing combination of cohorts can lead to technical artefacts.
Figure 4.25 displays such an effect when one integrates the ARVC,HCM and UCL-ex cohorts, retaining the
variants that are called in both cases and controls. Additionally, the technical PCA was performed on the
rotated matrix. Figure 4.26 shows the top two PCs from this. Figure 4.26B shows these loadings coloured
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Variant Gene ARVC Counts(n=407) HCM Counts(n=957) ARVC.Freq HCM.Freq PT
rs193922652 MYH6 12 35 3.34% 4% 5.305 ∗ 10−41
rs111679193 PKP2 30 52 8.36% 5.94% 1.302 ∗ 10−14
chr17:68174142 - T KCNJ2 3 28 1.11% 3.2% 2.260 ∗ 10−14
chr2:179660461 T - TTN 70 149 19.5% 17.03% 4.029 ∗ 10−14
chr18:28681054 - G DSC2 20 58 5.57% 6.63% 1.016 ∗ 10−12
Table 4.12: The most significant common (≥ 20 total calls) SNPs/INDELs from the Linear Mixed Model
with technical Kinship correction of the ARVC vs HCM comparison. The columns, in order from left to
right, are the genes containing the variant, its exact position, the number of counts in the ARVC and HCM
samples, the resultant frequencies and corrected pvalue. The absolute genomic position is reported for the
variants that do not effect the coding sequence.
Threshold Nb.SNPs.Below Nb.SNPs.Above
1e-03 39 10068
1e-04 25 10082
1e-05 19 10088
1e-06 12 10095
1e-07 12 10095
1e-08 10 10097
1e-09 9 10098
1e-10 8 10099
1e-11 7 10100
1e-12 4 10103
1e-13 4 10103
1e-14 1 10106
Table 4.13: The number of SNPs/INDELs that are significant in the ARVC/HCM comparison at a number
of thresholds.
by gene of origin. Gene was used to represent genome location and from this you can see that missingness
varies systemically across the genome. This graph is dominated in the centre by Titin. Given that Titin
dwarfs the other genes in length, at some 34Mb long, it is expected to contribute the most to the PCA.
108
lll
l
l
l
l
lll
ll
l
l
l
l
l l
l
l
l
l
l
l
l
ll
l
l l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
lll l
l
l ll
l
ll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l
l l
l
l
ll
l
lll
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
l l
l
l l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
ll l
ll
l
l
l
l
l
l
ll l l
l
l
l l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
l
l ll l
l
l
ll
l
ll
l
l
ll
l
llllll
l l
l
l
l
l ll l
l
l
ll
l
l
l l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l ll ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l l
l l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
llll
l
l
l l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll ll
l
l
ll
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
ll
l
l
ll
l
l
l l
l l ll
l
ll
l
l
l
ll l
l
l
l l
l
l
l
l
ll
l
l
ll
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l l ll
l
ll
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l l
l l
l
l
lll l
ll ll
l
l
l
l l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
ll
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l l
l
l
l
l
ll
ll
l
l
l
l
l l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
ll
l
l
l
l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l ll
l l
l
l
l
l
l
ll l
l
ll
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
ll
l
l
l
l
lll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
lllll
ll
l
l
l
l
l
l
l
l l
l l
l
l
l
l l
l
l
l
l
ll
l
l l
l
l
l
l
l
l
l
ll
l
l
lll
l
l
l
l l
l
ll l
l
l
l l
ll
l
l
l
l
l
l
l
l l
l
l
l
l l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll ll
l l
l
l
l
l
l
l
l
l
lll
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
lll
l
l
l
l
ll
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l l
l l l
ll
l
l
l
l
l
l
l l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
ll
l l
l
l
l l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l l
ll
l
ll
l
l
l
l
l
l
l
l
l
l l
ll
l
ll
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l l
l
l l
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
ll
l
l
l
l
l
l
l
l
l
l
l l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
ll
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l lll
l
l
l
l
l
l l
l
l
l
l
l
lll
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l l
l
l
l ll
l
l
l
l
l l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
ll
l l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
lll
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll ll
l
l
l
l l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
ll
ll
l
lll
l
ll
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l ll
l
l
ll
l
l
l
l
l
l
l
l
ll l
l
l
l
ll
l
l
ll
l
l
l
l
ll
l
l
l l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll ll
ll
l
lll
ll
l
ll
ll
l
l
l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
ll
l
l
l
l
l
l
l
ll
l lllll
l
l
l
ll l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l lll
l
lll
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l lll l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
ll
ll
l
l
ll
l
l
ll l
l
l
l
l
l
ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
ll l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l ll
l
l
l
l l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l ll l
l
l
l
ll ll
l l
l
l
l ll
l
lll ll
l l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
ll
l
l
ll
l
l
l
l
l
l
l
lll
l
l l
l
l
l
l
l
l
−0.03
−0.02
−0.01
0.00
0.01
−0.02 −0.01 0.00
PC1
PC
2
Cohort
l
l
l
ARVC
Control
HCM
Samples
Figure 4.25: Technical PCA of the HCM/ARVC Joint Analysis. The ARVC (red), HCM (blue) and UCL-ex
control (green) samples are shown.
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Figure 4.26: Technical PCA of the ARVC/HCM joint analysis. Here, the data is rotated so that the
Eigenvectors correspond to the variants, rather than individuals, which is the norm. (A) PC one (X-Axis)
against PC2. The points represent SNPs and INDELs and are coloured according to gene of origin. (B)
PC1 against PC3 of the same data, again coloured by gene. (C) PC1 against PC3 but here coloured based
on GC content of SNPs, as defined by ± 50 base pair bins around each variant.
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4.7 Discussion
4.7.1 Single variant model optimisation
Studies that perform case control associations through the analysis of exome sequencing data have a variety
of sample preparation related confounders to differentiate from true signals [Nothnagel et al., 2011; Lam
et al., 2012]. We have herein described a model that implements a novel approach to deal with such
cryptic artefacts. A kinship matrix can be calculated that estimates the extent to which pairwise similarity
between individuals is based on the missing/nonMissing status of their respective variants, Single Nucleotide
Polymorphism (SNP) and/or Insertions/Deletions (INDELs). By including this alongside a RD kinship
matrix in a Linear Mixed Model that tests for an association between disease status and genotype, you can
get a measure of association that is free from noise caused by SNPs with spurious call patterns.
For the association tests performed here, an additive genetic model was assumed. This is the norm
in GWAS and operates by representing the major (more common) allele as 0 and the minor allele as 1.
Homozygote wildtypes are therefore given a count of 0 for a given SNP, while heterozygotes are 1 and
homozgygotes for the minor allele are 2, respectively. The 4334 samples in the UCL-ex consortium that
served as the test dataset for model development were exome sequenced, which generated 900,000 calls of
SNPs or INDELs.
Long a mainstay of genetics, linear regressions of all single genotyped SNPs has been robustly studied
in association studies [Lourenc¸o et al., 2011]. Applying linear regression, while controlling for population
stratification, to a case control analysis of all groups in UCL-ex yields an inflated false positive across many
SNPs (Figure 4.9). This makes it difficult, if not impossible, to gain an accurate idea of what the true disease
causing/associated variants are. To improve the ability of the model to correct for the data artefacts driving
this Type 1 error inflation, a Principal Component Analysis was performed on the binary missing/nonMissing
genotype matrix (PCtech). The Principal Component plot in Figure 4.4 reinforces the notion that factors
such as sample preparation or sequencing chemistry used to process samples can influence the variant call
rate more than the sample phenotype. An effective technique to overcome such noise will be a boon to
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modern exome sequencing studies that require ever larger sample sizes. This will instantly make available
many samples, that until then will have been incompatible because of such technical artefacts. The Technical
Principal Components were included in two forms of linear regression, which differed based on whether the
phenotype or the genotype was the dependent variable. For the former, a corrected pvalue was obtained for
all SNPs and CNVs. This correction failed to effectively correct the data to a χ2 distribution (Figure 4.9).
This was the case for the three cohorts tested even when the analysis was restricted to solely the common
variants.
To gain more power than the process of including an arbitrary number of PCtechs in the association
tests, a linear mixed model (LMM) was then used instead of a linear regression. LMMs contain a random
effects component, which can include a kinship matrix that traditionally is a measure of the pairwise genetic
similarity between all individuals in the study. We have modified this to what we call a ”Technical Kinship”
matrix (TK). The kinship is calculated on the missing/nonMissing genotype matrix. This estimates the
extent to which observations’ genotyping success rates are similar. Figure 4.8 shows that the mere inclusion
of this matrix does not yield the expected χ2 distribution. Biases caused by spurious calls from different
capture technologies or sequencing platforms are unlikely to be overly common [Nothnagel et al., 2011].
Through a process of repeated pruning, it was found that by restricting the analysis to variants that had at
least 20 calls of the alternative allele, Equation 4.8 adequately adjusts for artefacts (Figure 4.8) for some of
the traits tested.
Not all artefacts will manifest as a binary missing/nonMissing factor. As shown in Figure 4.17, a
PCA of a RD kinship matrix does cluster samples based on research group of origin. Figure 4.16B includes
the sequencing platform and chemistry information, which is known for just a subset of samples within
UCL-ex. The fact that this is captured by using RD as a proxy as per Figure 4.17 is thus clear. This was the
motivation behind adapting Equation 4.8 to include a RD kinship matrix, yielding Equation 4.9, the final
model used for single variant testing. Application of this model gave a pvalue of 0.00358 for the negative
control and 1 ∗ 10−16 for the positive control in Table 4.7, which shows the model has sufficient sensitivity
and specificity.
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4.7.2 Model application to Crohn’s Disease
Linkage analysis was employed to identify the first CD susceptibility locus [Hugot et al., 1996]. 25 Caucasian
families, each with at least two affected individuals were genotyped for 270 polymorphic markers that were
spread throughout most of the genome. A region on chromosome 16 was identified as conferring susceptibility
to CD (p = 0.01). In-depth analysis of this locus subsequently identified variations in the NOD2 gene as
involved in CD susceptibility. Two missense variations and a frame-shift altered the leucine rich repeat
domain (LRR) in NOD2 [Hugot et al., 2001]. Via the LRR, NOD2 detects the presence of muramyl
dipeptide, a component of bacterial cell walls. It also activates nuclear factor Kappa B (NFB). NFB is
a major transcription factor that is involved in cancer, inflammation, immunity and synaptic plasticity
[Gilmore, 2006; Ogura et al., 2001]. As a result of recent GWAS meta-analyses, there are now to thought to
be at least 71 CD susceptibility loci [Franke et al., 2010].
Equation 4.9 was used for single variant testing on the IBD cohort in UCL-ex (Table 4.8). The
NOD2 SNP Chr16:50744565T-G has a pvalue of 1.60 ∗ 10−7. While not the strongest association for this
trait, which is for a variant in GRM3, a gene with no known association with Crohn’s Disease, it remains
evidence of model efficacy. In addition, a variant in ITGAM, 16 31336912 T C, has a pvalue of 6.23 ∗ 10−15.
ITGAM one has had a disputed role in Crohn’s for some time [Kenny et al., 2012; de Jong et al., 2003].
It may related to the functioning of a microRNA hsa-miR-155, reduced levels of which have been shown to
have a protective effect against colitis while lowering the number of CD11b+ T helper cells [Singh et al.,
2014]. The QQ-plot in Figure 4.20 still displays evidence of inflation which explains the domination of the
list by presumed false positives. Despite best efforts, it was not impossible to improve this further. The
difficulty of interpreting this cohort was exacerbated by the fact that 203/799 (25%) of the cases came from
2 large families. While in the case of the SCD analysis it was practical to remove related individuals without
having too deleterious an impact on sample size, here that is not the case. This NOD2 variant was seen in
both families and in unrelated cases however so it remains a plausible result.
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4.7.3 Model application to SCD and ARVC
68 patients were diagnosed with SCD and their exomes included in UCL-ex. A basic linear regression was
initially used. Many variants were flagged as highly significant but were based upon the presence of a
singleton, typically because of one call of the non-reference allele across all samples. This can be rectified by
removing variants with a MAF of <1:1000 or by using an exact test.
The SCD samples were initially analysed with the non-proband family members excluded. Table
4.3 contains those that have a pvalue of ≤ 1 ∗ 10−10. The QQplots in Figure 4.12 show that this data has a
high inflation factor meaning it is not clean enough to be interpretable and informative clinically. The most
significant variants are in open reading frames so are most likely not transcribed.
Table 4.4 contains the 9 variants that have a pvalue of ≤ 1 ∗ 10−10 for the SCD cohort when the J
wave family is included. Of these, three are in genes that have previously been shown to be associated with
heart development or disease. ADAM19 has been shown to have a role in the development of the endocardial
cushion and congenital heart disease [Kurohara et al., 2004; Goldmuntz et al., 2011]. Just last year, FSTL1
was found to a potent activator of regeneration of the adult mammalian heart following myocardial infarction
[Wei et al., 2015]. Finally, the expression of BTG2 is increased when oxidative stress occurs in cardiomyocytes
[Choi et al., 2013]. However, it does have many other functions so is likely a false positive [Tong et al., 2015].
None of these genes are already reported strong candidates for SCD so caution must be paid to their
veracity. All variants in this list, excluding chr5:156915410C-T and chr9:20944681C-G, are present only in
members of a single family pedigree (Figure 4.11). This family was identified after the proband presented
with Ventricular Fibrillation, and was subsequently identified to have a J wave abnormality on ECG, along
with four immediate family members. This includes both parents and 2/6 siblings, indicative of a recessive
model of inheritance. None of these variants co-segregated with the J wave phenotype in this family, so are
unlikely to be causative and are therefore thought to be benign private mutations.
Validation of private mutations can often be complicated by the large number of rare variants with
uncertain effects that are present in the general population, even in candidate genes. Furthermore, given
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the incomplete penetrance and variable phenotype of SCD, this approach would be even more difficult
here. Efforts to improve the predictive accuracy of variant pathogenicity is an ongoing effort. This includes
improving algorithms to predict biological function or evolutionary conservation (eg SIFT and PolyPhen) and
more clinically oriented work that attempts to associate certain variants or genes with specific presentations
of a given condition [Lopes et al., 2014; Syrris et al., 2007]. It is expected that in the future such progress
will help with the interpretation of variant lists generated by HTS such as that discussed here. As it stands,
including related individuals in the study complicates the interpretation while offering little benefit which is
in agreement with most of the literature that espouses removing them or controlling for relatedness.
The ARVC analysis’ top SNPs are in Table 4.10. Only four reach a pvalue of ≤ 1 ∗ 10−10. Three are
in genes with no known association with ARVC. The fourth however, the non-synonymous chr2:179482565C-
T rs199640194 is in Titin exon 253. This however is a singleton with an exact Fisher pvalue of 0.034. As
stated already, only 28 cases were available for this analysis. This does not have enough power to detect
anything except the strongest of signals so a lack of strongly significant pvalues was to be expected.
4.7.4 Comparing the genetic architecture of ARVC to that of HCM
The clinical presentations of HCM and ARVC is somewhat similar. By comparing ARVC samples directly
against HCM samples, it was thought that insight may be gained about any genetic variants that are more
associated with one cardiomyopathy than the other. A targeted sequencing approach including the exonic and
flanking/intronic noncoding regions of 73 genes was sequenced. Table 4.12 details the 5 variants most able to
discriminate between ARVC and HCM pathogenesis. With a pvalue of 4.447e-33 for the chr14:23858281GC -
variant, the MYH6 gene seems more strongly associated with HCM than ARVC. This is in line with previous
studies, one of which recently showed that allele specific silencing of certain MYH6 transcripts suppresses
HCM [Carniel et al., 2005; Jiang et al., 2013].
PKP2 variants have been robustly shown to cause ARVC [Li Mura et al., 2013; Roberts et al., 2013;
Cerrone and Delmar, 2014]. A recent study of 90 subjects identified 78 variants in known ARVC genes;
PKP2 mutations consisted 31 (58%) of these. Furthermore, PKP2 carriers were significantly more likely to
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exhibit Ventricular Tachycardia than those with other putatively causative variants [Bao et al., 2013]. This
lends credence to our findings that the chr12:33026249T>C SNP in PKP2 is significantly more common in
ARVC cases than HCM cases (8.36% & 5.94%, respectively, p = 1.302958e-14).
4.7.5 Gene based tests
Association tests have limited power to detect rare variants at the single variant level. It could therefore be
argued that the inability of Equation 4.8 to correct artefacts when their MAF is low is of little consequence.
This has led to a plethora of solutions that involve the combination of rare variants into region based testing
procedures. These can be broadly categorised as the Cohort Allelic Sum tests [Morgenthaler and Thilly,
2007], the Combined Multivariate and Collapsing Tests [Li and Leal, 2008a], Weighted Sum Tests [Madsen
and Browning, 2009] or Kernel Association tests. A multivariate test such as the Sequence Kernel Association
Test [Wu et al., 2011] combines single variant test statistics while not declaring alleles that are more frequent
in cases as necessarily deleterious, as is the case with some alternative methods. As Equation 4.8 controlled
for artefacts in common variants but not rare variants, SKAT was applied to UCL-ex. Variants were excluded
from the SKAT procedure if an initial linear regression, where genotype was the outcome, indicated that
the top ten technical Principal Components indicated artefactual status. As described in Section 4.2.8,
SKAT and a binomial test were applied to the rare variants that were predicted to be of functional import
(those that cause non-synonymous, LOF or splicing changes). By comparing the gene based tests with no
correction, as shown in Figure 4.21, to the scores from the corrected model (Figure 4.13), it appears that
the correction has no noticeable impact. This is similar to the results from Equation 4.6 that showed that
the first ten technical principal components fail to adequately control for artefacts.
4.7.6 Application to SCD
A different gene based testing procedure was used that compared the linear mixed model with technical
kinship (TK) correction to permutations that established a null distribution for the data free from phenotype
specific batch effects. Here, the X-chromosome gene SPACA5B is strongly associated with SCD. Without
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TK, SPACA5B has a pvalue of 1, but its inclusion changes that to 1.26e-08, two orders of magnitude lower
than the lowest permuted pvalue. Whilst this is encouraging evidence for an association, knowledge of a
biological relevance is lacking. It is known to be expressed in the acrosome, the cap like structure of the
sperm that is involved in fertilisation (GeneCards). It may yet have a functional role in SCD. The fact that
it is on the X chromosome may reflect the epidemiological observation that SCD has a higher prevalence in
men than women.
It is not uncommon for association studies to flag genes that have no readily relevant role that could
be linked to disease pathogenesis. Typically, such findings are tested by examining more cases and controls,
through sequencing or from publically available data, to identify if the association remains. This may then
be combined with functional examination of the protein from cell culture to a model organism such as a
mouse. While this approach can work well, it can be onerous. To increase confidence in an association, we
recommend subjecting significant genes to an additional round of (eg 10000) permutations. If the corrected
pvalue remains outside the range of all of the permutations, then it is likely a real association.
Finding a novel causative gene in this way is unlikely. Through using this correction, we expect to
render artefacts insignificant and not necessarily to increase the p-value of true associations. This hypothesis
combined with the paucity of supporting literature lead me to consider genes such as SPACA58 to be false
positives.
4.7.7 Chapter summary
This chapter is the first demonstration of an attempt to use alternative Kinship matrices to control for factors
other that PS. While the final model used does show an improvement in the distribution of association test
statistics across a range of cohorts, clear inflation of the test statistic distribution remains. This is in addition
to the possibility that real signals may also be removed by the correction. It was not possible to find a single
kinship or particular combination thereof that worked sufficiently well across all cohorts. Thus, the major
limitation is the inability to distinguish technical artefacts from actual association signals.
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Chapter 5
Discussion
5.1 Application to other non-cardiovascular cohorts
5.1.1 Single variant analysis
Model 4.9 was applied to the principal cohorts within UCL-ex. This included SCD (Section 4.3.2), IBD
(Section 4.4.6) and ARVC (Section 4.5.1) cohorts. The results for 12 additional phenotypes are included in
the Appendix but not discussed further. These include cohorts with:
• Huntington’s Disease
• 3 Ophthalmology conditions
• IBD - An additional ethnically distinct Icelandic IBD cohort
• An unknown Neurological condition
• A Dermatology condition
• Keratoconus
• Primary Immuno Deficiency
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• A Prion condition
• A Mitochondrial defect
• Bone Marrow Failure
Two of these, the IBD and ARVC cohorts, proved quite amenable to this model, with principal genes NOD2
and TTN remaining significant with this correction. An in-depth clinical knowledge of these conditions is
required for a full evaluation of the veracity of any single variant or gene lists. In general however, this
combined with the improved genomic inflation factor (Figure 4.19) indicates that the model works well in
at least some situations.
5.1.2 Dealing with rare variants or limited cases
As mentioned already, various methods for accurate rare variant association tests were attempted. Published
methods such as SKAT generally perform better than basic binomial or Fisher tests because they are more
capable of modelling complex genetic architecture. The gene based results for ARVC and HCM in Section
2.2.2 robustly agreeing with the known genetic architecture of these conditions reinforces this point. Even
these methods struggle however when faced with factors such as cryptic relatedness or batch effects that
cannot be readily controlled for by currently available methods. That is to say, a mixed model methodology
for region based testing that can incorporate multiple kinship matrices and fixed covariates such as that
developed here for single variants has not yet been developed. The attempts discussed here are a start but
it is beyond the scope of this PhD to progress it further. As a result, until this is robustly developed, any
results from these models under development should be viewed with caution.
In order to refine our understanding of the clinical sub-types of conditions such as HCM and ARVC,
more specific phenotypes should be used in association studies. For example, patients with apical HCM
have been shown to have less fibrosis and diastolic dysfunction than those without apical involvement [Kim
et al., 2015]. This difference may have a genetic basis and could perhaps be tested by separating cases into
apical and non apical. The obvious problem with this approach would be the resultant reduction in sample
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size lowering the power to detect association. Table 4.10 shows the association results for ARVC based on
4334 samples. It also highlights the difficulty faced when even a number as large as this contains just 28
cases. It was impossible to get reliable results with such few cases so a balance should be achieved between
statistical power and clinical utility. Some methods have been developed in an attempt to improve power
amidst phenotypic heterogeneity. 2010 saw the discussion of a multinomial regression modeling framework
that categorised type 2 diabetes(T2D) cases by Body Mass Index. This allowed discrimination to be made
between the genetic basis of obese and non-obese forms of T2D [Morris et al., 2010]. This was improved upon
by the development of a multiclass likelihood ratio approach which determines itself the optimum number
of subphenotypes and builds a risk model prediction for each [Wen and Lu, 2013].
5.2 Limitations of the methodology for technical artefacts
My results show an improvement in the distribution of association test statistics across a range of cohorts.
The advantages to including alternative kinship matrices, such as Read Depth and Missingness have been
demonstrated. However, for several of the cohorts considered in this thesis, clear inflation of the test statistic
distribution remains. In addition, real association signals can, in some cases, be removed by the technical
correction. The major limitation is the inability to distinguish technical artefacts from actual association
signals. In situations where the sequencing (or more generally technical) batches are fully confounded with
the case control batches, no statistical methodology can separate signal from noise.
This issue is reflected by the fact that some cohorts are highly corrected with the Technical Kinship
and/or the Read Depth Kinship matrices. It was thus not possible to find a single kinship or particular
combination thereof that worked sufficiently well across all cohorts. By using spectral decomposition as
discussed in Section 1.7, it is possible to include a single kinship that is solved in the same time as a
standard linear regression. However, for multiple kinships, it is necessary to use an approximation, such as
GRAMMAR. This was not perfect however, as the variance component estimations from Section 4.4.8 (page
100) show that some cohorts naively exhibit a perfect or close to perfect (≥ 95%) correlation with these
Kinship Matrices. The SNP filtering that was ultimately used corrected for this in some cohorts by lowering
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the variance explained. In these cases the joint model retained enough power to detect the strongest signals,
but some associations were presumably lost. This is to be expected however with any model that corrects
for factors such as PS or technical artefacts. Over correction is less of an issue than under correction as we
are interested in only the top variants i.e. an inflation factor of 0.9 is better than 1.1.
5.3 Implications for experimental design
Obviously, the ideal experimental design involves homogeneous case control cohorts from the technical stand-
point. However, this is not always feasible given the costs of sequencing controls. This issue is particularly
strong for rare diseases. Indeed, while for complex traits with small effect sizes, equal case control cohorts
maximize the power to detect associations, the situation is different for rare diseases with large effect sizes.
The optimum ratio of controls to cases is equal to the odds ratio parameter, which raises the need for
large control cohorts that are ideally shared across studies. This idea has been applied very successfully by
the Wellcome Trust Case Control Consortium (WTCCC) that has provided shared controls to the medical
genetics community [Lee et al., 2014; Todd et al., 2007; Lindgren et al., 2009].
However, there are practical situations where the approach can be effective at correcting sub-optimal
case control designs. For example, if cases were sequenced using capture technology A, and controls were
sequenced using a combination of technologies A and B, the technical correction will appropriately remove
variants present in excess in samples sequenced using technology A, independently of the case control status.
Hence, even a limited number of controls sequenced using technology A can be sufficient to provide useful
information to separate signal from background. Similarly, the addition of cases sequenced using technology
B can serve the same purpose to verify that candidate variants present in technology A cases are also found in
excess in technology B cases. Statistically, factors that may induce some systematic artefact, eg technology
used, sample plate information, where the sample was sequenced, who prepared it etc may by partially
modelled for as a random effect. However, there are limits, as the number of fixed or random effects included
in the model should be limited to avoid removing all signal.
As discussed already, many possible sources of artefacts exist. PCR bias [Kanagawa, 2003], PCR
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artefacts [Kurata et al., 2004] and amplification inefficiencies or drift [Walsh PS, Erlich HA, 1992; Mutter
and Boynton, 1995] to name a few. In the early rounds of PCR, certain amplicons may be stochastically
amplified more than others, resulting in a skewed distribution later on. As this drift bias is random, it is likely
not a large factor in systematic differences between cases and controls however. Bias can also be caused by
a relative difference in the size of genomes in the solution being amplified; smaller genomes have been shown
to be overamplified compared to larger genomes [Pinard et al., 2006]. This last problem can be overcome by
amplifying the target genome in isolation, readily achieved through methods such as microfluidic droplets
and microdissections [Woyke et al., 2010].
The concentration of the DNA template is also important. It is increasingly difficult to equally
amplify the entirety of a sequence as its concentration lowers [Chandler et al., 1997]. This can pose problems
as research moves towards lower starting quantities of target DNA; for example in the cases of single cell
or cell-free DNA [Woyke et al., 2010]. This has led to the development of Amplication free methods which
lower or eliminate traditional sources of bias [Karlsson et al., 2015].
5.3.1 Remaining sources of artefacts, impact of sequence capture and transition
to WGS
My analysis of exome data points to a variety of artefacts that remain difficult to control for without applying
drastic quality control measures. Exploratory analysis of the data clearly shows that the artefacts identified
are correlated with sequencing batches, which are in turn associated with sequence capture technologies.
However, this does not imply that all these artefacts are created by the sequencing technology itself. For
example, manual curation of the results of the HCM and ARVC association results (Chapter 2, Tables 3
and 4) identified several cases of C>A/G>T transversion artefacts, as described in [Costello et al., 2013],
which are likely to result from oxidation of DNA during acoustic shearing in samples containing reactive
contaminants from the extraction process. Two examples of this are shown in Figure 5.1. This is most likely
a property of the sequencing batch, or perhaps of the sequencing facility during a specific period of time,
which typically happens to be confounded with capture technology in this case. Another issue when calling
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variants is the difficulty that aligners have when dealing with repetitive regions. Homopolymer sequences
are often miscalled as indels, so care must be taken to ensure that this is not just due to misalignment.
Figure 5.2 shows one such erroneous call. Manually examining the reads via IGV in this way is invaluable
in determining if this call is real. Nevertheless, other sources of artefacts, for example capture of paralogue
sequences that are mismapped to target regions, are a consequence of capture technology choices.
Figure 5.1: Two examples of C>A Transversion Artefacts shown in two HCM samples via IGV. On the left,
a RBM20 variant, chr10:112540622A-C, and on the right a TTN variant chr2:179436669A-C.
A conclusion from these observations is that some of these challenges will be alleviated by the
transition from exome/capture sequencing to WGS, because of the removal of a potential source of differential
bias between cohorts. In addition, the analysis of non-coding regions remains an unsolved challenge. Even for
broad capture techniques, in the case of the HCM and ARVC targeted sequencing datasets, the higher level
of polymorphisms in non coding regions combined with the absence of large reference datasets such as EXaC
[Consortium et al., 2015] prevented us from obtaining meaningful association results. This is particularly
frustrating as likely causal variants are detected in only half of HCM patients, and it is likely that regulatory
regions contribute to at least some extent to that missing heritability.
Given the limitations highlighted above, ongoing projects such as Genomics England appear to be
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Figure 5.2: TTN homopolymer run. The insertion that was called here, chr2:179563646-A, is bounded by
black vertical dashed lines. The DNA sequence of the region is labelled below, highlighting the extent of the
homopolymer region.
a major step forward toward a refined understanding of cardiovascular disease genetics. ARVC, HCM and
DCM alongside many other conditions are included in this projects remit (Figure 5.3). This project will
achieve the combined aims of (i) increasing sample size to improve statistical power, (ii) reduce the technical
artefacts that complicate the analysis of sequence data and cross-cohort comparison and (iii) provide a new
window into the yet unexplored role of regulatory regions. These data will provide a unique opportunity to
revisit and expand the outcome of exon centric association studies that are presented in this thesis.
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Figure 5.3: The types of cardiovascular disease that are included in the 100,000 Genomes Project. For more
information on factors such as diagnostic criteria of these conditions refer to the Genomics England website.
5.4 Comparison to other methods
There are many companies that offer capture platforms for WES. The platforms that they provide have
improved considerably over time. Despite this, many issues still exist, as discussed extensively already
(Section 1.6.2). Some solutions have been proposed to solve these issues. Consider the case of ArtQ from
the Introduction. While this worked in that specific case, it is far from a general solution. More far reaching,
another approach is assigning genotypes through the use of imputation [Davies et al., 2016]. The efficacy
of such an approach will vary depending on the discrete pattern of missingness, be it missing completely at
random, missing at random or not missing at random. However, it has been shown to have biases too and
indeed these are more pronounced for rare variants [Palmer and Pe’er, 2016]. Thus, this approach would not
be ideal for the data in UCL-ex, which is dominated by rare variants.
Chapter 4 provides the first demonstration of an attempt to use alternative Kinship matrices to
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control for factors other than PS. This approach is promising in that it does not require an idea of the
cause of the data, unlike ArtQ. Furthermore, the concepts’ derivation from standard methods of correcting
PS in GWAS means it is statistically robust. However, at the time of submission of this thesis, this had
not progressed sufficiently to offer adequate interpretable results. It is therefore difficult to comprehensively
compare its performance against other methods. Work is ongoing, and it is being integrated into the principle
pipeline for analysing WES at the UCL Genetics Institute.
An interesting alternative was proposed in [Palmer and Pe’er, 2016]. Multiple Imputation (MI)
functions better than traditional imputation as it probabilistically assigns genotypes by generating posterior
probabilities that are weighted by the confidence in the data. This intuitively makes sense: you would expect
variants that are of lower quality to be downweighted in comparison to high quality variants. Such methods
provide a benchmark against which other solutions need to be compared to identify if they provide a genuine
improvement.
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Appendix
.1 Chapter 2 - Cardiac Case Control
.1.1 Molecular Autopsy of Sudden Arrhythmic Death Syndrome Gene panel
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Channelopathy associated or candidate genes
1 AKAP9 (A kinase (PRKA) anchor protein (yotiao) 9)
2 ANK2 (ankyrin 2, neuronal)
3 ANKRD1 (ankyrin repeat domain 1 (cardiac muscle)
4 CACNA1B (calcium channel, voltage-dependent, N type, alpha 1B subunit)
5 CACNA1C (calcium channel, voltage-dependent, L type, alpha 1C subunit)
6 CACNA1D (calcium channel, voltage-dependent, L type, alpha 1D subunit)
7 CACNA2D1 (calcium channel, voltage-dependent, alpha 2/delta subunit 1)
8 CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)
9 CASQ2 (calsequestrin 2 (cardiac muscle))
10 CAV3 (caveolin 3)
11 DPP6 (dipeptidyl-peptidase 6)
12 GJA1 (gap junction protein, alpha 1, 43kDa)
13 GJA5 (gap junction protein, alpha 5, 40kDa)
14 GPD1L (glycerol-3-phosphate dehydrogenase 1-like)
15 HCN1 (hyperpolarization activated cyclic nucleotide-gated potassium channel 1)
16 HCN4 (hyperpolarization activated cyclic nucleotide-gated potassium channel 4)
17 KCNA5 (potassium voltage-gated channel, shaker-related subfamily, member 5)
18 KCND3 (potassium voltage-gated channel, Shal-related subfamily, member 3)
19 KCNE1 (potassium voltage-gated channel, Isk-related family, member 1)
20 KCNE1L (KCNE1-like)
21 KCNE2 (potassium voltage-gated channel, Isk-related family, member 2)
22 KCNE3 (potassium voltage-gated channel, Isk-related family, member 3)
23 KCNE4 (potassium voltage-gated channel, Isk-related family, member 4)
24 KCNH2 (potassium voltage-gated channel, subfamily H (eag-related), member 2)
25 KCNJ11 (potassium inwardly-rectifying channel, subfamily J, member 11)
26 KCNJ12 (potassium inwardly-rectifying channel, subfamily J, member 12)
27 KCNJ2 (potassium inwardly-rectifying channel, subfamily J, member 2)
28 KCNJ3 (potassium inwardly-rectifying channel, subfamily J, member 3)
29 KCNJ5 (potassium inwardly-rectifying channel, subfamily J, member 5)
30 KCNJ8 (potassium inwardly-rectifying channel, subfamily J, member 8)
31 KCNQ1 (potassium voltage-gated channel, KQT-like subfamily, member 1)
32 KCNQ2 (potassium voltage-gated channel, KQT-like subfamily, member 2)
33 NPPA (natriuretic peptide A)
34 RANGRF (RAN guanine nucleotide release factor)
35 RYR2 (ryanodine receptor 2 (cardiac))
36 SCN1B (sodium channel, voltage-gated, type I, beta subunit)
37 SCN2B (sodium channel, voltage-gated, type II, beta subunit)
38 SCN3B (sodium channel, voltage-gated, type III, beta subunit)
39 SCN4B (sodium channel, voltage-gated, type IV, beta subunit)
40 SCN5A (sodium channel, voltage-gated, type V, alpha subunit)
41 SCNN1B (sodium channel, non-voltage-gated 1, beta subunit)
42 SCNN1G (sodium channel, non-voltage-gated 1, gamma subunit)
43 SNTA1 (syntrophin, alpha 1)
00 Cardiomyopathy associated or candidate genes
01 ABCC9 (ATP-binding cassette, sub-family C member 9)
02 ACTC1 (Actin, alpha cardiac muscle 1)
03 ACTN2 (Actinin, alpha 2)
03 AGL (amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase)
04 BAG3 (BCL2-associated athanogene 3)
05 BRAF (v-raf murine sarcoma viral oncogene homolog B1)
Table 1: Name according to HGNC of the candidate genes for the Molecular Autopsy of Sudden Cardiac
Death study
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Cardiomyopathy associated or candidate genes
1 CALR3 (calreticulin 3)
2 CRYAB (crystallin, alpha B)
3 CSRP3 (cysteine and glycine-rich protein 3 (cardiac LIM protein)
4 DES (desmin)
5 DMD (dystrophin)
6 DSC2 (desmocolin 2)
7 DSG2 (desmoglein 2)
8 DSP (desmoplakin)
9 DTNA (dystrobrevin, alpha)
10 EMD (emerin)
11 EYA4 (eyes absent homolog 4)
12 FHL1 (four and a half LIM domains 1)
13 FHL2 (four and a half LIM domains 2)
14 FKTN (fukutin)
15 FLNC (filamin C, gamma)
16 FXN (frataxin)
17 GAA (glucosidase, alpha; acid)
18 GATAD1 (GATA zinc finger domain containing 1)
19 GLA (galactosidase, alpha)
20 HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog)
21 ILK (integrin-linked kinase)
22 JPH2 (junctophilin 2)
23 JUP (junction plakoglobin)
24 KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog)
25 LAMA4 (laminin, alpha 4)
26 LAMP2 (lysosomal-associated membrane protein 2)
27 LDB3 (LIM domain binding 3)
28 LMNA (lamin A/C)
29 MAP2K1 (mitogen-activated protein kinase kinase 1)
30 MYBPC3 (myosin binding protein C, cardiac)
31 MYH6 (myosin, heavy polypeptide 6, cardiac muscle, alpha)
32 MYH7 (myosin, heavy polypeptide 7, cardiac muscle, alpha)
33 MYL2 (myosin, light chain 2, regulatory, cardiac, slow)
34 MYL3 (myosin, light chain 3, alkali; ventricular, skeletal, slow)
35 MYLK2 (myosin light chain kinase 2)
36 MYOT (myotilin)
37 MYOZ2 (myozenin 2)
38 MYPN (myopalladin)
39 NEBL (nebulette)
40 NEXN (nexilin (F actin binding protein))
41 NRAS (neuroblastoma RAS viral (v-ras) oncogene homolog)
42 PDLIM3 (PDZ and LIM domain 3)
43 PKP2 (plakophilin 2)
44 PLEC (plectin)
45 PKP4 (plakophilin 4)
46 PLN (phospholamban)
47 PNN (pinin, desmosome associated protein)
48 PRKAG2 (protein kinase, AMP-activated, gamma 2 non-catalytic subunit)
49 PSEN1 (presenilin 1)
50 PSEN2 (presenilin 2)
Table 2: Name according to HGNC of the candidate genes for the Molecular Autopsy of Sudden Cardiac
Death study
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Cardiomyopathy associated or candidate genes
1 PTPN11 (protein tyrosine phosphatase, non-receptor type 11)
2 RAF1 (v-raf-1 murine leukemia viral oncogene homolog 1)
3 RBM20 (RNA binding motif protein 20)
4 SGCD (sarcoglycan, delta (35kDa dystrophin-associated glycoprotein))
5 SHOC2 (soc-2 suppressor of clear homolog (C. elegans))
6 SLC25A4 (solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4)
7 SOS1 (son of sevenless homolog 1 (Drosophila))
8 TAZ (tafazzin)
9 TCAP (titin-cap)
10 TGFB3 (transforming growth factor, beta 3)
11 TMEM43 (transmembrane protein 43)
12 TMPO (thymopoietin)
13 TNNC1 (troponin C type 1 (slow))
14 TNNI3 (troponin I type 3 (cardiac))
15 TNNT2 (troponin T type 2 (cardiac))
16 TPM1 (tropomyosin 1 (alpha))
17 TTN (titin)
18 TTR (transthyretin)
19 VCL (vinculin)
00 Others
01 ADRB2 (adrenoceptor beta 1)
02 ADRB2 (adrenoceptor beta 2)
03 ADRB3 (adrenoceptor beta 3)
04 BMPR2 (bone morphogenetic protein receptor, type II (serine/threonine kinase)
05 CTF1 (cardiotrophin 1)
06 DNM1L (dynamin 1-like)
07 ELN (elastin)
08 GATA4 (GATA binding protein 4)
09 potassium inwardly-rectifying channel, subfamily J, member 11
10 LRP6 (low density lipoprotein receptor-related protein 6)
11 NKX2-5 (NK2 homeobox 5)
12 TBX20 (T-box 20)
13 FBN1 (fibrillin 1)
14 FBN2 (fibrillin 2)
15 TGFBR1 (transforming growth factor, beta receptor I)
16 TGFBR2 (transforming growth factor, beta receptor II)
17 ACTA2 (actin, alpha 2, smooth muscle, aorta)
Table 3: Name according to HGNC of the candidate genes for the Molecular Autopsy of Sudden Cardiac
Death study
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.1.2 ARVC/HCM Gene Panel
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ENSEMBL HUGO Chromosome Start End
1 ENSG00000118194 TNNT2 1 201359008 201377762
2 ENSG00000118729 CASQ2 1 115700007 115768781
3 ENSG00000159166 LAD1 1 201373244 201399915
4 ENSG00000160789 LMNA 1 156082573 156140089
5 ENSG00000198626 RYR2 1 237042205 237833988
6 ENSG00000144283 PKP4 2 158456964 158682879
7 ENSG00000153237 CCDC148 2 158171081 158456753
8 ENSG00000155657 TTN 2 178525989 178830802
9 ENSG00000175084 DES 2 219418377 219426739
10 ENSG00000237298 TTN-AS1 2 178521183 178779963
11 ENSG00000114854 TNNC1 3 52451102 52454070
12 ENSG00000125046 SSUH2 3 8619400 8745040
13 ENSG00000160808 MYL3 3 46857872 46882169
14 ENSG00000170876 TMEM43 3 14124940 14143679
15 ENSG00000182533 CAV3 3 8733800 8841808
16 ENSG00000183873 SCN5A 3 38548057 38649673
17 ENSG00000145362 ANK2 4 112818109 113383740
18 ENSG00000154553 PDLIM3 4 185500660 185535612
19 ENSG00000096696 DSP 6 7541575 7586717
20 ENSG00000152661 GJA1 6 121435692 121449727
21 ENSG00000198523 PLN 6 118548298 118560730
22 ENSG00000055118 KCNH2 7 150944961 150978315
23 ENSG00000178209 PLEC 8 143915147 143976734
24 ENSG00000035403 VCL 10 73995193 74121363
25 ENSG00000122367 LDB3 10 86668449 86736068
26 ENSG00000203867 RBM20 10 110644397 110839469
27 ENSG00000053918 KCNQ1 11 2444684 2849109
28 ENSG00000129170 CSRP3 11 19182030 19210573
29 ENSG00000134571 MYBPC3 11 47331397 47352702
30 ENSG00000057294 PKP2 12 32790745 32896840
31 ENSG00000111245 MYL2 12 110910819 110920722
32 ENSG00000092054 MYH7 14 23412738 23435718
33 ENSG00000100941 PNN 14 39175183 39183218
34 ENSG00000119699 TGFB3 14 75958099 75982991
35 ENSG00000197616 MYH6 14 23381990 23408277
36 ENSG00000259083 RP11-407N17.4 14 39174885 39175880
37 ENSG00000140416 TPM1 15 63042632 63071915
38 ENSG00000159251 ACTC1 15 34788096 34796139
39 ENSG00000123700 KCNJ2 17 70168673 70180048
40 ENSG00000173801 JUP 17 41754604 41786931
41 ENSG00000173991 TCAP 17 39664187 39666555
42 ENSG00000046604 DSG2 18 31498043 31549008
43 ENSG00000134755 DSC2 18 31058840 31102415
44 ENSG00000129991 TNNI3 19 55151767 55157773
45 ENSG00000267110 CTD-2587H24.4 19 55154757 55160671
46 ENSG00000159197 KCNE2 21 34364024 34371389
47 ENSG00000180509 KCNE1 21 34446688 34512275
Table 4: Genes sequenced in the ARVC/HCM Gene panel
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.2 Chapter 3 - HCM Copy Number Variant analysis gene panel
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Gene Ensembl Number Chromosome:Start-End Number(bp)
MYBPC3 ENSG00000134571 Chr11:47352958-47374253 21295
MYH7 ENSG00000092054 Chr14:23881948-23904870 22922
TNNI3 ENSG00000129991 Chr19:55663137-55669100 5963
TNNT2 ENSG00000118194 Chr1:201328143-201346805 18662
TPM1 ENSG00000140416 Chr15:63334838-63364111 29273
MYL2 ENSG00000111245 Chr12:111348626-111358404 9778
MYL3 ENSG00000160808 Chr3:46899357-46904973 5616
ACTC1 ENSG00000159251 Chr15:35080297-35087927 7630
TNNC1 ENSG00000114854 Chr3:52485108-52488057 2949
MYH6 ENSG00000197616 Chr14:23851199-23877482 26283
TTN ENSG00000155657 Chr2:179390720-179672150 281430
PDLIM3 ENSG00000154553 Chr4:186422852-186456712 33860
CSRP3 ENSG00000129170 Chr11:19203578-19223589 20011
DES ENSG00000175084 Chr2:220283099-220291459 8360
LMNA ENSG00000160789 Chr1:156084461-156109878 25417
LDB3 ENSG00000122367 Chr10:88428426-88495822 67396
VCL ENSG00000035403 Chr10:75757872-75879912 122040
TCAP ENST00000309889 Chr17:37821599-37822806 1207
PLN ENSG00000198523 Chr6:118869442-118881586 12144
RBM20 ENSG00000203867 Chr10:112404155-112599227 195072
JUP ENSG00000173801 Chr17:39910859-39942964 32105
DSP ENSG00000096696 Chr6:7541870-7586946 45076
PKP2 ENSG00000057294 Chr12:32943682-33049780 106098
DSG2 ENSG00000046604 Chr18:29078027-29128813 50786
DSC2 ENSG00000134755 Chr18:28645944-28682388 36444
RYR2 ENSG00000198626 Chr1:237205702-237997288 791586
TMEM43 ENST00000306077 Chr3:14166440-14185180 18740
TGF-3 ENST00000238682 Chr14:76424442-76448092 23650
KCNQ1 ENSG00000053918 Chr11:2466221-2870339 404118
KCNH2 ENSG00000055118 Chr7:150642050-150675014 32964
SCN5A ENSG00000183873 Chr3:38589554-38691164 101610
KCNE1 ENSG00000180509 Chr21:35818989-35828063 9074
KCNE2 ENSG00000159197 Chr21:35736323-35743440 7117
ANK2 ENST00000394537 Chr4:113970785-114304894 334109
CASQ2 ENSG00000118729 Chr1:116242628-116311426 68798
CAV3 ENSG00000182533 Chr3:8775496-8788450 12954
KCNJ2 ENSG00000123700 Chr17:68165676-68176181 10505
PLEC ENSG00000178209 Chr8:144989321-145025044 35723
GJA1 ENST00000282561 Chr6:121756745-121770872 14127
PKP4 ENSG00000144283 Chr2:159313476-159537938 224462
PNN ENSG00000100941 Chr14:39644387-39652421 8036
Table 5: Name of the targeted genes, Ensembl accesion number, chromsomal positon and size sequenced for
the HCM CNV study.
134
.3 Chapter 4 - Single Variant Results for additional UCLex Co-
horts
For each of the tables in this section the layout is the same so, a common legend is provided: SNP details
the position of the tested variant (hg19). Gene is the HUGO name for the gene in which the SNP resides.
FisherPvalue is the pvalue from Fisher’s exact test. LRpvalue is the Linear Regression pvalue with no
covariates or kinship matrices. LMMpvalue is the pvalue from Equation 4.9. OR is the risk odds ratio.
’Homs’ are homozygotes for the minor allele, while ’Hets’ are heteroozygotes.
SNP Gene FisherPvalue LRpvalue LMMpvalue OR nb.Homs.Huntingtons nb.Homs.ctrls nb.Hets.Huntingtons nb.Hets.ctrls
1 1 7723921 T C CAMTA1 8.82E-04 1.00E-16 1.00E-16 81 0 0 2 2
2 18 72223597 - TGT CNDP1 1.19E-12 1.00E-16 1.00E-16 NA 1 0 4 0
3 3 49845468 C T UBA7 8.46E-04 1.00E-16 1.00E-16 83 0 0 2 2
4 11 44228488 C T EXT2 9.16E-04 1.00E-16 1.87E-11 80 0 0 2 2
Table 6: Huntingtons Single Variant Results
SNP Gene FisherPvalue LRpvalue LMMpvalue OR nb.Homs.Eye nb.Homs.ctrls nb.Hets.Eye nb.Hets.ctrls
1 10 100189567 C G HPS1 8.70E-12 1.00E-16 1.00E-16 358 0 0 7 1
2 10 115368200 C T NRAP 9.47E-13 1.00E-16 1.00E-16 NA 0 0 7 0
3 10 123970354 A G TACC2 2.97E-09 1.00E-16 1.00E-16 NA 0 0 5 0
4 10 124753444 A G IKZF5 3.30E-09 1.00E-16 1.00E-16 NA 0 0 5 0
5 10 16992007 G C CUBN 2.23E-06 1.00E-16 1.00E-16 100 0 0 4 2
6 10 27524067 T C ACBD5 8.82E-07 1.00E-16 1.00E-16 192 0 0 4 1
7 10 3193452 G A PITRM1 3.70E-05 1.00E-16 1.00E-16 139 0 0 3 1
8 10 84745067 A G NRG3 9.58E-13 1.00E-16 1.00E-16 NA 0 0 7 0
9 11 100211919 T C CNTN5 2.12E-07 1.00E-16 1.00E-16 NA 0 0 4 0
10 11 433357 G - ANO9 7.45E-06 1.00E-16 1.00E-16 25 0 0 5 9
11 1 150530506 G T ADAMTSL4 7.74E-09 1.00E-16 1.00E-16 296 0 0 5 1
12 1 153279608 C T PGLYRP3 3.62E-09 1.00E-16 1.00E-16 NA 0 0 5 0
13 1 154920148 G A PBXIP1 8.66E-10 1.00E-16 1.00E-16 70 0 0 7 5
14 11 56237921 C T OR5M3 6.56E-11 1.00E-16 1.00E-16 NA 0 0 6 0
15 11 56237921 C T OR8U8 6.56E-11 1.00E-16 1.00E-16 NA 0 0 6 0
16 1 158670285 G C OR6K2 3.32E-11 1.00E-16 1.00E-16 183 0 0 7 2
17 1 171605478 G A MYOC 5.80E-07 1.00E-16 1.00E-16 52 0 0 5 5
18 1 174210750 G A RABGAP1L 1.64E-04 1.00E-16 1.00E-16 48 0 0 3 3
19 1 182353781 A C GLUL 6.62E-07 1.00E-16 1.00E-16 206 0 0 4 1
20 11 85445453 T C SYTL2 3.27E-05 1.00E-16 1.00E-16 145 0 0 3 1
Table 7: Opthalmology Condition 1 Single Variant Results
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SNP Gene FisherPvalue LRpvalue LMMpvalue OR NA..3 nb.Homs.ctrls NA..4 nb.Hets.ctrls
1 11 120175740 C T POU2F3 8.51E-09 1.00E-16 1.00E-16 NA 0 0 4 0
2 22 29621158 C T EMID1 6.14E-11 1.00E-16 1.00E-16 NA 0 0 5 0
3 22 30688584 C T TBC1D10A 6.64E-11 1.00E-16 1.00E-16 NA 0 0 5 0
4 2 56420484 C A CCDC85A 5.38E-06 1.00E-16 1.00E-16 272 0 0 3 1
5 3 169700534 A C SEC62 9.23E-10 1.00E-16 1.00E-16 466 0 0 5 1
6 8 25234859 G A DOCK5 9.78E-09 1.00E-16 1.00E-16 NA 0 0 4 0
7 11 2432745 G A TRPM5 9.77E-04 1.00E-16 2.45E-16 67 0 0 2 3
8 16 51175457 C T SALL1 3.32E-06 1.00E-16 5.19E-16 320 0 0 3 1
9 17 17124804 C T FLCN 8.16E-06 1.00E-16 1.08E-15 161 0 0 3 2
10 3 38307622 G A SLC22A13 8.37E-06 1.00E-16 3.42E-15 159 0 0 3 2
11 19 334440 T G MIER2 7.43E-06 1.00E-16 1.47E-13 166 0 0 3 2
12 1 53932322 A G DMRTB1 1.58E-04 1.00E-16 9.16E-13 36 0 0 3 9
13 1 55014014 G A ACOT11 1.23E-05 1.00E-16 2.06E-12 140 0 0 3 2
14 12 55420621 G A NEUROD4 7.54E-06 1.00E-16 9.22E-12 165 0 0 3 2
15 9 19785979 G A SLC24A2 1.16E-07 1.00E-16 1.18E-11 215 0 0 4 2
16 1 889212 G A NOC2L 1.55E-07 1.00E-16 2.38E-11 200 0 0 4 2
17 1 114394645 A C PTPN22 7.54E-06 1.00E-16 3.67E-11 165 0 0 3 2
18 1 201868510 G T LMOD1 1.10E-05 1.00E-16 3.97E-11 146 0 0 3 2
19 17 9631505 C T USP43 6.72E-04 3.90E-15 4.27E-11 94 0 0 2 2
20 1 979517 T A AGRN 2.74E-07 1.00E-16 4.32E-11 142 0 0 4 3
Table 8: Icelandic IBD Cohort Single Variant Results
SNP Gene FisherPvalue LRpvalue LMMpvalue OR nb.Homs.Neur nb.Homs.ctrls nb.Hets.Neur nb.Hets.ctrls
1 1 109806800 A G CELSR2 6.12E-07 1.00E-16 1.00E-16 NA 0 0 4 0
2 11 19077074 CT GT MRGPRX2 1.13E-09 1.00E-16 1.00E-16 254 0 0 6 1
3 11 19077075 T G MRGPRX2 3.18E-10 1.00E-16 1.00E-16 NA 0 0 6 0
4 1 161695685 TACG GACG FCRLB 1.26E-10 1.00E-16 1.00E-16 240 0 0 7 1
5 11 6977031 A G ZNF215 1.12E-06 1.00E-16 1.00E-16 NA 0 0 4 0
6 11 700213 G A TMEM80 1.13E-06 1.00E-16 1.00E-16 NA 0 0 4 0
7 11 76928315 - ATCT GDPD4 2.61E-06 1.00E-16 1.00E-16 145 0 0 4 1
8 12 123342763 G A HIP1R 5.42E-07 1.00E-16 1.00E-16 NA 0 0 4 0
9 13 25671955 T C PABPC3 1.80E-06 1.00E-16 1.00E-16 NA 0 0 4 0
10 13 39425226 G T FREM2 3.27E-08 1.00E-16 1.00E-16 NA 0 0 5 0
11 14 33291745 G A AKAP6 5.36E-07 1.00E-16 1.00E-16 NA 0 0 4 0
12 14 88893017 C T SPATA7 6.47E-07 1.00E-16 1.00E-16 NA 0 0 4 0
13 16 84270704 C T KCNG4 1.15E-06 1.00E-16 1.00E-16 NA 0 0 4 0
14 17 2227024 C G SRR 1.59E-08 1.00E-16 1.00E-16 NA 0 0 4 0
15 17 2227024 C G TSR1 1.59E-08 1.00E-16 1.00E-16 NA 0 0 4 0
16 17 39346627 CCACCCAACA - KRTAP9-1 2.78E-19 1.00E-16 1.00E-16 156 0 0 14 3
17 17 39346639 CTGTCAAACC - KRTAP9-1 3.84E-19 1.00E-16 1.00E-16 152 0 0 14 3
18 1 75037184 C G C1orf173 2.71E-08 1.00E-16 1.00E-16 NA 0 0 5 0
19 17 72366771 T G GPR142 1.01E-06 1.00E-16 1.00E-16 NA 0 0 4 0
20 19 20002909 A C ZNF253 5.68E-07 1.00E-16 1.00E-16 79 0 0 5 2
Table 9: Neurology Single Variant Results
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SNP Gene FisherPvalue LRpvalue LMMpvalue OR NA..3 nb.Homs.ctrls NA..4 nb.Hets.ctrls
1 9 140878697 C T CACNA1B 6.99E-04 6.83E-15 1.21E-16 70 0 1 2 3
2 15 42192873 C T EHD4 2.01E-04 1.00E-16 1.81E-16 174 0 0 2 2
3 1 175365772 G A TNR 6.93E-06 1.25E-15 6.83E-13 123 1 0 1 5
4 19 48714997 G A CARD8 3.77E-04 2.32E-06 3.24E-10 101 1 0 0 4
Table 10: Opthalmology Condition 2 Single Variant Results
SNP Gene FisherPvalue LRpvalue LMMpvalue OR nb.Homs.Skin nb.Homs.ctrls nb.Hets.Skin nb.Hets.ctrls
1 10 121140398 A G GRK5 5.47E-07 1.00E-16 1.00E-16 143 0 0 4 2
2 10 128923854 A G DOCK1 1.62E-09 1.00E-16 1.00E-16 414 0 0 5 1
3 10 129216722 A G DOCK1 5.22E-13 1.00E-16 1.00E-16 343 0 0 7 2
4 10 135099022 G T TUBGCP2 1.79E-08 1.00E-16 1.00E-16 NA 0 0 4 0
5 10 16975189 C T CUBN 3.31E-05 1.00E-16 1.00E-16 99 0 0 3 2
6 10 31799735 A G ZEB1 6.24E-08 1.00E-16 1.00E-16 NA 0 0 4 0
7 10 38406867 G T ZNF37A 2.54E-06 1.00E-16 1.00E-16 72 0 0 4 4
8 10 72181468 C T EIF4EBP2 8.99E-04 5.73E-15 1.00E-16 80 0 0 2 2
9 10 73562724 G A CDH23 1.43E-16 1.00E-16 1.00E-16 420 0 0 9 2
10 10 79553803 C T DLG5 2.17E-11 1.00E-16 1.00E-16 24 0 0 11 38
11 10 79576826 C T DLG5 5.12E-12 1.00E-16 1.00E-16 28 1 0 9 29
12 10 79616631 C T DLG5 4.35E-12 1.00E-16 1.00E-16 28 1 0 9 34
13 10 82403828 TGT - SH2D4B 3.45E-15 1.00E-16 1.00E-16 NA 0 0 8 0
14 10 90537864 G C LIPN 4.04E-10 1.00E-16 1.00E-16 67 1 0 5 8
15 10 90575223 T C LIPM 1.54E-10 1.00E-16 1.00E-16 86 1 0 5 6
16 10 93904826 A G CPEB3 1.85E-11 1.00E-16 1.00E-16 159 1 0 5 3
17 10 95275274 A G CEP55 7.43E-09 1.00E-16 1.00E-16 41 1 0 5 10
18 1 109823574 A G PSRC1 1.80E-05 1.00E-16 1.00E-16 122 0 0 3 2
19 11 107375857 G T ALKBH8 2.33E-05 1.00E-16 1.00E-16 112 0 0 3 2
20 11 114401546 G A NXPE1 4.98E-11 1.00E-16 1.00E-16 119 0 0 7 4
Table 11: Dermatology Single Variant Results
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SNP Gene FisherPvalue LRpvalue LMMpvalue OR NA..3 nb.Homs.ctrls NA..4 nb.Hets.ctrls
1 10 106209864 G T CCDC147 4.52E-04 1.00E-16 1.00E-16 81 0 0 2 9
2 10 117704227 A G ATRNL1 3.67E-04 1.00E-16 1.00E-16 91 0 1 2 6
3 10 1421303 A C ADARB2 5.51E-06 1.00E-16 1.00E-16 121 1 0 1 9
4 10 1421304 G C ADARB2 5.51E-06 1.00E-16 1.00E-16 121 1 0 1 9
5 10 24833905 C T KIAA1217 7.82E-04 1.00E-16 1.00E-16 59 1 0 0 12
6 10 29581461 A G LYZL1 3.75E-04 1.00E-16 1.00E-16 90 0 0 2 8
7 10 3823777 T C KLF6 7.12E-05 1.00E-16 1.00E-16 299 0 0 2 2
8 10 3824081 G A KLF6 5.34E-05 1.00E-16 1.00E-16 347 0 0 2 2
9 10 43596103 G A RET 1.41E-04 1.00E-16 1.00E-16 169 0 1 2 2
10 10 75184902 G A MSS51 1.38E-06 1.00E-16 1.00E-16 220 1 0 1 5
11 10 84744970 C T NRG3 3.46E-06 1.00E-16 1.00E-16 145 1 0 1 8
12 10 91477375 G T KIF20B 4.68E-04 1.00E-16 1.00E-16 81 0 0 2 8
13 10 97154762 G A SORBS1 5.26E-04 1.00E-16 1.00E-16 74 0 0 2 10
14 1 100387183 T A AGL 1.46E-04 1.00E-16 1.00E-16 166 0 0 2 4
15 1 10709186 G A CASZ1 1.31E-04 1.00E-16 1.00E-16 176 1 0 0 4
16 1 109803697 G A CELSR2 8.29E-06 1.00E-16 1.00E-16 103 0 0 3 11
17 11 100141950 G A CNTN5 2.54E-04 1.00E-16 1.00E-16 112 0 0 2 10
18 11 102196019 A G BIRC3 8.31E-05 1.00E-16 1.00E-16 240 0 0 2 3
19 11 107375667 C T ALKBH8 1.47E-04 1.00E-16 1.00E-16 166 0 0 2 4
20 11 111753245 C T C11orf1 6.34E-04 1.00E-16 1.00E-16 66 0 1 2 9
Table 12: Keratoconus Single Variant Results
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SNP Gene FisherPvalue LRpvalue LMMpvalue OR nb.Homs.Immune nb.Homs.ctrls nb.Hets.Immune nb.Hets.ctrls
1 10 48429512 G A GDF10 2.26E-07 1.00E-16 1.00E-16 148 0 0 5 1
2 1 197072458 T C ASPM 1.62E-06 1.00E-16 1.00E-16 NA 0 0 4 0
3 12 68720470 A G MDM1 3.07E-04 4.29E-13 1.00E-16 45 0 0 3 2
4 19 11565623 G T ELAVL3 1.20E-06 1.00E-16 1.00E-16 NA 1 0 2 0
5 1 9787030 G A PIK3CD 7.85E-10 1.00E-16 1.00E-16 NA 0 0 6 0
6 20 25258960 T C PYGB 6.65E-04 2.53E-10 1.00E-16 29 0 0 3 3
7 2 127453624 G A GYPC 5.42E-06 1.00E-16 1.00E-16 119 1 0 2 1
8 2 241463616 G A ANKMY1 3.29E-04 3.05E-13 1.00E-16 44 0 0 3 2
9 2 46588218 C T EPAS1 6.41E-04 1.35E-10 1.00E-16 29 0 0 3 3
10 3 51671458 G A RAD54L2 2.91E-04 5.39E-14 1.00E-16 46 0 0 3 2
11 6 33283594 G A ZBTB22 5.59E-05 1.04E-11 1.00E-16 16 0 0 5 9
12 6 33372831 T C KIFC1 2.17E-05 1.37E-11 1.00E-16 13 0 0 6 13
13 6 38906754 T C DNAH8 3.50E-04 8.22E-13 1.00E-16 43 0 0 3 2
14 6 38906754 T C LOC100131047 3.50E-04 8.22E-13 1.00E-16 43 0 0 3 2
15 7 150918769 G A ABCF2 3.07E-04 2.79E-13 1.00E-16 45 0 0 3 2
16 X 10085293 G A WWC3 2.95E-04 1.00E-16 1.00E-16 46 0 0 3 2
17 16 57095409 G A NLRC5 2.05E-08 1.00E-16 1.03E-16 43 1 0 5 5
18 14 103450076 G A CDC42BPB 6.84E-06 1.00E-16 1.10E-16 112 0 0 4 1
19 3 48658942 C T TMEM89 3.13E-07 1.00E-16 3.26E-16 36 1 0 4 6
20 1 12433865 C T VPS13D 4.51E-04 6.95E-09 3.95E-16 14 0 0 4 8
Table 13: Primary Immuno Deficiency Single Variant Results
SNP Gene FisherPvalue LRpvalue LMMpvalue OR NA..3 nb.Homs.ctrls NA..4 nb.Hets.ctrls
1 1 152681693 TGTGGT - LCE4A 7.93E-75 1.00E-16 1.00E-16 189 3 0 52 10
2 X 73811755 C G RLIM 1.85E-60 5.52E-16 5.91E-13 59 0 0 57 27
3 7 150325310 C T GIMAP6 9.24E-04 4.27E-03 2.64E-12 31 0 0 3 2
4 1 248616401 G A OR2T2 1.95E-38 1.34E-05 9.55E-11 6 2 21 101 279
5 1 248616408 C T OR2T2 5.41E-37 6.23E-05 1.21E-10 5 2 22 102 299
6 2 10584626 C T ODC1 3.83E-04 2.05E-01 1.53E-10 6 1 0 5 21
Table 14: Prion Single Variant Results
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SNP Gene FisherPvalue LRpvalue LMMpvalue OR nb.Homs.Mito nb.Homs.ctrls nb.Hets.Mito nb.Hets.ctrls
1 10 120934107 - A PRDX3 5.84E-08 1.00E-16 1.00E-16 127 0 0 5 2
2 1 153314126 C T PGLYRP4 1.75E-04 1.00E-16 1.00E-16 47 0 0 3 3
3 12 111772320 C T CUX2 3.57E-05 1.00E-16 1.00E-16 141 0 0 3 1
4 12 15650326 T C PTPRO 5.12E-05 1.00E-16 1.00E-16 125 0 0 3 1
5 1 228595950 C T TRIM17 1.73E-04 1.00E-16 1.00E-16 47 0 0 3 3
6 12 55759555 C T OR6C75 3.50E-05 1.00E-16 1.00E-16 142 0 0 3 1
7 14 21841524 A G SUPT16H 1.02E-04 1.00E-16 1.00E-16 67 0 0 3 2
8 17 65925556 A G BPTF 8.78E-05 1.00E-16 1.00E-16 70 0 0 3 2
9 19 24102851 A G ZNF726 2.08E-04 1.00E-16 1.00E-16 44 0 0 3 3
10 1 982833 C T AGRN 2.86E-09 1.00E-16 1.00E-16 NA 0 0 5 0
11 2 108994856 C T SULT1C4 4.23E-05 1.00E-16 1.00E-16 133 0 0 3 1
12 2 170092467 G A LRP2 3.57E-04 7.75E-15 1.00E-16 33 0 0 3 4
13 3 138187558 C T ESYT3 1.49E-04 1.00E-16 1.00E-16 49 0 0 3 3
14 3 193081064 G A ATP13A5 3.68E-05 1.00E-16 1.00E-16 139 0 0 3 1
15 3 58855204 C T C3orf67 1.95E-07 1.00E-16 1.00E-16 80 0 0 5 3
16 4 13616292 T A BOD1L1 1.46E-04 1.00E-16 1.00E-16 50 0 0 3 3
17 5 72980694 C T RGNEF 6.05E-05 1.00E-16 1.00E-16 80 0 0 3 2
18 5 75989260 C T IQGAP2 7.58E-05 1.00E-16 1.00E-16 74 0 0 3 2
19 5 90136800 A C GPR98 3.19E-05 1.00E-16 1.00E-16 147 0 0 3 1
20 7 100635250 C A MUC12 3.52E-04 4.51E-13 1.00E-16 31 0 0 3 5
Table 15: Mitochondrial disease Single Variant Results
SNP Gene FisherPvalue LRpvalue LMMpvalue OR nb.Homs.Bone nb.Homs.ctrls nb.Hets.Bone nb.Hets.ctrls
1 11 66099992 G T RIN1 3.81E-07 1.00E-16 1.00E-16 NA 0 0 5 0
2 1 170955836 C T C1orf129 9.79E-06 1.00E-16 1.00E-16 NA 0 0 4 0
3 16 3614342 G A NLRC3 7.16E-04 2.59E-10 1.00E-16 49 0 0 3 1
4 5 146763533 A G STK32A 7.12E-04 1.50E-10 1.00E-16 49 0 0 3 1
5 9 117139815 G A AKNA 9.83E-06 1.59E-10 1.00E-16 18 1 0 4 7
6 11 66334727 C T CTSF 7.28E-06 1.16E-15 1.52E-16 45 0 0 5 2
7 3 72495945 A G RYBP 7.24E-04 4.88E-10 3.40E-16 49 0 0 3 1
8 22 50187923 G T BRD1 4.59E-04 1.67E-10 1.63E-15 58 0 0 3 1
9 9 123673632 C T TRAF1 9.77E-06 1.00E-16 1.07E-14 NA 0 0 4 0
10 5 156381625 C T TIMD4 7.44E-04 1.60E-10 1.67E-14 48 0 0 3 1
11 7 4830898 C G AP5Z1 6.77E-04 1.42E-10 2.87E-14 50 0 0 3 1
12 7 44180307 G A MYL7 5.83E-04 9.08E-11 7.23E-14 53 0 0 3 1
13 11 65146965 A G SLC25A45 6.59E-04 2.12E-10 1.13E-13 51 0 0 3 1
14 10 102739999 C T SEMA4G 6.49E-04 1.54E-10 1.39E-13 51 0 0 3 1
15 10 102739999 C T MRPL43 6.49E-04 1.54E-10 1.39E-13 51 0 0 3 1
16 15 65983590 A G DENND4A 2.81E-04 1.94E-08 2.94E-13 12 0 0 5 7
17 5 141694394 C T SPRY4 1.50E-04 1.08E-09 1.07E-12 86 0 0 3 1
18 X 100169508 G A XKRX 5.13E-05 2.64E-14 1.12E-12 65 0 0 4 1
19 7 35293222 T A TBX20 1.64E-04 1.10E-11 1.29E-12 32 0 0 4 2
20 19 16006368 G A CYP4F2 7.09E-06 1.00E-16 1.32E-12 NA 0 0 4 0
Table 16: Bone Marrow Failure Single Variant Results
140
SNP Gene FisherPvalue LRpvalue LMMpvalue OR NA..3 nb.Homs.ctrls NA..4 nb.Hets.ctrls
1 19 36002488 C A DMKN 6.23E-04 1.00E-16 1.00E-16 97 0 0 2 2
2 19 36027710 C T GAPDHS 8.59E-04 1.00E-16 2.29E-16 71 0 0 2 3
3 2 235951605 C T SH3BP4 8.35E-06 1.00E-16 7.68E-15 160 1 0 1 2
4 17 39115095 G A KRT39 3.08E-07 1.00E-16 9.71E-14 437 1 0 1 3
5 16 71483003 C T ZNF23 3.21E-06 1.00E-16 1.45E-13 323 0 0 3 1
6 1 11188142 C T MTOR 8.05E-04 2.95E-15 2.51E-12 74 1 0 0 3
7 1 152192053 C T HRNR 7.93E-04 1.00E-16 7.07E-12 74 0 0 2 3
8 5 132652228 G A FSTL4 7.93E-04 1.00E-16 1.64E-11 74 0 0 2 3
9 1 17396685 G A PADI2 7.82E-04 1.00E-16 3.07E-11 75 0 0 2 3
10 5 156923974 C T ADAM19 1.01E-05 1.00E-16 5.70E-11 39 0 0 4 11
11 19 55086356 - GT LILRA2 5.17E-05 1.00E-16 2.08E-10 59 0 0 3 6
12 19 55086359 GC - LILRA2 7.40E-05 1.00E-16 4.02E-10 50 0 0 3 7
13 4 111539617 T A PITX2 7.77E-04 1.00E-16 9.52E-10 75 0 0 2 3
Table 17: Opthalmology Condition 3 Single Variant Results
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